



CURRICULUM VITAE

12/12/22

BIOGRAPHICAL

Name: Adam Matthew Brufsky, MD, PhD, FACP **Birth Date:** 7/29/62
Home Address: 1798 Tragone Drive **Birth Place:** Washington, D.C.
Upper St. Clair, PA 15241
Home Phone: (412) 220-0122
Business Address: Magee-Women's Hospital **Citizenship:** United States
Women's Cancer Center
300 Halket Street Suite 4628
Pittsburgh, PA 15213
Business Phone: (412) 641-6500
Spouse: Jill A. Brufsky, Pharm D

EDUCATION AND TRAINING

UNDERGRADUATE:

1980-1983 Dartmouth College A.B., 1984
Hanover, NH Chemistry (*Cum Laude*)

GRADUATE:

1983-1990 University of Connecticut School of Medicine M.D., 1990
Farmington, CT Medicine
1985-1990 University of Connecticut School of Medicine Ph.D., 1990
Farmington, CT Developmental Biology
Major Advisor: David Rowe, MD

POSTDOCTORAL TRAINING:

1990-1991 Brigham and Women's Hospital Intern
Boston, MA Internal Medicine
Program Director: Marshall Wolf, MD

1991–1992	Brigham and Women’s Hospital Boston, MA Program Director: Marshall Wolf, MD	Junior Assistant Resident Internal Medicine
1992-1995	Dana-Farber Cancer Institute Boston, MA Program Director: Robert Mayer, MD	Fellow Medical Oncology
1993	Dana-Farber Cancer Institute Boston, MA Program Director: Jerome Ritz, MD	Fellow Bone Marrow Transplantation

APPOINTMENTS AND POSITIONS

1990-1995	Harvard Medical School Boston, MA	Clinical Fellow in Medicine
1990–1995	Brigham and Women’s Hospital Boston, MA	Clinical Fellow in Medicine
1992–1995	Dana-Farber Cancer Institute Boston, MA	Clinical Fellow in Medicine
1995-1996	Harvard Medical School Boston, MA	Instructor in Medicine
1995-1996	Brigham and Women's Hospital Boston, MA	Associate Physician
1995-1996	Dana-Farber Cancer Institute Boston, MA	Associate Physician
1996-2006	University of Pittsburgh Pittsburgh, PA	Assistant Professor of Medicine
1996-	UPMC Hillman Cancer Center Pittsburgh, PA	Member
1998-	Magee-Womens Hospital/UPMC Hillman Comprehensive Breast Cancer Center Pittsburgh, PA	Associate Director Co-Director (2002-present)

2003-2022	University of Pittsburgh Department of Medicine	Associate Division Chief Hematology/Oncology
2006-2022	University of Pittsburgh Cancer Centers Pittsburgh, PA	Director Academic Medical Oncology
2006-2009	University of Pittsburgh Pittsburgh, PA	Associate Professor of Medicine
2009-2017	University of Pittsburgh Cancer Institute	Associate Director, Clinical Investigation
2022-	UPMC Hillman Cancer Center	Associate Director Strategic Initiatives
2009-	University of Pittsburgh Pittsburgh, PA	Professor of Medicine

**CERTIFICATION AND LICENSURE
SPECIALTY CERTIFICATION:**

Internal Medicine American Board of Internal Medicine	1993 (recertified 2013)
Medical Oncology American Board of Internal Medicine	1995 (recertified 2015)

MEDICAL LICENSURE:

Massachusetts Medical License #75597	1992
Pennsylvania Medical License #MD-059093-L	1996

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

American Medical Association	1990-present
Massachusetts Medical Society Member, Blood Banking Committee	1992-present 1994
American College of Physicians	1994-present

American Society of Clinical Oncology	1995-present
American Association for Cancer Research	1996-present
Allegheny County Medical Society	1996-present
Pennsylvania Medical Society	1996-present
Pennsylvania Society for Oncology-Hematology	1996-present
Member, Executive Board	2019-present

HONORS

Summer Student, Chemistry/Molecular Biology National Institutes of Health	1981-1982
M.D. /Ph.D. Fellowship University of Connecticut School of Medicine	1983-1990
Young Investigator Award American Society of Bone and Mineral Research	1988
Scholar in Medicine University of Connecticut School of Medicine	1989-1990
Biochemistry Award 26th Annual National Medical Student Research Forum	1990
Internal Medicine Award University of Connecticut School of Medicine (top student in Internal Medicine)	1990
Linda Ives Award University of Connecticut School of Medicine (top student in pediatric research)	1990
Upjohn Award University of Connecticut School of Medicine (top student in medical research)	1990
Emil Frei III Fellowship Dana-Farber Cancer Institute	1994
Young Investigator Award American Society of Clinical Oncology	1995
Excellence in Innovative Clinical Trial Development	2002

University of Pittsburgh Cancer Institute

Vision of Hope Award Astra-Zeneca Oncology	2003
America's Top Doctors Castle Connolly Corporation	2005-2021
Fellow, American College of Physicians	2005
Merill J. Egorin Excellence in Scientific Leadership Award University of Pittsburgh Cancer Institute	2011
PNC Bank/UPCI Director's Distinguished Scholar Award University of Pittsburgh Cancer Institute	2014

PUBLICATIONS

Refereed Articles:

1. Genovese C, **Brufsky A**, Shapiro J, Rowe D. Detection of mutations in human type I collagen mRNA in osteogenesis imperfecta by indirect RNase protection. *J Biol Chem* 1989; 264(16):9632–7. (Joint First Author)
2. **Brufsky A**, Malchoff DM, Javier EC, Reardon G, Rowe D, Malchoff CD. A glucocorticoid receptor mutation in a subject with primary cortisol resistance. *Trans Am Assoc Phys* 1990; 103:53–63. (First Author)
3. Malchoff DM, **Brufsky A**, Reardon G, McDermott P, Javier M, Rowe D, Malchoff CD. A mutation in the glucocorticoid receptor in primary cortisol resistance. *J Clin Invest* 1993; 91(5):1918–25. (Joint First Author)
4. **Brufsky A**, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I, Kaufman D, Kantoff P. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. *Urology* 1997; 49:913-920. (First Author)
5. Giovannucci E, Stampfer M, Krithivas K, Brown M, **Brufsky A**, Talcott J, Hennekens CH, Kantoff P. The CAG repeat within the androgen receptor and its relationship to prostate cancer. *Proc Natl Acad Sci USA* 1997; 94(7):3320-3323.
6. Bastacky S, Dhir R, Nangia AJ, **Brufsky A**, Becich MJ. Choriocarcinomatous differentiation in a high grade urethral carcinoma: Case report and literature review. *J Urol Pathol* 1997; 6:223-233.

7. Smith MR, Kantoff PW, Oh W, Elson G, Manola J, McMullin M, Jacobsen J, **Brufsky A**, Kaufman D. Phase II trial of the antiestrogen toremifene for androgen-independent prostate cancer. *Prostate J* 1999; 1(4): 185-189.
8. Peters DG, Kassam AB, Heidrich O'Haire E, Yonas H, Ferrell RE, **Brufsky A** Comprehensive transcript analysis from small quantities of mRNA by SAGE-Lite. *Nucleic Acids Res* 1999; 27(24): e39. (Corresponding Senior Author)
9. Redinbaugh EM, Schuerger JM, Weiss LM, **Brufsky A**, Arnold RM. Health care professionals' grief: a model based on the occupational style and coping. *Psycho-Oncology* 2001; 10(3):187-93.
10. Peters DG, Kassam AB, Feingold E, Heidrich O'Haire E, Yonas H, Ferrell RE, **Brufsky A**. Molecular analysis of an intracranial aneurysm: coordinated expression of genes involved in wound healing and tissue remodeling. *Stroke* 2001; 32:1036-1042.
11. Winters SJ, **Brufsky A**, Weissfeld J, Trump DL, Dyky MA, Hadeed V. Testosterone, SHBG, and body composition in young adult African-American and Caucasian men. *Metabolism* 2001; 50(10): 1242-1247.
12. Hmelo CE, Ramakrishnan S, Day RS, Shirey B, **Brufsky A**, Johnson C, Baar J, Huang Q. Oncology thinking cap: scaffolded use of a simulation to learn clinical trial design. *Teach Learn Med* 2001; 13(3) 183-191.
13. Wahlberg BJ, Burholt DR, Kornblith P, Richards TJ, **Brufsky A**, Herberman RB, Vujanovic NL. Measurement of NK activity by the microcytotoxicity assay (MCA): a new application for an old assay. *J Immunol Methods* 2001; 253(1-2): 69-81.
14. Bunker CH, Patrick AL, Konety BR, Dhir R, **Brufsky AM**, Vivas CA, Becich MJ, Trump DL, Kuller LH. High prevalence of screening-detected prostate cancer among Afro-Caribbeans; The Tobago Prostate Cancer Survey. *Can Epid Biomarkers Prev* 2002; 11(8): 726-729.
15. Faul C, **Brufsky A**, Goertzen K, Flickinger J, Kunschner A, Jacob H, Vogel V, Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery. *Eur J Ca* 2003; 39(6): 763-768. (Joint First Author)
16. Oh W, Manola J, Bittman L, **Brufsky A**, Kaplan I, Kaufman D, Kantoff P. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and follow-up. *Urology*. 2003 Jul; 62(1): 99-104.
17. Rosenzweig P, Bender K, Lucke J, Yasko J, **Brufsky A**. The decision to prematurely terminate a trial of rHU-EPO due to thrombotic events. *J Pain Sympt Manag* 2004; 27(2). 185-190. (Senior Author)
18. Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, **Brufsky A**, Evans T, Troetschel M, Walko C, Day R, Chen HX, Finkelstein S. The low over-

expression of HER-2/neu in Advanced Colo-Rectal Cancer limits the usefulness of Trastuzumab (Herceptin®) and Irinotecan as therapy. A Phase II trial. *Cancer Invest* 2004, 22(6):858-65.

19. Day RS, Manning BK, Garrott D, **Brufsky AM**, Baar J, Egorin MJ, Shirey WE, Friedman C. Evaluation of the OncoTCap (Oncology Thinking Cap) Simulation in Teaching Medical Students about Clinical Trials: Some Successes and Some Surprises. *J Cancer Ed*, 2004, 19(3):149-55.
20. Rosenzweig M, Bender CM., **Brufsky AM**. The Nurse as Principal Investigator in a Pharmaceutically Sponsored Drug Trial: Considerations and Challenges. *Onc Nur Forum* 2005; 32(2): 293-9. (Senior Author)
21. Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SA, Zuhoswki EG, Lan J, Potter DM, Ivy SP, **Brufsky A**, Wong M, Tutchko S, Egorin MJ. Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17- Demethoxygeldanamycin (17AAG, NSC 330507), A Novel Inhibitor of Heat Shock Protein 90, in Patients With Refractory Advanced Cancers. *Clin Cancer Res* 2005; 11(9): 3385-91.
22. Low JA, Wedam SB, Lee J, Berman A, **Brufsky A**, Yang X, Poruchynsky M, Steinberg S, Fojo T, Swain SM. A Phase II Clinical Trial of Ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. *J Clin Oncol* 2005; 23(12): 2726-34.
23. Gerstzen PC, Burton S, Welch WC, **Brufsky AM**, Lembersky BC, Ozhasoglu C, Vogel WL. Single fraction radiosurgery for the treatment of spinal breast metastases. *Cancer* 2005; 104: 2244-2254.
24. **Brufsky A**, Paton VE, Lembersky B, Lieberman G, Sciffman K, Klein P. Estrogen receptor status does not affect the clinical benefit of Herceptin® (trastuzumab) therapy for metastatic breast cancer. *Clin Breast Cancer* 2005; 6(3): 247-252. (First Author)
25. Kondziolka D, Martin, J, Flickinger, JC, Friedland, D, **Brufsky, AM**, Baar, J, Agarwala, S, Kirkwood, JJ, Lunsford, DL. Long-term Survivors after Gamma Knife Radiosurgery for Brain Metastases. *Cancer* 2005; 104(12): 2784-2791.
26. Limentani SA, **Brufsky AM**, Jahanzeb M, Erban JK, Kneuper-Hall R, Lewis D. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer. *Clin Breast Cancer* 2006; 6(6): 511-517. (Joint First Author)
27. Bender CM, Sereika SM., Berga SL, Vogel VG, **Brufsky AM**, Paraska KK, Ryan CM Cognitive impairment associated with adjuvant therapy in breast cancer. *Psycho-Oncology* 2006; 15(5): 422-430.
28. Winters SJ, Wang C, Abdelrahman E, Dyky MA, **Brufsky A**. Inhibin-B levels in young adult men and prepubertal boys: Is obesity the cause for the contemporary decline in sperm count because of fewer Sertoli cells? *J Androl* 2006; 27(4): 560-564. (Senior Author)

29. Janjic B, Andrade P, Wang X, Almunia C, Kudela M, Gambotto P, **Brufsky A**, Jacobs S, Friedland D, Stroller R, Gillet D, Herberman R, Kirkwood J, Maillere B, Zarour HM. Spontaneous CD4+ T Cell Responses Against TRAG-3 in Patients with Melanoma and Breast Cancers. *J Immunol* 2006; 177(4): 2717-2727.
30. Trump DL, Polakowski S, Potter DM, Muindi J, **Brufsky AM**, Johnson C. Phase II Trial of High Dose, Intermittent Calcitriol (1,25 dihydroxyvitamin D3) + Dexamethasone in Androgen Independent Prostate Cancer. *Cancer* 2006; 106(10): 2136-2142.
31. **Brufsky A**. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. *Semin Oncol* 2006; 33(2 Suppl 7): S13-S17. (First Author)
32. Theriault RL, Biermann JS, Brown E, **Brufsky A**, Demers L, Grewal RK, Guise T, Jackson R, McEnery K, Podoloff D, Ravdin P, Shapiro CL, Smith M, Van Poznak CH. NCCN Task Force Report: Bone Health and Cancer Care. *J Natl Compr Canc Network* 2006; 4 (Suppl 2): S1-S20.
33. Esposito, NN, Mohan D, **Brufsky AM**, McManus K, Lin Y, Kapali M, Ahmed S, Swalsky PA, Finkelstein SD, Dabbs DJ Phylloides Tumor: a clinicopathologic and immunohistochemical study of 30 cases. *Arch Path Lab Med* 2006; 130(10):1516-1521.
34. Greenspan SL, Bhattacharya RK, Sereika SM, **Brufsky A**, Vogel VG. Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo controlled clinical trial. *J Clin Endocrinol Metab* 2007; 92(1):131-136.
35. **Brufsky A**, Harker G, Beck T, Carroll R, Tan-Chiu E, Seidler C, Lacerna L, Thomas E, Perez E. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. *J Clin Oncol* 2007; 25(7): 829-836 (First Author).
36. Limentani SA, **Brufsky, AM**, Erban, J, Jahanzeb M, Lambert-Fells R, Lewis, D. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. *J Clin Oncol* 2007; 25(10):1232-8. (Joint First Author).
37. Bender CM, Sereika SM, Ryan CM, Casillo FE, Vogel VG, Berga SL, Cohen SM, Rastogi P, **Brufsky AM**. Memory impairments with anastrozole versus tamoxifen therapy in women with early stage breast cancer. *Menopause* 2007;14(6): 995-8. (Senior Author)
38. **Brufsky AM**. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors. *Clin Breast Cancer* 2007 Dec; 8 Suppl 1:S22-34. (First Author)
39. **Brufsky AM**. Bone health issues in women with early stage breast cancer receiving aromatase inhibitors. *Curr Oncol Rep* 2008; 10(1): 18-26. (First Author)

40. Chivukula M, Bhargava R, **Brufsky A**, Surti U, Dabbs DJ. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. *Mod Pathol*. 2008; 21(4): 363-8.
41. **Brufsky AM**. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. *The Oncologist* 2008; 13(2): 187-95. (First Author)
42. **Brufsky AM**, Bundred N, Coleman R, Lambert-Falls R, Mena R, Dong M, Schenk N, Lacerna L, Perez E. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. *The Oncologist* 2008; 13(5):503-14. (First Author)
43. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Roberston J, **Brufsky A**, Possinger K, Rennie P, Lowe E, Piccart M. A double-blind, randomized placebo controlled trial of fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy in post-menopausal women with hormone receptor positive advanced breast cancer: results from EFACT. *J Clin Oncol* 2008; 26(10): 1664-70.
44. Greenspan SL, **Brufsky A**, Lembersky B, Bhattacharya RK, Vujevich KT, Periera S, Sereika SM, Vogel VG. Risedronate prevents bone loss in breast cancer survivors: a 2 year, randomized, double-blind, placebo-controlled clinical trial. *J Clin Oncol* 2008; 26(16): 2644-52.
45. Heron DC, **Brufsky A**, Beriwhal S, Kurman M. Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy. *Ann Oncol* 2008; 19(9): 1639-43. (Joint First Author)
46. Hadji P, Body JJ, Aapro M, **Brufsky A**, Tubiana-Hulin M, Guise T Coleman RE, Lipton A. Practical guidance for the management of aromatase inhibitor-associated bone loss. *Ann Oncol* 2008; 19(8): 1407-16.
47. O'Shaughnessy JA, **Brufsky AM**. RIBBON 1 and RIBBON 2: Phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. *Clin Breast Cancer* 2008; 8(4): 370-3. (Senior Author)
48. Bender CM, Pacella ML, Sereika SM, **Brufsky AM**, Vogel VG, Rastogi P, Casillo FE, Richey SM, Ryan CM. What do perceived cognitive problems reflect? *J Support Oncol* 2008; 6(5): 238-42.
49. Chivukula M, Haynik DM, **Brufsky A**, Carter G, Dabbs DJ. Pure pleomorphic lobular carcinoma in situ (PLCIS) on core needle biopsies: clinical significance and immunoprofile *Am J Surg Path* 2008; 32(11): 1721-6.
50. Flanagan MB, Dabbs DJ, **Brufsky AM**, Beriwhal S, Bhargava R. Histopathologic variables predict Oncotype Dx recurrence score. *Mod Pathol* 2008; 21(10): 1255-61.
51. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roche H, Liu MC, Greil R, Ciruelos E, Loible S, Gori S, Wardley A, Yardley D, **Brufsky A**, Blum JL, Rubin SD, Dharan

B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paloetti P, Winer ER. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. *Clin Cancer Res* 2009; 15(4):1452-9.

52. **Brufsky A**, Bosserman L, Caradonna R, Haley B, Jones M, Moore H, Dong M, Warsi G, Perez E. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST Study 36-Month Follow-Up. *Clin Breast Cancer* 2009; 9(2) 77-85. (First Author)
53. Rosenzweig, M., Wiehagen, T., **Brufsky, A.**, Arnold, R. Challenges of illness in metastatic breast cancer: A low income African American perspective. *Pall and Supp Care* 2009; 7: 143–152. (Joint Senior Author)
54. Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, **Brufsky A**, Ottman S, Carson WE 3rd, Shapiro CL. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. *Breast Cancer Res Treat.* 2009; 117(1):83-9.
55. Bohn OL, Nasir I, **Brufsky A**, Tseng GC, Bhargava R, MacManus K, Chivukula M. Biomarker profile in breast carcinomas presenting with bone metastasis. *Int J Clin Exp Pathol.* 2009 Nov 10 3(2):139-46.
56. Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson R, **Brufsky AM**, Lembersky BL, Ahrendt G. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: A single institutional experience with 359 cases. *Cancer* 2010 116(6): 1431-1439.
57. McClure MK, McClure RJ, Day R, **Brufsky AM**. Randomized controlled trial of the Breast Cancer Recovery Program for women with breast cancer-related lymphedema. *Am J Occup Ther* 2010 64(1): 59-72. (Senior Author)
58. Hough B, **Brufsky A**, Lentzsch S. Metastasis breast cancer or multiple myeloma: Camouflage by lytic lesions. *J Oncol* 2010; Epub Mar 7.
59. Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, **Brufsky AM**, Lembersky BC, Ahrendt G. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. *Cancer.* 2010; 116(6): 1431-9.
60. Conlin A, Seidman A, Bach A, Lake M, Dickler M, D'Andrea G, Traina T, Danso M, **Brufsky AM**, Saleh MN, Clawson A, Hudis C. Phase II study of weekly nanoparticle albumin bound (nab) paclitaxel in combination with carboplatin and trastuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer. *Clin Breast Cancer* 2010, Aug 1:10(4): 281-7.
61. Donnenberg VS, Donnenberg AD, Zimmerlin L, Landreneau RJ, Bhargava R, Wetzel RA, Basse P, **Brufsky AM**. Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. *Cytometry B Clin Cytom* 2010; 78(5): 287-301.

62. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, **Brufsky A**, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S. GSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. *J Natl Cancer Inst* 2010; 102(19): 1496-1512.
63. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, **Brufsky AM**, Clezardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: advancing treatment and prevention. *Cancer Treat Rev* 2010; 36(8): 615-20.
64. Seidman AD, **Brufsky A**, Ansari RH, Hart LL, Stein RS, Schwartzberg LS, Stewart JF, Russell CA, Chen SC, Fein LE, De La Cruz Vargas JA, Kim SB, Cavalheiro J, Zhao L, Gill JF, Obasagu Ck, Orlando M, Tai DF. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. *Ann Oncol* 2011; 22(5): 1094-1101.
65. Bhargava R, Dabbs DJ, Beriwal S, Yidiz IA, Badve P, Soran A, Johnson RR, **Brufsky AM**, Lembersky BC, McGuire K, Ahrendt G. Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. *Mod Pathol*. 2011; 24(3): 367-374.
66. Rosenzweig M, **Brufsky A**, Rastogi P, Puhalla S, Simon J, Underwood S. The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity. *Oncol Nurs Forum* 2011; 38(1): 85-9.
67. Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, **Brufsky AM**, Minton SE, Giguere JK, Smith JW 2nd, Richards PD, Gernhardt D, Huang X, Liao KF, Kern KA, Davis J. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. *Clin Breast Cancer* 2011; 11(2): 82-92.
68. Kondziolka D, Kano H, Harrison GL, Yang HC, Liew DN, Niranjan A, **Brufsky AM**, Flickinger JC, Lunsford LD. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. *J Neurosurg* 2011; 114(3) 792-800.
69. van Londen GJ, Perera S, Vujevich K, Rastogi P, Lembersky B, **Brufsky A**, Vogel V, Greenspan Sl. The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer. *Breast Can Res Treat* 2011; 125(2): 441-6.
70. Wheeler DS, Barrick SR, Grubisha MJ, **Brufsky AM**, Friedman PA, Romero G. Direct interaction between NHERF-1 and Frizzled regulates β -catenin signaling. *Oncogene* 2011; 30(1): 32-42.
71. Sherrod AM, **Brufsky A**, Puhalla S. A case of late onset gemcitabine lung toxicity. *Clin Insights Oncol* 2011; 5: 171-176. (Senior Author)

72. Jung SY, Sereika SM, Linkow F, **Brufsky A**, Weissfeld JL, Rosenzweig M. The effect of delays in treatment for breast cancer metastasis on survival. *Breast Can Res Treat*. 2011; 130(3): 953-964. (Joint Senior Author)
73. **Brufsky A**, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Yood M, Tripathy D, Birkner, M, Brammer MG, Yardley DA. RegistHER: Patient characteristics and time course of central nervous system metastases in patients with HER2-positive metastatic breast cancer. *Clin Can Res* 2011;17(14):4834-4843. (First Author)
74. Robert NJ, Dieras V, Glaspy J, **Brufsky A**, Bondarenko I, Lipatov O, Perez E, Yardley D, Zhou X, Phan S. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). *J Clin Oncol* 2011; 29:1252-1260.
75. **Brufsky A**, Hoelzer K, Beck T, Whorf R, Keaton M, Nadella P, Brill-Jackson E, Kroener J, Middleman E, Frontiera M, Paul D, Panella T, Bromund J, Zhao L, Orlando M, Tai F, Marciniak MD, Obasaju C, Hainsworth J. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. *Clin Breast Cancer*. 2011; 11(4): 211-20. (First Author)
76. Jankowitz RC, Cooper K, Erlander MG, Ma XJ, Kesty NC, Li H, Chivukula M, **Brufsky A**. Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer. *Breast Cancer Res* 2011; 13(5): R98. (Senior Author)
77. **Brufsky AM**, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: A randomized, double-blind, placebo-controlled, Phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol*. 2011; 29(32):4286-93. (First Author)
78. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group (**Brufsky AM**). Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*. 2011 Oct 6; 365(14):1273-83.
79. Hadji P, Aapro MS, Body JJ, Bundred NJ, **Brufsky A**, Coleman RE, Gnant M, Guise T, Lipton A. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. *Ann Oncol* 2011; 22(12): 2546-55.
80. Jung SY, Rosenzweig M, Linkow V, **Brufsky A**, Weissfeld JL, Sereika SM. Factors associated with mortality after breast cancer metastasis. *Cancer Causes Control*. 2012; 23(1):103-12. (Joint Senior Author)

81. Jung SY, Rosenzweig M, Linkow F, **Brufsky A**, Weissfeld JL, Sereika SM. Comorbidity as a mediator of survival disparity between younger and older women diagnosed with metastatic breast cancer. *Hypertension* 2012; 59(2): 205-211. (Joint Senior Author)
82. Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, **Brufsky AM**, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. *N Engl J Med* 2012; 366(4): 310-320.
83. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group (**Brufsky AM**). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med*. 2012 Jan 12; 366(2):109-19.
84. **Brufsky A**, Harker WG, Beck JT, Carroll R, Jin L, Warsi G, Argonza-Aviles E, Ericson S, Perez EA. Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal patients receiving letrozole. *Cancer* 2012; 118(5): 1192-1201. (First Author)
85. Finegold D, Baty C, Knickelbein K, Perschke S, Noon S, Campbell D, Karlsson J, Huang D, Kimak M, Lawrence E, Feingold E, Meriney S, **Brufsky AM**, Ferrell R. Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment. *Clin Cancer Res* 2012; Apr 15; 18(8): 2382-90. (Joint Senior Author)
86. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey JR, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson CI, **Brufsky AM**, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM. Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients. *Clin Cancer Res*. 2012; Jun 15; 18(12): 3478-86.
87. Cortes J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, **Brufsky A**, Robert N, Vidal M, Munoz E, Perex J, Dawood S, Saura C, Di Cosimo S, González-Martin A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. *Ann Oncol*. 2012; 23(5): 1130-7.
88. **Brufsky A**, Valero V, Tiangco B, Dakhil SR, Brize A, Bousfoul N, Rugo HS, Yardley DA. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. *Breast Can Treat Res* 2012; 133(3):1067-75. (First Author)
89. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer Ms, Rathi V, Fehrenbacher L, **Brufsky A**, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, TanpChiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing Doxorubicin and Cyclophosphamide followed by Paclitaxel (ACP) with ACP plus Trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol* 2012; 30(31): 3792-3799.

90. Kaufman PA, **Brufsky A**, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardly DA. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. *Breast Cancer Res Treat.* 2012; 135(3): 875-83.
91. Martin M, Bell R, Bourgeois H, **Brufsky A**, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase iii trial of denosumab versus zoledronic acid. *Clin Can Res.* 2012; 18(17):4841-4849.
92. Beusterien K, Grinspan J, Tencer T, **Brufsky A**, Visovsky C. Patient preferences for chemotherapies used in breast cancer. *Int J Womens Health.* 2012; 4:279-87. (Joint Senior Author)
93. Patterson AH, Anderson SJ, Lembersky BC, Fehrenacher L, Falkson CI, King KM, Wier LM, **Brufsky AM**, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Pere EA, Zheng P, Geyer CE Jr, Swain SM, Costantino JP, Mamounas EP, Wolmark N. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicenter, placebo-controlled, randomized trial. *Lancet Oncol.* 2012; 13(7): 734-42.
94. The Cancer Genome Atlas Network, (**Brufsky A**), et al. Comprehensive molecular portraits of human breast tumours. *Nature.* 2012; Oct 4; 490(7418): 61-70.
95. Schreiber KL, Martel MO, Schol H, Shaffer JR, Greco C, Viray N, Taylor LN, McLaughlin M, **Brufsky A**, Ahrendt G, Boybjerg D, Edwards RR, Belfer I. Persistent pain in postmastectomy patients: Comparison of psychophysical, medical, surgical, and psychosocial characteristics between patients with and without pain. *Pain.* 2013; 154(5):660-8.
96. Klein ME, Dabbs DJ, Shuai Y, **Brufsky AM**, Jankowitz R, Puhalla SL, Bhargava R. Prediction of the Oncotype DC recurrence score: use of pathology-generated equations derived by linear regression analysis. *Mod Pathol* 2013; 26(5): 658-64.
97. Bender CM, Sereika SM, Ryan CM, **Brufsky AM**, Puhalla S, Berga SL. Does lifetime exposure to hormones predict pretreatment cognitive function in women before adjuvant therapy for breast cancer? *Menopause.* 2013; 20(9): 922-9.
98. Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, **Brufsky AM**, Aft R, Tevaarwerk AJ, Swenson K, Lind P, Mauri D. Adjuvant therapy with zoledronic acid in patients with breast cancer: A systematic review and meta-analysis. *Oncologist.* 2013; 18(4): 353-61.
99. Tripathy D, Kaufman PA, **Brufsky AM**, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. *Oncologist.* 2013; 18(5): 501-10.

100. **Brufsky AM**, Sereika SM, Mathew A, Tomifumi O, Singh V, Rosenzweig M. Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. *Breast J.* 2013; 19(5): 504-11. (First Author)
101. Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC, Fornander T, Stål O, **Brufsky AM**, Sgroi D, Erlander MG. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early-and late-distant recurrence. *Clin Cancer Res.* 2013; 19(15): 4196-205. (Joint Senior Author)
102. Belfer I, Schreiber KL, Shaffer JR, Shnol H, Blaney K, Morando A, Englert D, Greco C, **Brufsky A**, Ahrendt G, Kehlet H, Edwards RR, Bovbjerg DH. Persistent postmastectomy pain in breast cancer survivors: analysis of clinical, demographic, and psychosocial factors. *J Pain.* 2013; 14(10): 1185-95.
103. **Brufsky A**, Lokay K. How to develop and deliver pathway-based care. *Hematol Oncol Clin North Am.* 2013; 27(4): 843-50. (First Author)
104. Swain SM, Tang G, Geyer CE Jr, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff JA, **Brufsky AM**, Biggs DD, Levine EA, Zapas JL, Provencher L, Northfelt DW, Paik S, Costantino JP, Mamounas EP, Wolmark N. Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial. *J Clin Oncol.* 2013; 31(26): 3197-204.
105. Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, **Brufsky AM**, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. *Lancet Oncol.* 2013 Nov; 14(12):1183-92.
106. Rugo HS, **Brufsky AM**, Ulcickas Yood M, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA. Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. *Breast Cancer Res Treat.* 2013 Oct; 141(3): 461-70.
107. Park BH, Kook S, Lee S, Jeong JH, **Brufsky A**, Lee BC. An isoform of C/EBP β , LIP, regulates expression of the chemokine receptor CXCR4 and modulates breast cancer cell migration. *J Biol Chem.* 2013 Oct 4; 288(40): 28656-67.
108. Jiang X, Xue D, **Brufsky A**, Khan S, Neapolitan R. A new method for predicting patient survivorship using efficient bayesian network learning. *Cancer Inform.* 2014;13: 47-57.
109. Bender CM, Gentry AL, **Brufsky AM**, Casillo FE, Cohen SM, Dailey MM, Donovan HS, Dunbar-Jacob J, Jankowitz RC, Rosenzweig MQ, Sherwood PR, Sereika SM. Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. *Oncol Nurs Forum.* 2014 May;41(3):274-85.

110. Yardley DA, Tripathy D, **Brufsky AM**, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C, Ulcickas Yood M. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. *Br J Cancer*. 2014 May 27;110(11):2756-64.
111. Yardley DA, Kaufman PA, **Brufsky A**, Yood MU, Rugo H, Mayer M, Quah C, Yoo B, Tripathy D. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. *Breast Cancer Res Treat*. 2014 Jun;145(3):725-34.
112. Leone JP, Bhattacharya S, Socinski MA, Sohnen A, Chiosea S, Puhalla S, **Brufsky A**. Metastasis of breast carcinoma to the maxillary sinus. *Breast J*. 2014 May-Jun;20(3):318-9
113. Paganì O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribí K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; **TEXT and SOFT Investigators**; International Breast Cancer Study Group. Adjuvant exemestane, with ovarian suppression in premenopausal breast cancer. *N Engl J Med*. 2014;371(2): 107-18.
114. Orsak G, Stevens AM, **Brufsky A**, Kajumba M, Dougall AL. The effects of Reiki therapy and companionship on quality of life, mood, and symptom distress during chemotherapy. *J Evid Based Complementary Altern Med*. 2015; 20(1):20-7.
115. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley, BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; **SOFT Investigators**; International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. *N Engl J Med*. 2015 Jan 29; 372(5):436-46.
116. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; **CLEOPATRA Study Group**. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med*. 2015 Feb 19; 372(8):724-34.
117. Leone JP, Lee AV, **Brufsky AM**. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. *Cancer Med*. 2015 Jul; 4(7): 989-94.
118. Greenspan SL, Vujevich KT, **Brufsky A**, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S. Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial. *Osteoporos Int*. 2015 Jun; 26(6): 1857-64.
119. Bender CM, Merriman JD, Gentry AL, Ahrendt GM, Berga SL, **Brufsky AM**, Casillo FE, Dailey MM, Erickson KI, Kratožil FM, McAuliffe PF, Rosenzweig MQ, Ryan CM, Sereika SM. Patterns of change in cognitive function with anastrozole therapy. *Cancer*. 2015 Aug 1; 121(15):2627-36.

120. Leone JP, Bhargava R, Theisen BK, Hamilton RL, Lee AV, **Brufsky AM**. Expression of high affinity folate receptor in breast cancer brain metastasis. *Oncotarget*. 2015; 6(30): 30327-30333.
121. Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, **Brufsky AM**, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. *Lancet Oncol*. 2015 Sep; 16(9):1037-48.
122. Brown DD, Dabbs DJ, Lee AV, McGuire KP, Ahrendt GM, Bhargava R, Davidson NE, **Brufsky AM**, Johnson RR, Oesterreich S, McAuliffe PF. Developing in vitro models of human ductal carcinoma in situ from primary tissue explants. *Breast Cancer Res Treat*. 2015 Sep; 153(2): 311-21.
123. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, **Brufsky AM**, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med*. 2015; 373 (21): 2005-2014.
124. Yardley DA, **Brufsky A**, Coleman RE, Conte PF, Cortes J, Glück S, Nabholz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. *Trials*. 2015 Dec 16; 16: 575.
125. Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, **Brufsky AM**, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. *Lancet* 2016; 387(10021):849-856.
126. Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, **Brufsky AM**, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. *Lancet* 2016; 387(10021): 857-865.
127. Gurda GT, Ambros T, Nikiforova MN, Nikiforov YE, Lucas PC, Dabbs DJ, Lee AV, **Brufsky AM**, Puhalla SL, Bhargava R. Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer. *Appl Immunohistochem Mol Morphol*. 2017; 25(6): 392-398.

128. Jiang Y, Sereika SM, Bender CM, **Brufsky AM**, Rosenzweig MQ. Beliefs in chemotherapy and knowledge of cancer and treatment among African American women with newly diagnosed breast cancer. *Oncol Nurs Forum* 2016 Mar 1; 43(2):180-9.
129. Wang P, Bahreini A, Gyanchandani R, Lucas P, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, Kurland BF, Weiss K, Mathew A, Leone JP, Davidson NE, Nikiforova MN, **Brufsky AM**, Ambros TF, Stern AM, Puhalla S, Lee AW, Oesterreich S. Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions and cell free DNA of breast cancer patients. *Clin Cancer Res.* 2016; 22(5): 1130-1137.
130. Koleck TA, Bender CM, Sereika SM, **Brufsky AM**, Lembersky BC, McAuliffe PF, Puhalla SL, Rastogi P, Conley YP. Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory study. *Springerplus* 2016 Apr 9, 5: 422.
131. Gyanchandani R, Lin Y, Lin HM, Cooper KL, Normolle DP, **Brufsky AM**, Fastuca M, Crosson W, Oesterreich S, Davidson NE, Bhargava R, Dabbs DJ, Lee AV. Intra-tumor heterogeneity affects gene expression profile test prognostic risk stratification in early breast cancer. *Clin Cancer Res.* 2016; 22(21): 5392-5369.
132. Ellis PG, **Brufsky AM**, Beriwal S, Lokay KG, Benson HO, McCutcheon SB, Krebs M. Pathways clinical decision support for appropriate use of key biomarkers. *J Oncol Pract.* 2016 Jun;12(6): e681-7.
133. Yardley DA, Reeves J, Dees EC, Osborne C, Paul D, Ademuyiwa F, Soliman H, Guthrie T, Andersen J, Krekow L, Choksi J, Daniel B, Danso M, Favret A, Oommen S, **Brufsky A**, Bromund JL, Lin Y, Ibrahim AB, Richards PD. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. *Clin Breast Cancer.* 2016; 16(6): 471-9.
134. Puhalla S, Wilks S, **Brufsky AM**, O'Shaughnessy J, Schwartzberg LS, Berrak E, Song J, Vahdat L. Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study. *Breast Cancer* 2016 Dec 7(8):231-239.
135. **Brufsky AM**, Ormerod C, Bell Dickson R, Citron ML. Understanding the needs of patients with metastatic breast cancer: results of the Make Your Dialogue Count survey. *Breast J.* 2017; 23(1):17-25.
136. Yee MK, Sereika SM, Bender CM, **Brufsky AM**, Connolly MC, Rosenzweig MQ. Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer. *Cancer* 2017; 123(11): 2061-2069.

137. Merriman, JD, Sereika, S, **Brufsky, AM**, McAuliffe, PF, McGuire, K, Myers, JS, Phillips, ML, Ryan, C, Gentry, AL, Jones, LS, Bender, CM. Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. *Psycho-Oncology* 2017; 26: 44-52.
138. Koleck TA, Bender CM, Sereika SM, Ryan CM, Ghotkar P, **Brufsky AM**, Jankowitz RC, McAuliffe PF, Clark BZ, Conley YP. Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer. *Cancer Med.* 2017 Feb;6(2):339-348.
139. Koleck TA, Bender CM, Clark BZ, Ryan CM, Ghotkar P, **Brufsky A**, McAuliffe PF, Rastogi P. An exploratory study of polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors. *Breast Cancer.* 2017; 9:95-110.
140. Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gomez HL, Gehrenbacher L, Vukelja SJ, Lyss AP, Paul D, **Brufsky AM**, Jeong JH, Colangelo LH, Swain SM, Marmounas EP, Jones SE, Wolmark N. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46I/USOR 07132, and NSABP B-49 (NRG Oncology). *J Clin Oncol* 2017; 35:2647-2655.
141. Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, **Brufsky A**, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. *Clin Cancer Res.* 2017; 23(11): 2691-2701.
142. Farrugia DJ, Landmann A, Zhu L, Diego EJ, Johnson RR, Bonaventura M, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, **Brufsky AM**, Lembersky BC, Ahrendt GM, McAuliffe PF, Bhargava R. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. *Mod Pathol.* 2017; 30(8): 1078-1085.
143. Yardley DA, Arrosmith ER, Daniel BR, Eakle J, **Brufsky A**, Drosick DR, Kudrik F, Bosserman LD, Keaton MR, Goble SA, Bubis JA, Priego VM, Pendergrass K, Manalo Y, Bury M, Gravenor DS, Rodriguez GI, Inhorn RC, Young RR, Harwin WN, Silver C, Hainsworth JD, Burris HA 3rd. Titan: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple negative breast cancer. *Breast Cancer Res Treat.* 2017; 164(3): 649-658.
144. Priedigkeit N, Hartmaier RJ, Chen Y, Varesliza D, Basudan A, Watters RJ, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Puhalla SL, Davidson NE, Oesterreich S, **Brufsky AM**, Young L, Lee AV. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. *JAMA Oncol.* 2017; 3(5):666-671.

145. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. N Engl J Med. 2017 Jul 13;377(2):122-131.
146. Gurda GT, Ambros T, Nikiforova MN, Nikiforov YE, Lucas PC, Dabbs DJ, Lee AV, **Brufsky AM**, Puhalla SL, Bhargava R. Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer. Appl Immunohistochem Mol Morphol. 2017; 25(6): 392-398.
147. Mathew A, Rajagopal PS, Villgran V, Sandhu GS, Jankowitz RC, Jacob M, Rosenzweig M, Oesterreich S, **Brufsky A**. Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast. Geburtshilfe Frauenheilkd. 2017 Jun;77(6):660-666.
148. Bear HD, Tang G, Rastogi P, Geyer CE Jr, Zoon CK, Kidwell KM, Robidoux A, Baez-Diaz L, **Brufsky AM**, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Ann Surg Oncol. 2017; 24(7): 1853-1860.
149. Yardley DA, Arrowsmith ER, Daniel BR, Eakle J, **Brufsky A**, Drosick DR, Kudrik F, Bosserman LD, Keaton MR, Goble SA, Bubis JA, Priego VM, Pendergrass K, Manalo Y, Bury M, Gravenor DS, Rodriguez GI, Inhorn RC, Young RR, Harwin WN, Silver C, Hainsworth JD, Burris HA 3rd. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2017;164(3):649-658.
150. Schroeder B, Zhang Y, Stål O, Fornander T, **Brufsky A**, Sgroi DC, Schnabel CA. Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer. Nature Breast Cancer 2017; 3:28.
151. Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, **Brufsky AM**, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35(23):2647-2655.
152. Kota K, **Brufsky A**, Oesterreich S, Lee A. Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification. Cureus. 2017; 9(7): e1434.
153. Mathew A, Achkar T, Abberbock S, Sandhu GS, Jacob ME, Villgran VD, Rosenzweig MQ, Puhalla S, **Brufsky AM**. Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer. Breast J. 2017 Aug 28 [Epub ahead of print].
154. Priedigkeit N, Watters RJ, Lucas PC, Basudan A, Bhargava R, Horne W, Kolls JK, Fang Z, Rosenzweig MQ, **Brufsky AM**, Weiss KR, Oesterreich S, Lee AV. Exome-capture RNA

sequencing of decade-old breast cancers and matched decalcified bone metastases. *JCI Insight*. 2017 Sep 7; 2(17) [E Pub ahead of print].

155. Wang J, Heng YJ, Eliassen AH, Tamimi RM, Hazra A, Carey VJ, Ambrosone CB, de Andrade VP, **Brufsky A**, Couch FJ, King TA, Modugno F, Vachon CM, Hunter DJ, Beck AH, Hankinson. Alcohol consumption and breast tumor gene expression. *Breast Cancer Res*. 2017;19(1):108.
156. Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL III, **Brufsky AM**, Julian TB, Margolese RG, McCarron EC, Ganz P. Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology/NSABP B-30. *J Natl Cancer Inst*. 2018 Feb 1; 110 (2) [Epub ahead of print: 24 August 2017]
157. Gyanchandani R, Kota KJ, Jonnalagadda AR, Minter T, Knapick BA, Oesterreich S, **Brufsky AM**, Lee AV, Puhalla SL. Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. *Oncotarget*. 2017;8(40):66901-669
158. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; **EBCTCG**. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. *N Engl J Med*. 2017 Nov 9;377(19):1836-1846.
159. Hartmaier RJ, Trabucco SE, Friedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali SM, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL, Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, **Brufsky AM**, Frampton GM, Stephens PJ, Chmielecki J, Lee AV. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. *Ann Oncol*. 2018 Apr 1;29(4):872-880.
160. Clark BZ, Farrugia DJ, Landmann A, Diego EJ, Dabbs DJ, Puhalla SL, Jankowitz RC, **Brufsky AM**, Ahrendt GM, McAuliffe PF, Bhargava R. Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer. *Am J Clin Pathol*. 2018 Mar 7;149(4):332-343.
161. Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, **Brufsky A**, Stella PJ, Burnette B, Telli M, Makower DF, Cheema P, Truica CI, Wolff AC, Soori GS, Haley B, Wassenaar TR, Goldstein LJ, Miller KD, Sparano JA. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. *J Clin Oncol*. 2018 Jun 1;36(16):1556-1563.
162. Bender CM, Merriman JD, Sereika SM, Gentry AL, Casillo FE, Koleck TA, Rosenzweig MQ, **Brufsky AM**, McAuliffe P, Zhu Y, Conley YP. Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer. *Oncol Nurs Forum*. 2018 May 1;45(3):308-326.

163. Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, **Brufsky AM**, Ahrendt GM, McAuliffe PF, Bhargava R. Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease? *Am J Clin Pathol*. 2018 May 31;150(1):34-42.
164. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, **Brufsky AM**, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med*. 2018 Jul 12;379(2):111-121.
165. Francis PA, Pagni O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; **SOFT and TEXT Investigators** and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *N Engl J Med*. 2018 Jul 12;379(2):122-137.
166. Yardley DA, Coleman R, Conte P, Cortes J, **Brufsky A**, Shtivelband M, Young R, Bengala C, Ali H, Eakel J, Schneeweiss A, de la Cruz-Merino L, Wilks S, O'Shaughnessy J, Glück S, Li H, Miller J, Barton D, Harbeck N; tnacity Investigators. nab-Paclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial. *Ann Oncol*. 2018; 29(8): 1763-1770.
167. Dabbs DJ, Clark BZ, Serdy K, Onisko A, **Brufsky AM**, Smalley S, Perkins S, Bhargava R. Pathologist's health-care value in the triage of Oncotype DX(®) testing: a value-based pathology study of tumour biology with outcomes. *Histopathology*. 2018; 73(4): 692-700.
168. Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, **Brufsky AM**, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). *J Clin Oncol*. 2018; 36(25): 2621-2629.
169. Gyanchandani R, Kvam E, Heller R, Finehout E, Smith N, Kota K, Nelson JR, Griffin W, Puhalla S, **Brufsky AM**, Davidson NE, Lee AV. Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. *Sci Rep*. 2018 Nov 23;8(1):17313.
170. Stearns V, **Brufsky AM**, Verma S, Cotter MJ, Lu DR, Dequen F, Joy AA. Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women

With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. *Clin Breast Cancer*. 2018; 18(6): e1239-e1245.

171. Basudan A, Priedigkeit N, Hartmaier RJ, Sokol ES, Bahreini A, Watters RJ, Boisen MM, Bhargava R, Weiss KR, Karsten MM, Denkert C, Blohmer JU, Leone JP, Hamilton RL, **Brufsky AM**, Elishaev E, Lucas PC, Lee AV, Oesterreich S. Frequent ESR1 and CDK Pathway Copy Number Alterations in Metastatic Breast Cancer. *Mol Cancer Res*. 2019; 17(2):457-468.
172. Heng YJ, Wang J, Ahearn TU, Brown SB, Zhang X, Ambrosone CB, de Andrade VP, **Brufsky AM**, Couch FJ, King TA, Modugno F, Vachon CM, DuPre NC, Garcia-Closas M, Troester MA, Hunter DJ, Eliassen AH, Tamimi RM, Hankinson SE, Beck AH. Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues. *Breast Cancer Treat Res*. 2019; 173(3): 667-677.
173. Pandey A, **Brufsky AM**. Metastatic Breast Cancer Patient with Activating HER2 Exon 20 Insertion Mutation with Response to Pozitotinib: Case Report of Compassionate Drug Use. *Clin Breast Cancer* 2019; 19(1): e7-e11.
174. Merriman JD, Sereika SM, Conley YP, Koleck TA, Zhu Y, Phillips ML, Bertocci MA, **Brufsky AM**, Bender CM. Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer. *Biol Res Nurs*. 2019; 21(1): 50-60.
175. Bortsov AV, Devor M, Kaunisto MA, Kalso E, **Brufsky A**, Kehlet H, Aasvang E, Bittner R, Diatchenko L, Belfer I. CACNG2 polymorphisms associate with chronic pain after mastectomy. *Pain*. 2019;160(3):561-568.
176. Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, **Brufsky AM**, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL 3rd, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2019;20(1):88-99.
177. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; **KATHERINE Investigators**. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. *N Engl J Med*. 2019 Feb 14;380(7):617-628.
178. Varešlija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, O'Halloran PJ, Ward E, Cocchiglia S, Hartmaier R, Castro CA, Zhu L, Tseng GC, Lucas PC, Puhalla SL, **Brufsky AM**, Hamilton RL, Mathew A, Leone JP, Basudan A, Hudson L, Dwyer R, Das S, O'Connor DP, Buckley PG, Farrell M, Hill ADK, Oesterreich S, Lee AV, Young LS. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. *J Natl Cancer Inst*. 2019;111(4):388-398.

179. Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, **Brufsky A**, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. *Clin Cancer Res.* 2019;25(8):2433-2441.
180. Han M, Salamat A, Zhu L, Zhang H, Clark BZ, Dabbs DJ, Carter GJ, **Brufsky AM**, Jankowitz RC, Puhalla SL, Johnson RR, Soran A, Steiman JG, McAuliffe PF, Diego EJ, Bhargava R. Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy. *Mod Pathol.* 2019; 32(6):807-816.
181. Smith NG, Gyanchandani R, Shah OS, Gurda GT, Lucas PC, Hartmaier RJ, **Brufsky AM**, Puhalla S, Bahreini A, Kota K, Wald AI, Nikiforov YE, Nikiforova MN, Oesterreich S, Lee AV. Targeted mutation detection in breast cancer using MammaSeq™. *Breast Cancer Res.* 2019; 21(1):22.
182. Jiang X, Wells A, **Brufsky A**, Neapolitan R. A clinical decision support system learned from data to personalize treatment recommendations towards preventing breast cancer metastasis. *PLoS One.* 2019;14(3): e0213292.
183. Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, **Brufsky A**, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. *Ann Oncol.* 2019;30(7):1179.
184. Klar N, Rosenzweig M, Diergaard B, **Brufsky A**. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer. *Clin Breast Cancer.* 2019; Aug;19(4):304-310.
185. Sambade MJ, Prince G, Deal AM, Trembath D, McKee M, Garrett A, Keith K, Ramirez J, Midkiff B, Blackwell K, Sammons S, Leone JP, **Brufsky A**, Morikawa A, Brogi E, Seidman A, Ewend M, Carey LA, Moschos SJ, Hamilton RL, Vincent B, Anders C. Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. *Breast Cancer Res Treat.* 2019;176(2):321-328.
186. Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, **Brufsky AM**, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. *N Engl J Med.* 2019;380(25):2395-2405.
187. Stopeck A, **Brufsky A**, Kennedy L, Bhatta S, Bhowmik D, Buchanan J, Despiegel N, Hechmati G. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. *J Med Econ.* 2019; 26:1-11.

188. Fournier MV, Goodwin EC, Chen J, Obenauer JC, Tannenbaum SH, **Brufsky AM**. A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence. *Sci Rep*. 2019;9(1):14863.
189. **Brufsky A**, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, Stearns V. Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR(+)/HER2(-) Advanced Breast Cancer Enrolled in an Expanded Access Program. *Clin Breast Cancer*. 2019 Oct;19(5):317-325.
190. Tripathy D, **Brufsky A**, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G, O'Shaughnessy J, Rugo HS, Swain SM, Yardley DA, Chu L, Li H, Antao V, Hurvitz SA. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. *Oncologist* 2020 Feb;25(2): e214-e222. doi: 10.1634/theoncologist.2019-0446. Epub 2019 Oct 14.
191. Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, **Brufsky AM**, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledg3 GW Jr. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. *JAMA Oncol*. *JAMA Oncol*. 2020 Mar 1;6(3):367-374. doi: 10.1001/jamaoncol.2019.4794.
192. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; **DESTINY-Breast01 Investigators**. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. *N Engl J Med*. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
193. Cobleigh M, Yardley DA, **Brufsky AM**, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Hurvitz SA, O'Shaughnessy J, Mason G, Antao V, Li H, Chu L, Jahanzeb M. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. *Clin Cancer Res*. 2020 Mar 1;26(5):1105-1113. doi: 10.1158/1078-0432.CCR-19-2350.
194. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; **CLEOPATRA study group**. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. *Lancet Oncol*. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. PMID: 32171426.
195. **Brufsky A**. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. *J Med Virol*. 2020 Jul;92(7):770-775. doi: 10.1002/jmv.25887. Epub 2020 Apr 27.

196. **Brufsky A**, Lotze MT. DC/L-SIGNs of hope in the COVID-19 pandemic. *J Med Virol*. 2020 May 6;10.1002/jmv.25980. doi: 10.1002/jmv.25980. Epub ahead of print. PMID: 32374430; PMCID: PMC7267543.
197. **Brufsky A**. Distinct viral clades of SARS-CoV-2: Implications for modeling of viral spread. *J Med Virol*. 2020 Apr 20;10.1002/jmv.25902. doi: 10.1002/jmv.25902. Epub ahead of print. PMID: 32311094; PMCID: PMC7264516.
198. Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delalogue S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bechuk J, Keyvanjah K, Bryce R, **Brufsky A**; NALA Investigators. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. *J Clin Oncol*. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17. PMID: 32678716; PMCID: PMC7499616.
199. Lundstrom K, Seyran M, Pizzol D, Adadi P, Mohamed Abd El-Aziz T, Hassan SS, Soares A, Kandimalla R, Tambuwala MM, Aljabali AAA, Kumar Azad G, Pal Choudhury P, Uversky VN, Sherchan SP, Uhal BD, Rezaei N, **Brufsky AM**. Viewpoint: Origin of SARS-CoV-2. *Viruses*. 2020 Oct 22;12(11): E1203. doi: 10.3390/v12111203. PMID: 33105685.
200. Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, **Brufsky A**, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L, Rugo HS, Tripathy D, Chan A; CONTROL Study Investigators. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. *Ann Oncol*. 2020 Sep;31(9):1223-1230. doi: 10.1016/j.annonc.2020.05.012. Epub 2020 May 25. PMID: 32464281.
201. Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, **Brufsky AM**, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. *Clin Cancer Res*. 2020 Jun 1;26(11):2546-2555. doi: 10.1158/1078-0432.CCR-19-2933. Epub 2020 Feb 7. PMID: 32034076.
202. **Brufsky A**, Marti JLG, Nasrazadani A, Lotze MT. Boning up: amino- bisphosphonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. *J Transl Med*. 2020 Jun 29;18(1):261. doi: 10.1186/s12967-020-02433-6. PMID: 32600410; PMCID: PMC7322393.
203. **Brufsky A**, Lotze MT. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic. *J Med Virol*. 2020 May 27;10.1002/jmv.26067. doi: 10.1002/jmv.26067. Epub ahead of print. PMID: 32458475; PMCID: PMC7283725.
204. Heng YJ, Hankinson SE, Wang J, Alexandrov LB, Ambrosone CB, de Andrade VP, **Brufsky AM**, Couch FJ, King TA, Modugno F, Vachon CM, Eliassen AH, Tamimi RM, Kraft P. The

Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network. *Cancer Epidemiol Biomarkers Prev.* 2020 Mar;29(3):599-605. doi: 10.1158/1055-9965.EPI-19-1087. Epub 2020 Jan 13. PMID: 31932411; PMCID: PMC7060119.

205. Tung NM, Robson ME, Venz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, **Brufsky A**, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. *J Clin Oncol.* 2020 Oct 29: JCO2002151. doi: 10.1200/JCO.20.02151. Epub ahead of print. PMID: 33119476.
206. Dhakal A, Antony Thomas R, Levine EG, **Brufsky A**, Takabe K, Hanna MG, Attwood K, Miller A, Houry T, Early AP, Soniwalla S, O'Connor T, Opyrchal M. Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. *Breast Cancer (Auckl).* 2020 Jul 23; 14:1178223420944864. doi: 10.1177/1178223420944864. PMID: 32753876; PMCID: PMC7378710.
207. Bhargava R, Esposito NN, O'Connor SM, Li Z, Turner BM, Moisini I, Ranade A, Harris RP, Miller DV, Li X, Moosavi H, Clark BZ, **Brufsky AM**, Dabbs DJ. Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study. *Mod Pathol.* 2020 Jul 13. doi: 10.1038/s41379-020-0620-2. Epub ahead of print. PMID: 32661297.
208. Jiang X, Wells A, **Brufsky A**, Shetty D, Shajihan K, Neapolitan RE. Leveraging Bayesian networks and information theory to learn risk factors for breast cancer metastasis. *BMC Bioinformatics.* 2020 Jul 10;21(1):298. doi: 10.1186/s12859-020-03638-8. PMID: 32650714; PMCID: PMC735063.
209. Bhargava R, Clark BZ, Carter GJ, **Brufsky AM**, Dabbs DJ. The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer. *Mod Pathol.* 2020 Aug;33(8):1563-1570. doi: 10.1038/s41379-020-0521-4. Epub 2020 Mar 17. PMID: 32203092; PMCID: PMC7384988.
210. Blohmer M, Zhu L, Atkinson JM, Beriwal S, Rodríguez-López JL, Rosenzweig M, **Brufsky AM**, Tseng G, Lucas PC, Lee AV, Oesterreich S, Jankowitz RC. Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology. *Breast Cancer Res.* 2020 Jun 26;22(1):70. doi: 10.1186/s13058-020-01309-3. PMID: 32586354; PMCID: PMC7318761.
211. Seyran M, Pizzol D, Adadi P, El-Aziz TMA, Hassan SS, Soares A, Kandimalla R, Lundstrom K, Tambuwala M, Aljabali AAA, Lal A, Azad GK, Choudhury PP, Uversky VN, Sherchan SP, Uhal BD, Rezaei N, **Brufsky AM**. Questions concerning the proximal origin of SARS-CoV-2. *J Med Virol.* 2021 Mar;93(3):1204-1206. doi: 10.1002/jmv.26478. Epub 2020 Dec 30. PMID: 32880995; PMCID: PMC7898912.

212. Smith SM, Boppana A, Traupman JA, Unson E, Maddock DA, Chao K, Dobesh DP, Brufsky A, Connor RI. Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. *J Med Virol.* 2021 Jan;93(1):409-415. doi: 10.1002/jmv.26227. Epub 2020 Jul 17. PMID: 32589756; PMCID: PMC7361926.
213. Seyran M, Takayama K, Uversky VN, Lundstrom K, Palù G, Sherchan SP, Attrish D, Rezaei N, Aljabali AAA, Ghosh S, Pizzol D, Chauhan G, Adadi P, Mohamed Abd El-Aziz T, Soares AG, Kandimalla R, Tambuwala M, Hassan SS, Azad GK, PalChoudhury P, Baetas-da-Cruz W, Serrano-Aroca Á, **Brufsky AM**, Uhal BD. The structural basis of accelerated host cell entry by SARS-CoV-2. *FEBS J.* 2021 Sep;288(17):5010-5020. doi: 10.1111/febs.15651. Epub 2020 Dec 14. PMID: 33264497; PMCID: PMC7753708.
214. Gomez Marti JL, Wells A, **Brufsky AM**. Dysregulation of the mevalonate pathway during SARS-CoV-2 infection: An in-silico study. *J Med Virol.* 2021 Apr;93(4):2396-2405. doi: 10.1002/jmv.26743. Epub 2020 Dec 29. PMID: 33331649.
215. Gomez Marti JL, **Brufsky AM**. Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway. *Expert Opin Pharmacother.* 2021 Jun;22(8):947-952. doi: 10.1080/14656566.2021.1897104. Epub 2021 Mar 11. PMID: 33703986; PMCID: PMC7967711.
216. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, **Brufsky A**, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. *N Engl J Med.* 2021 Apr22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PMID: 33882206.
217. Seyran M, Hassan SS, Uversky VN, Pal Choudhury P, Uhal BD, Lundstrom K, Attrish D, Rezaei N, Aljabali AAA, Ghosh S, Pizzol D, Adadi P, El-Aziz TMA, Kandimalla R, Tambuwala MM, Lal A, Azad GK, Sherchan SP, Baetas-da-Cruz W, PalùG, Brufsky AM. Urgent Need for Field Surveys of Coronaviruses in Southeast Asia to Understand the SARS-CoV-2 Phylogeny and Risk Assessment for Future Outbreaks. *Biomolecules.* 2021 Mar 9;11(3):398. doi: 10.3390/biom11030398. PMID: 33803118; PMCID: PMC7999587.
218. Deguchi S, Serrano-Aroca Á, Tambuwala MM, Uhal BD, **Brufsky AM**, Takayama K. SARS-CoV-2 research using human pluripotent stem cells and organoids. *Stem Cells Transl Med.* 2021 Jul 24. doi: 10.1002/sctm.21-0183. Epub ahead of print. PMID: 34302450.
219. Bender CM, Sereika SM, Gentry AL, Duquette JE, Casillo FE, Marsland A, **Brufsky AM**, Evans S, Gorantla VC, Grahovac TL, McAuliffe PF, Steiman JG, Zhu Y, Erickson KI. Physical activity, cardiorespiratory fitness, and cognitive function in postmenopausal women with breast cancer. *Support Care Cancer.* 2021 Jul;29(7):3743-3752. doi: 10.1007/s00520-020-05865-4. Epub 2020 Nov 19. PMID: 33210238; PMCID: PMC8131400.
220. Bhargava R, Esposito NN, O'Connor SM, Li Z, Turner BM, Moisini I, Ranade A, Harris RP, Miller DV, Li X, Moosavi H, Clark BZ, **Brufsky AM**, Dabbs DJ. Magee Equations™ and

response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study. *Mod Pathol.* 2021 Jan;34(1):77-84. doi: 10.1038/s41379-020-0620-2. Epub 2020 Jul 13. PMID: 32661297.

221. Serrano-Aroca Á, Takayama K, Tuñón-Molina A, Seyran M, Hassan SS, Pal Choudhury P, Uversky VN, Lundstrom K, Adadi P, Palù G, Aljabali AAA, Chauhan G, Kandimalla R, Tambuwala MM, Lal A, Abd El-Aziz TM, Sherchan S, Barh D, Redwan EM, Bazan NG, Mishra YK, Uhal BD, **Brufsky A**. Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era. *ACS Nano.* 2021 May 25;15(5):8069-8086. doi: 10.1021/acsnano.1c00629. Epub 2021 Apr 7. PMID: 33826850; PMCID: PMC8043205.
222. Albain KS, Gray RJ, Makower DF, Faghieh A, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Wood WC, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, **Brufsky AM**, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW, Sparano JA. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. *J Natl Cancer Inst.* 2021 Apr 6;113(4):390-399. doi: 10.1093/jnci/djaa148. PMID: 32986828.
223. Hassan SS, Lundstrom K, Barh D, Silva RJS, Andrade BS, Azevedo V, Choudhury PP, Palu G, Uhal BD, Kandimalla R, Seyran M, Lal A, Sherchan SP, Azad GK, Aljabali AAA, **Brufsky AM**, Serrano-Aroca Á, Adadi P, Abd El-Aziz TM, Redwan EM, Takayama K, Rezaei N, Tambuwala M, Uversky VN. Implications derived from S-protein variants of SARS-CoV-2 from six continents. *Int J Biol Macromol.* 2021 Sep 24; 191:934-955. doi: 10.1016/j.ijbiomac.2021.09.080. Epub ahead of print. PMID: 34571123; PMCID: PMC8462006.
224. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; **OlympiA Clinical Trial Steering Committee and Investigators**. Adjuvant Olaparib for Patients with BRCA1 or BRCA2 Mutated Breast Cancer. *N Engl J Med.* 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. PMID: 34081848.
225. Hassan SS, Aljabali AAA, Panda PK, Ghosh S, Attrish D, Choudhury PP, Seyran M, Pizzol D, Adadi P, Abd El-Aziz TM, Soares A, Kandimalla R, Lundstrom K, Lal A, Azad GK, Uversky VN, Sherchan SP, Baetas-da-Cruz W, Uhal BD, Rezaei N, Chauhan G, Barh D, Redwan EM, Dayhoff GW 2nd, Bazan NG, Serrano-Aroca Á, El-Demerdash A, Mishra YK, Palu G, Takayama K, **Brufsky AM**, Tambuwala MM. A unique view of SARS-CoV-2 through the lens of ORF8 protein. *Comput Biol Med.* 2021 Jun; 133:104380. doi: 10.1016/j.combiomed.2021.104380. Epub 2021 Apr 15. PMID:33872970; PMCID: PMC8049180.

226. Hassan SS, Attrish D, Ghosh S, Choudhury PP, Uversky VN, Aljabali AAA, Lundstrom K, Uhal BD, Rezaei N, Seyran M, Pizzol D, Adadi P, Soares A, Abd El- Aziz TM, Kandimalla R, Tambuwala MM, Azad GK, Sherchan SP, Baetas-da-Cruz W, Lal A, Palù G, Takayama K, Serrano-Aroca Á, Barh D, **Brufsky AM**. Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2. *Int J Biol Macromol*. 2021 Jun 30; 181:801-809. doi: 10.1016/j.ijbiomac.2021.03.199. Epub 2021 Apr 16. PMID: 33862077; PMCID: PMC8051021.
227. Bardia A, Hurvitz SA, Rugo HS, **Brufsky A**, Cortes J, Loibl S, Piccart M, Cowden J, Spears P, Carey LA. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. *Future Oncol*. 2021 Sep 1. doi: 10.2217/fon-2021-0868. Epub ahead of print. PMID: 34467774.
228. **Brufsky A**, Liu X, Li B, McRoy L, Layman RM. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice. *Target Oncol*. 2021 Sep;16(5):601-611. doi: 10.1007/s11523-021-00826-1. Epub 2021 Aug 2. PMID: 34338965; PMCID: PMC8484164.
229. Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; **IMpassion131 investigators**. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. *Ann Oncol*. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1. PMID: 34219000.
230. Khanam R, Fanous IS, Fadhel EN, Hyder T, **Brufsky A**. Voltage-Gated Calcium Channel Antibody-Induced Oropharyngeal Dysphagia Presenting as a Paraneoplastic Neurological Complication in Breast Cancer. *Cureus*. 2021 Mar 3;13(3): e13677. doi: 10.7759/cureus.13677. PMID: 33824828; PMCID: PMC8012257.
231. **Brufsky A**, Kim SB, Zvirbule Ž, Eniu A, Mebis J, Sohn JH, Wongchenko M, Chohan S, Amin R, Yan Y, McNally V, Miles D, Loi S. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. *Ann Oncol*. 2021 May;32(5):652-660. doi: 10.1016/j.annonc.2021.01.065. Epub 2021 Feb 1. PMID: 33539944.
232. Hurvitz SA, Saura C, Oliveira M, Trudeau ME, Moy B, Delaloge S, Gradishar W, Kim SB, Haley B, Ryvo L, Dai MS, Milovanov V, Alarcón J, Kalmadi S, Cronemberger E, Souza C, Landeiro L, Bose R, Bebhuk J, Kabbinavar F, Bryce R, Keyvanjah K, **Brufsky AM**. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. *Oncologist*. 2021 Aug;26(8):e1327-e1338. doi: 10.1002/onco.13830. Epub 2021 Jun 7. PMID: 34028126; PMCID: PMC8342591.
233. Roussos Torres ET, Rafie C, Wang C, Lim D, **Brufsky A**, LoRusso P, Eder JP, Chung V, Downs M, Geare M, Piekarz R, Streicher H, Anforth L, Rudek MA, Zhu Q, Besharati S, Cimino-

Mathews A, Anders RA, Stearns V, Jaffee EM, Connolly RM. Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). *Clin Cancer Res.* 2021 Jun 16. doi: 10.1158/1078-0432.CCR-20-5017. Epub ahead of print. PMID: 34135021.

234. Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, **Brufsky A**, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A. Clinical Outcomes with Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. *J Natl Compr Canc Netw* 2021 Mar 24;1-8. doi: 10.6004/jnccn.2020.7662. Epub ahead of print. PMID:33761455.
235. Mamounas EP, Untch M, Mano MS, Huang CS, Geyer CE Jr, von Minckwitz G, Wolmark N, Pivot X, Kuemmel S, DiGiovanna MP, Kaufman B, Kunz G, Conlin AK, Alcedo JC, Kuehn T, Wapnir I, Fontana A, Hackmann J, Polikoff J, Saghatchian M, **Brufsky A**, Yang Y, Zimovjanova M, Boulet T, Liu H, Tesarowski D, Lam LH, Song C, Smitt M, Loibl S. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. *Ann Oncol.* 2021 Aug;32(8):1005-1014. doi: 10.1016/j.annonc.2021.04.011. Epub 2021 Apr 28. PMID: 33932503.
236. Rugo HS, Cristofanilli M, Loibl S, Harbeck N, DeMichele A, Iwata H, Park YH, **Brufsky A**, Theall KP, Huang X, McRoy L, Bananis E, Turner NC. Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. *Oncologist.* 2021 Aug;26(8): e1339-e1346. doi: 10.1002/onco.13833. Epub 2021 Jun 12. PMID: 34037282; PMCID: PMC8342589.
237. DeMichele A, Cristofanilli M, **Brufsky A**, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS. Comparative effectiveness of first line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. *Breast Cancer Res.* 2021 Mar 24;23(1):37. doi: 10.1186/s13058-021-01409-8. PMID: 33761995; PMCID: PMC7989035.
238. Moy B, Oliveira M, Saura C, Gradishar W, Kim SB, **Brufsky A**, Hurvitz SA, Ryvo L, Fagnani D, Kalmadi S, Silverman P, Delaloge S, Alarcon J, Kwong A, Lee KS, Ang PCS, Ow SGW, Chu SC, Bryce R, Keyvanjah K, Bebachuk J, Zhang B, Oestreich N, Bose R, Chan N. Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens. *Breast Cancer Res Treat.* 2021 Jul;188(2):449-458. doi: 10.1007/s10549-021-06217-4. Epub 2021 Apr 28. PMID: 33909203; PMCID: PMC8260518.
239. Kaufman PA, Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, **Brufsky AM**, Rugo HS, Cobleigh M, Swain SM, Tripathy D, Morris A, Antao V, Li H, Jahanzeb M. Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. *Breast Cancer Res Treat.* 2021 Jul;188(1):179-190. doi: 10.1007/s10549-021-06103-z. Epub 2021 Feb 28. PMID: 33641083.

240. Paterson AHG, Lucas PC, Anderson SJ, Mamounas EP, **Brufsky A**, Baez-Diaz L, King KM, Lad T, Robidoux A, Finnigan M, Sampayo M, Tercero JC, Mairret JJ, Wolff AC, Fehrenbacher L, Wolmark N, Gomis RR. MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice. *JNCI Cancer Spectr.* 2021 May 28;5(4): pkab054. doi:10.1093/jncics/pkab054. PMID: 34377934; PMCID: PMC8346694.
241. Carleton N, Zou J, Fang Y, Koscumb SE, Shah OS, Chen F, Beriwal S, Diego EJ, **Brufsky AM**, Oesterreich S, Shapiro SD, Ferris R, Emens LA, Tseng G, Marroquin OC, Lee AV, McAuliffe PF. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women with Early-Stage, Estrogen Receptor-Positive Breast Cancer. *JAMA Netw Open.* 2021 Apr 1;4(4): e216322. doi: 10.1001/jamanetworkopen.2021.6322. PMID: 33856473; PMCID: PMC8050744.
242. **Brufsky A**, Liu X, Li B, McRoy L, Layman RM. Correction to Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice. *Target Oncol.* 2021 Nov;16(6):865. doi: 10.1007/s11523-021-00847-w. PMID: 34652714.
243. Gomez Marti JL, **Brufsky A**, Wells A, Jiang X. Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer. *Cancers (Basel).* 2022 Jan 5; 14(1):253. doi: 10.3390/cancers14010253. PMID: 35008417.
244. Ganz PA, Bandos H, Geyer CE Jr, Robidoux A, Paterson AHG, Polikoff J, Baez-Diaz L, **Brufsky AM**, Fehrenbacher L, Parsons AW, Ward PJ, Provencher L, Hamm JT, Stella PJ, Carolla RL, Margolese RG, Shibata HR, Perez EA, Wolmark N. Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer. *Breast Cancer Res Treat.* 2022 Feb;192(1):153-161. PMID: 35112166 Clinical Trial.
245. Nasrazadani A, Marti JLG, Kip KE, Marroquin OC, Lemon L, Shapiro SD, **Brufsky AM**. Breast cancer mortality as a function of age. *Aging (Albany NY).* 2022 Feb 8;14(3):1186-1199. PMID: 35134749.
246. Law JW, Mitra D, Kaplan HG, Alfred T, **Brufsky AM**, Emir B, McCracken H, Liu X, Broome RG, Zhang C, DiCristo C, Chen C. Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network. *Curr Oncol.* 2022 Feb 12;29(2):1047-1061. PMID: 35200588.
247. Hassan SS, Choudhury PP, Dayhoff GW 2nd, Aljabali AAA, Uhal BD, Lundstrom K, Rezaei N, Pizzol D, Adadi P, Lal A, Soares A, Mohamed Abd El-Aziz T, **Brufsky AM**, Azad GK, Sherchan SP, Baetas-da-Cruz W, Takayama K, Serrano-Aroca A, Chauhan G, Palu G, Mishra YK, Barh D, Santana Silva RJ, Andrade BS, Azevedo V, Goes-Neto A, Bazan NG, Redwan EM, Tambuwala M, Tambuwala M, Uversky VN. The importance of accessory protein variants in

the pathogenicity of SARS-CoV-2. Arch Biochem Biophys. 2022 Mar 15; 717:109124. PMID: 35085577.

248. Hassan SS, Kodakandla V, Redwan EM, Lundstrom K, Pal Choudhury P, Abd El-Aziz TM, Takayama K, Kandimalla R, Lal A, Serrano-Aroca A, Azad GK, Aljabali AAA, Palu G, Chauhan G, Adadi P, Tambuwala M, **Brufsky AM**, Baetas-da-Cruz W, Barh D, Azevedo V, Bazan NG, Andrade BS, Santana Silva RJ, Uversky VN. An issue of concern: unique truncated ORF8 protein variants of SARS-CoV-2. PeerJ. 2022 Mar 21;10e13136. PMID: 35241060.
249. Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA, **DESTINY-Breast03 Trial Investigators**. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022 Mar 24;386(12):1143-1154. PMID: 35320644 Clinical Trial.
250. Srivastava P, Wang T, Clark BZ, Yu J, Fine JL, Villatoro TM, Carter GJ, **Brufsky AM**, Gorantla VC, Huggins-Puhalla SL, Emens LA, Basili T, da Silva EM, Reis-Filho JS, Bhargava R. Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers. NPJ Breast Cancer. 2022 Apr 20;8(1):51. PMID: 35444182.
251. Peddi PF, Fasching PA, Liu D, Quinaux E, Robert NJ, Valero V, Crown J, Falkson C, **Brufsky A**, Cunningham JM, Weinshilboum RM, Pienkowski T, Eiermann W, Martin M, Bee V, Wang X, Wang L, Yang E, Slamon DJ, Hurvitz SA. Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. Clin Cancer Res. 2022 May 2;28(9):1854-1862. PMID: 35110416.
252. Geyer CE Jr, Bandos H, Rastogi P, Jacobs SA, Robidoux A, Fehrenbacher L, Ward PJ, Polikoff J, **Brufsky AM**, Provencher L, Paterson AHG, Hamm JT, Carolla RL, Baez-Diaz L, Julian TB, Swain SM, Mamounas EP, Wolmark N. Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). Breast Cancer Res Treat. 2022 Jun;193(3):555-564. PMID: 35230585.
253. Geyer CE Jr, Bandos H, Rastogi P, Jacobs SA, Robidoux A, Fehrenbacher L, Ward PJ, Polikoff J, **Brufsky AM**, Provencher L, Paterson AHG, Hamm JT, Carolla RL, Baez-Diaz L, Julian TB, Swain SM, Mamounas EP, Wolmark N. Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). Breast Cancer Res Treat. 2022 Jun;193(3):565. PMID: 35507135.
254. **Brufsky A**, Liu X, Li B, McRoy L, Layman RM. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis. Front Oncol. 2022 Jul 4; 12:865292. PMID: 35860587.

255. Patt D, Liu X, Li B, McRoy L, Layman RM, **Brufsky A**. Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis. *Clin Breast Cancer*. 2022 Aug;22(6):601-610. PMID: 35643624.
256. O'Shaughnessy J, **Brufsky A**, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortes J. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of Sacituzumab Govitecan in metastatic triple-negative breast cancer. *Breast Cancer Res Treat*. 2022 Sept;195(2):127-139. PMID: 35545724.
257. Rugo HS, **Brufsky A**, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. *NPJ Breast Cancer*. 2022 Oct 11;8(1):114. PMID: 36220852.
258. Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmana J, Bergh J, Bliss J, Delalogue S, Domcheck SM, Eisen A, Elsayf F, Fen LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Johannsson OP, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marme F, Martinez de Duenas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Spanic T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, **Brufsky AM**, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ, OlympiA Clinical Trial Steering committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. *Ann Oncol*. 2022 Oct 10; S0923-7594(22)04165-5. PMID: 36228963.

Review Articles, Books, Monographs, Invited Editorials:

1. **Brufsky A**. Analysis of genetic mutations of type I collagen in human heritable diseases of bone. Ph.D. Thesis, University of Connecticut School of Medicine, 1990.
2. Haluska F, **Brufsky A**, Canellos G. The cellular biology of the Reed-Sternberg cell. *Blood* 1994; 84 (4):1005–19.
3. **Brufsky A**, Kantoff P. Hormonal therapy for prostate cancer. In: Ernstoff MS, Heaney JA, Peschel RE (eds.), *Urologic Cancer*, Cambridge: Blackwell Science Inc., 1997, 160-180.
4. **Brufsky A**, Vogel V. Is there a role for intensive chemotherapy with stem cell support for the treatment of breast cancer: the Williams article reviewed. *Oncology* 2002; 13(12) 73-80. (First Author)

5. **Brufsky A.** Zoledronic acid for cancer therapy–induced and postmenopausal bone loss. *Exp Opin Pharm* 2008; 9(6): 1013-28 (First Author)
6. Puhalla S, **Brufsky A.** Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer. *Biologics* 2008; 2(3): 505-515. (Senior Author)
7. Chivakula M, **Brufsky A,** Davidson NE. Small beginnings: do they matter? The importance of lymphovascular invasion in early breast cancer. *J Natl Cancer Inst* 2009; 101(10) 698-699.
8. Puhalla S, **Brufsky A.** Bevacizumab in breast cancer; the best is yet to come? *Oncology* 2009; 23(4): 143-152. (Senior Author)
9. Puhalla S, **Brufsky A,** Davidson N. Adjuvant endocrine therapy for premenopausal women with breast cancer. *Breast* 2009 Oct; 18 Suppl 3:S122-30.
10. **Brufsky A.** First-line treatment of metastatic breast cancer: current strategies and emerging systemic therapies. *Comm Oncol* 2010; 7(3): 115-123. (First Author)
11. Reeder JG, **Brufsky AM.** The role of bisphosphonates in the adjuvant setting for breast cancer. *Oncology* 2010; 24(6): 462-475. (Senior Author)
12. **Brufsky AM.** The evolving role of bone-conserving therapy in patients with breast cancer. *Semin Oncol* 2010; 37(Suppl 11): S12-S19. (First Author)
13. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, **Brufsky AM,** Clézardin P, Croucher PI, Galow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: Advancing treatment and prevention. *Cancer Treat Rev* 2010; 36(8): 615-620.
14. **Brufsky A.** Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. *Am J Clin Oncol* 2010; 33(2): 186-95. (First Author)
15. Guise TA, **Brufsky A,** Coleman RE. Understanding and optimizing bone health in breast cancer. *Curr Med Res Opin.* 2010; 26(Suppl 3): 3-20.
16. **Brufsky A.** Adjuvant bisphosphonates for early-stage breast cancer. *Lancet Oncol.* 2011; 12(7): 610-1. (First Author)
17. Soran A, Finegold DN, **Brufsky A.** Lymphedema prevention and early intervention: a worthy goal. *Oncology (Williston Park).* 2012; 26(3): 249, 254-256. (Senior Author)
18. Jankowitz R, **Brufsky AM.** Adjuvant Treatment of HER2-Positive Breast Cancer: Winning Efforts Continue to Improve HER2-Positive Patient Outcome Long-term. *Breast Cancer Res.* 2012 Apr 30;14(2): 308. (Senior Author)

19. Hadji P, Gnant M, Body JJ, Bundred NJ, **Brufsky A**, Coleman RE, Guise TA, Lipton A, Aapro MS. Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention? *Cancer Treat Rev* 2012 Oct; 38(6):798-806.
20. Bhargava R, **Brufsky AM**, Davidson NE. Prognostic/Predictive immunohistochemistry assays for estrogen receptor-positive breast cancer: back to the future? *J Clin Oncol*. 2012; 30(36):4451-3.
21. Mehta AI, **Brufsky AM**, Sampson JH. Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood-brain barrier. *Cancer Treat Rev*. 2013; 39(3): 261-9.
22. **Brufsky A**. Precision oncology in breast cancer: better than ever, or less than before? *Breast J*. 2013; 19(4): 355-6.
23. Van Londen G, Beckjord EB, Dew MA, Cuijpers P, Tadic S, **Brufsky A**. Breast Cancer survivorship symptom management: Current perspective and future development. *Breast Cancer Management* 2013; 2(1): 71-81.
24. Puhalla S, **Brufsky A**. Treatment of HER2-positive breast cancer: looking backwards briefly. *Lancet Oncol*. 2013 Dec; 14(13): 1250-1.
25. Oesterreich S, **Brufsky AM**, Davidson NE. Using mice to treat (wo)men: mining genetic changes in patient xenografts to attack breast cancer. *Cell Rep*. 2013 Sep 26;4(6):1061-2.
26. Mathew A, **Brufsky A**. The bone substudy of MA27: does bone make a difference? *Lancet Oncol* 2014; 15(4): 375-377.
27. **Brufsky AM**. Predictive and Prognostic Value of the 21-Gene Recurrence Score in Hormone Receptor-positive, Node-positive Breast Cancer. *Am J Clin Oncol*. 2014; 37(4): 404-10.
28. **Brufsky AM**. Managing Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer Who Progress on Endocrine Therapies with Inhibitors of the PI3K Pathway. *Breast J*. 2014 Jul; 20(4): 347-57.
29. Mathew A, **Brufsky A**. Breast cancer: Zoledronic acid-more than just a bone drug. *Nat Rev Clin Oncol*. 2014 Oct;11(10): 564-5.
30. **Brufsky AM**. Current Approaches and Emerging Directions in HER2-resistant breast cancer. *Breast Cancer (Auckl)*. 2014; 8:109-18.
31. **Brufsky AM**. Length of chemotherapy and use of bevacizumab for breast cancer. *Lancet Oncol* 2014 15: 1285-1287.
32. Mathew A, **Brufsky AM**. The use of adjuvant bisphosphonates in the treatment of early-stage breast cancer. *Clin Adv Hematol Oncol*. 2014;12(11):749-56.

33. Mathew A, **Brufsky A**. Bisphosphonates in breast cancer: a triple winner? *Oncology*. 2015; 29(1): 37-9.
34. Mathew A, **Brufsky A**. Bisphosphonates in breast cancer. *Int J Cancer*. 2015; 137(4): 753-64.
35. Mathew A, **Brufsky A**. Bisphosphonates do not reduce breast cancer in postmenopausal women. *Ann Intern Med*. 2015; 162(2): JC5.
36. Mathew A, **Brufsky AM**, Davidson NE. Can circulating tumor cells predict resistance in metastatic breast cancer? *Clin Cancer Res*. 2015; 21(11): 2421-3.
37. **Brufsky AM**. Some Excitement, Some Disappointment. *Oncology*. 2015; 29(7): 494-5.
38. **Brufsky A**, Mathew A. Bisphosphonates, bone, and breast cancer recurrence. *Lancet*. 2015; 386 (10001): 1319-20.
39. **Brufsky AM**. Delaying chemotherapy in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. *Clin Med Insights Oncol*. 2015; 9:137-47.
40. Sgroi DC, **Brufsky A**. Biomarkers for early-stage breast cancer: clinical utility for extended adjuvant treatment decisions. *J Clin Oncol*. 2016 Aug 22. [Epub ahead of print]
41. **Brufsky AM**, Davidson NE. Multiparametric genomic assays for breast cancer: time for the next generation? *Clin Cancer Res*. 2016 Oct 15;22(20):4963-4965.
42. **Brufsky A**. Is there room for bevacizumab in metastatic breast cancer? *Lancet Oncol*. 2016 Sep;17(9):1175-6.
43. **Brufsky A**. *nab*-Paclitaxel for the treatment of breast cancer: an update across treatment settings. *Exp Hematol Oncol*. 2017; 6:7.
44. Mathew A, **Brufsky A**. Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer. *Lancet Oncol*. 2017 Apr; 18(4): 428-429.
45. Mathew A, **Brufsky A**. TACT2: improving treatment tolerability in early breast cancer. *Lancet Oncol*. 2017 Jul;18(7):843-845.
46. **Brufsky AM**, Dickler MN. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. *Oncologist*. 2018 May;23(5):528-539.
47. Beckwitt CH, **Brufsky A**, Oltvai ZN, Wells A. Statin drugs to reduce breast cancer recurrence and mortality. *Breast Cancer Res*. 2018 Nov 20;20(1):144.
48. Klar N, **Brufsky A**. Extended adjuvant therapy for early-stage breast cancer: Are there markers for its use? *Breast J*. 2019 Jan;25(1):7-8.

49. Nasrazadani A, **Brufsky AM**. CDK4/6 inhibitors: taking the place of chemotherapy? *Lancet Oncol*. 2019 Oct; 20(10):1329-1330
50. Nasrazadani A, **Brufsky AM**. Artificial intelligence-directed prognostication of breast cancer. *EBioMedicine*. 2019 Aug; 46:6-7.
51. **Brufsky A**, Mathew A. Adjuvant bisphosphonate therapy in early-stage breast cancer-Treating the soil to kill the seed. *Breast J*. 2020 Jan;26(1):65-68. Doi 10.1111/tbj.13730. Epub 2019 Dec 26. PMID: 31876101.
52. Nasrazadani A, **Brufsky A**. Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis. *Future Oncol*. 2020 Mar;16(7):247-254. doi: 10.2217/fo-2019-0719. Epub 2020 Feb 14. PMID: 32057254.
53. Nasrazadani A, **Brufsky AM**. Capivasertib inhibits a key pathway in metastatic breast cancer. *Lancet Oncol*. 2020 Mar;21(3):318-319. doi: 10.1016/S1470-2045(19)30857-5. Epub 2020 Feb 5. PMID: 32035019.
54. Marti JLG, Hyder T, Nasrazadani A, **Brufsky AM**. The Evolving Landscape of HER2-Directed Breast Cancer Therapy. *Curr Treat Options Oncol*. 2020 Aug 7;21(10):82. doi: 10.1007/s11864-020-00780-6. PMID: 32767149.
55. Soran A, Özbaş S, Doğan L, Sezgin E, Özmen V, Beriwal S, **Brufsky A**. Loco- Regional Treatment for Intact Primary Tumor in Patient with De Novo Metastatic Breast Cancer; Comments and Concerns of ECOG-ACRIN 2108 Trial. *Eur J Breast Health*. 2020 Jun 8;16(3):158-159. doi: 10.5152/ejbh.2020.080620. PMID: 32656512; PMCID: PMC7337916.
56. **Brufsky A**, Mathew A. Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter? *J Natl Cancer Inst*. 2020 Jul 1;112(7):659-660. doi: 10.1093/jnci/djz216. PMID: 31693134; PMCID: PMC7357314.
57. Brewer J, Gomez Marti JL, **Brufsky A**. Potential interventions for SARS-CoV-2 infections: Zinc showing promise. *J Med Virol*. 2021 Mar;93(3):1201-1203. doi: 10.1002/jmv.26523. Epub 2020 Oct 5. PMID: 32940918.
58. Hyder T, Marino CC, Ahmad S, Nasrazadani A, **Brufsky AM**. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management. *Front Endocrinol (Lausanne)*. 2021 Jul 27; 12:713700. doi:10.3389/fendo.2021.713700. PMID: 34385978; PMCID: PMC8353230.
59. Lundstrom K, Barh D, Uhal BD, Takayama K, Aljabali AAA, Abd El-Aziz TM, Lal A, Redwan EM, Adadi P, Chauhan G, Sherchan SP, Azad GK, Rezaei N, Serrano-Aroca Á, Bazan NG, Hassan SS, Panda PK, Pal Choudhury P, Pizzol D, Kandimalla R, Baetas-da-Cruz W, Mishra YK, Palu G, **Brufsky AM**, Tambuwala MM, Uversky VN. COVID-19 Vaccines and Thrombosis-Roadblock or Dead-End Street? *Biomolecules*. 2021 Jul 13;11(7):1020. doi: 10.3390/biom11071020. PMID: 34356644; PMCID: PMC8301964.

60. Gomez Marti JL, Nasrazadani A, **Brufsky AM**. Ovarian function suppression as a potential mechanism of chemotherapy. *EBioMedicine*. 2021 Aug; 70: 103489. doi:10.1016 /j.ebiom.2021.103489. Epub 2021 Jul 16. PMID: 34280778; PMCID: PMC8318981.
61. Redwan EM, Alghamdi MF, El-Aziz TMA, Adadi P, Aljabali AAA, Attrish D, Azad GK, Baetas-da-Cruz W, Barh D, Bazan NG, **Brufsky AM**, Chauhan G, Hassan SKS, Kandimalla R, Lal A, Lundstrom K, Mishra YK, Choudhury PP, Palù G, Panda PK, Pizzol D, Rezaei N, Serrano-Aroca Á, Sherchan SP, Seyran M, Takayama K, Tambuwala MM, Uhal BD, Uversky VN. The mechanism behind flaring/triggering of autoimmunity disorders associated with COVID-19. *Autoimmun Rev*. 2021 Oct;20(10):102909. doi: 10.1016/j.autrev.2021.102909. Epub 2021 Jul 16. PMID: 34274539; PMCID: PMC8282442.
62. Hyder T, Bhattacharya S, Gade K, Nasrazadani A, **Brufsky AM**. Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer. *Breast Cancer (Dove Med Press)*. 2021 Mar 30; 13:199-211. doi: 10.2147/BCTT.S273058. PMID: 33833568; PMCID: PMC8019614.
63. Carleton N, Nasrazadani A, Gade K, Beriwal S, Barry PN, **Brufsky AM**, Bhargava R, Berg WA, Zuley ML, van Londen GJ, Marroquin OC, Thull DL, Mai PL, Diego EJ, Lotze MT, Oesterreich S, Lee AV. Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women. *Lancet Healthy Longev*. 2022 Jan;3(1): e54-e66. doi: 10.1016/s2666-7568(21)00280-4. Epub 2022 Jan 2022 Jan 5. PMID: 35047868.

Published Abstracts:

1. **Brufsky A**, Stover M, Shapiro J, Rowe D. Rapid characterization and sequencing of an unusual RNA splicing mutation in a human genetic disease of bone. American Society for Bone and Mineral Research, 10th Annual Meeting, New Orleans LA, June 4–7, 1988.
2. Rowe DW, **Brufsky A**, Stover M, McKinstry M, Angilly J, Shapiro J. Localization and identification of mutations within the COL1A1 gene in patients with osteogenesis imperfecta by analysis of the pro alpha 1(I) collagen mRNA. New York Academy of Sciences Annual Meeting, April 10–17, 1989.
3. **Brufsky A**, Malchoff D, Javier E, Rowe D, Reardon G, Malchoff CD. Primary cortisol resistance associated with a molecular defect of the steroid binding region of the human glucocorticoid receptor. 26th Annual National Medical Student Research Forum, Galveston TX, April 19–21, 1990.
4. **Brufsky A**, Malchoff D, Javier E, Reardon G, Rowe D, Malchoff CD. A glucocorticoid receptor mutation in a subject with primary cortisol resistance. Association of American Physicians Annual Meeting, Washington DC, June 4–7, 1990.
5. McDermott P, Malchoff DM, **Brufsky A**, Javier E, Reardon G, Malchoff CD. A mutation of the human glucocorticoid receptor may cause primary cortisol resistance. 73d Annual Meeting of The Endocrine Society, Washington D.C., June 19–22, 1991.

6. Malchoff DM, **Brufsky A**, Hart P, Malchoff CD. The function of the human glucocorticoid receptor is altered by minor changes of amino acid 729: the mutation site in a subject with primary cortisol resistance. 74th Annual Meeting of The Endocrine Society, San Antonio TX, June 24–27 1992.
7. **Brufsky A**, Fontaine P, Berlane K, Kaplan, I, and Kantoff P. Finasteride and flutamide as androgen ablative therapy for advanced prostate cancer. 64th Annual Meeting of the New England Section, American Urological Association, Newport, RI, September 15-17, 1995.
8. **Brufsky A**, Fontaine-Rothe P, Berlane K, Kaplan I, and Kantoff P. Finasteride and flutamide as potency sparing androgen ablative therapy for advanced adenocarcinoma of the prostate. Proc Am Soc Clin Oncol 1996; 15:252 (abstr 645).
9. Trump DL, Smith D, Getzenberg R, **Brufsky A**, and Johnson C. 1, 25 dihydroxy vitamin D (D3): Clinical investigations of its use as a single agent and in combination in the therapy of advanced prostate cancer. Seventh Prout's Neck Meeting on Prostate Cancer: Biology and Treatment of Metastasis, October 17-20, 1996, Prout's Neck, ME.
10. Trump D, **Brufsky A**, Hofacker J, Branch R, Muindi J, Wilson J, and Adedoyin A. Enhancing systemic exposure to all-transretinoic acid (ATRA): Can response rate in prostate cancer be increased? Proc Am Assoc Can Res 1997; 38:600 (abstr 4032).
11. Oh W, **Brufsky A**, Hewitt H, Fontaine-Rothe P, Jiroutek M, Kaplan I, Kaufman D, Kantoff P. Secondary hormonal responses after initial peripheral androgen ablation therapy (AAT) with finasteride and flutamide in advanced prostate cancer (CAP). Proc Am Soc Clin Oncol 1998; 17:338a (abstr 1303).
12. Kaufman D, Kantoff P, Jacobsen J, Oh W, Elson G, **Brufsky A**, Smith M. Phase II trial of toremifene for androgen-independent prostate cancer. Proc Am Soc Clin Oncol 1999; 18:343a (abstr 1322).
13. Faul C, **Brufsky A**, Jacob H, Vogel V, Goertzen K. Concurrent CMF chemotherapy and external beam radiation as adjuvant therapy for early-stage breast cancer: toxicity and efficacy in a series of 120 patients. Proc ECCO, 1999.
14. Winters SJ, **Brufsky A**, Weissfeld J, Trump DL. Increased total testosterone and SHBG levels in young adult African American men. ENDO 2000 The Endocrine Society 82nd Annual Meeting, Atlanta, GA.
15. Trump DL, Serafine S, **Brufsky A**, Muindi J, Bernardi RJ, Potter D, Johnson CS. The effects of high dose 1, 25 dihydroxycholecalciferol (calcitriol) + dexamethasone in hormone refractory prostate cancer. Eleventh Workshop on Vitamin D, Nashville, TN, May 27-June 1, 2000.
16. Patrick AL, Bunker CH, **Brufsky AM**, Dhir R, Becich MJ. Preliminary screening results

suggest high prevalence of prostate cancer in Tobago. Caribbean Medical Research Council, Barbados, April 2000.

17. Patrick AL, Bunker CH, **Brufsky AM**, Konety BR, Vivas CA, Dhir R, Becich MJ, Trump DL, Kuller LH. Positive predictive value (PPV) of prostate specific antigen (> 4 ng/ml) and abnormal digital rectal exam for prostate cancer on the Caribbean Island of Tobago. *W Ind Med J*, 2000; 49(suppl 2):35.
18. Konety BR, Bunker CH, Krill D, Patrick AL, Vivas C, Wagner T, Dhir R, **Brufsky A**, Bartoletta R, Trump DL, Kuller LH, Becich MJ. Comparison of the features of prostate cancer diagnosed in the United States and in an Afro-Caribbean population. *J Urol* 2000; 163(suppl):56.
19. Trump DL, Serafine S, **Brufsky A**, Muindi J, Bernard R, Potter D, Johnson C. High dose calcitriol (1, 24(OH))₂ Vitamin D₃ + dexamethasone in androgen independent prostate cancer (AIPC). *Proc Am Assoc Can Res* 2000; 19:337a (abstr 1327).
20. Trump DL, Serafine S, **Brufsky A**, Muindi J, Bernardi R, Potter D, Johnson C. High Dose Calcitriol (1,25(OH)₂ Vitamin D₃) + Dexamethasone in Androgen Independent Prostate Cancer (AIPC). *Proc ASCO* 2000; 1327a.
21. **Brufsky A**, Heidrich E, Farrell R, McCarty K, Peters D. Analysis of differential gene expression in lymph node metastases of primary breast cancer. *Ann Oncol* 2000; 11 (4Supp): 11.
22. **Brufsky A**, Lebish J, Shanahan C, Dyky M-A, Jacobs S, Stoller R, Baar J, Kim H, Kane K, Belani C. Phase II Trials of Carboplatin/Docetaxel and Carboplatin/Docetaxel/Traztuzumab as First Line Therapy for Metastatic Breast Cancer. *Br Ca Treat Res* 2000; 15: 321a.
23. Trump D, Egorin M, Ramanathan R, Polakowski S, Jacobs S, **Brufsky A**, Mason-Liddil N, Kopit J, Bello A, Gupta E, Ogan M, Zeng J-N, LaCreta F, Hansel S, Perrone R, Rose W, Daniels R, Palme H, Griffin T, Malik R. A Novel Oral Taxane (BMS-275183): A Phase I Trial with Evaluation of Pharmacokinetics, Pharmacodynamics and Bioavailability. *Proc ASCO* 2001; 20: 433a.
24. Hwang J, Sinicrope F, Safran H, Earle M, Wong M, **Brufsky A**, Warnick E, Troetschel M, Ramanathan R. A Phase II Trial of Irinotecan and Trastuzumab (Herceptin®) in Patients (Pts) Overexpressing HER-2/neu in Metastatic Colorectal Cancer (CRC). *Proc ASCO* 2001; 20: 565a.
25. Buss MK, Galen E, Switzer G, Alexander C, **Brufsky AM**, Arnold RM. House staff Education on End of Life Issues. *Proc ASCO* 2001; 20: 1608a.
26. Garrott DA, Manning B, Friedman C, Day RS, **Brufsky A**, Shirey W. Preliminary evaluation of the OncoTCAP computer simulation of phase II clinical trial protocols for medical students. American Association for Cancer Education 35th Annual Meeting, October 18-21, 2001.

27. Day RS, Shirey W, Garrott D, **Brufsky A**, Baar J, Friedman C, Manning B. Broad Issues in Simulation-Based Computer Education: Lessons Learned from Experience. American Association for Cancer Education 35th Annual Meeting, October 18-21, 2001.
28. Gertzen K, Herron D, **Brufsky A**. Concurrent bisphosphonate and Samarium-153 for the treatment of osseous metastases in metastatic breast cancer. European Breast Cancer Conference, Barcelona Spain, March 2002.
29. **Brufsky A**, Matin K, Baar J, Cleary D, Lebish J, Jacobs S, Belani C. A phase II study of carboplatin and docetaxel as first line chemotherapy in metastatic breast cancer. Proc ASCO 2002; 21: 2020a.
30. Rosenzweig P, Bender K, Lucke J, Yasko J, **Brufsky A**. Increased thrombotic events in a clinical trial of Erythropoetin (EPO) in metastatic breast cancer. Proc ASCO 2002; 21: 1522.
31. Rastogi P, **Brufsky A**, Landsittel D, Wieand HS, Coppelli F, Vogel V. Differences in cardiac ejection fractions for breast cancer patients treated with doxorubicin or trastuzumab. Proc ASCO 2002; 21: 262a.
32. Trump DL, Egorin MJ, Ramanathan R, Capozzoli MJ, Polakowski S, Wong M, Fakih M, Stoller R, Jacobs S, **Brufsky A**, Mason-Liddil N, Kopit J, Bello A, Gupta E, Ogan M, Zeng J, LaCreta M, Hansel S, Perrone R, Rose W, Tubertini R, Palme T, Griffin T, Malik R. A new oral taxane (BMS-275183): phase I trial with evaluation of pharmacokinetics, pharmacodynamics and bioavailability. Proc ASCO 2002; 21: 398a.
33. Limentani S, Jahanzeb M, **Brufsky AM**, Lewis DA. Neoadjuvant treatment of women with breast cancer utilizing docetaxel and vinorelbine with growth factor support. Proc ASCO 2002; 21: 1939a.
34. Limentani SA, **Brufsky AM**, Jahanzeb M, Erban JK, Kneuper-Hall R, Lewis D. Neoadjuvant treatment of women with breast cancer utilizing docetaxel and vinorelbine with growth factor support. Br Ca Treat Res 17:162a.
35. **Brufsky A**, Cleary D, Jacobs S, Baar J, Belani C. First-line chemotherapy for metastatic breast cancer (MBC) with docetaxel (T), carboplatin (C), and trastuzumab (H) (TCH) : a phase II trial. Proc ASCO 2003; 22:71a.
36. Hergenroeder P, Peters D, Handley D, Dabbs D, **Brufsky A**. Towards a genetic signature of lymph node positive breast cancer. Proc ASCO 2003; 22:3483a.
37. Oh W, Manola J, Bittman L, **Brufsky A**, Kaplan I, Kaufman D, Kantoff P. Effect of castration after failure of finasteride and flutamide therapy in patients with advanced prostate cancer. Proc ASCO 2003; 22:1654a.

38. Limentani SA, **Brufsky AM**, Jahanzeb M, Erban JK, Kneuper-Hall R, Lewis D. Neoadjuvant treatment of women with breast cancer utilizing docetaxel and vinorelbine with growth factor support: high rates of pathologic complete response. Proc ASCO 2003; 18:131a.
39. Chang JC, Kalidas M, Zhou L, Yu S, Cate E, Lowe A, Wilson S, Bedell L, Milan S, **Brufsky A**, Garino LA, Miller J, Hutchins L, Lee M. Interleukin-2 and trastuzumab: preliminary results in clinical response and natural killer cell expansion in advanced Her2/neu positive metastatic breast cancer patients. Breast Cancer Treat Res 2003; 18:220a
40. Hergenroeder PF, Peters DG, Handley D, Lyons-Weiler J, Dabbs D, **Brufsky A**. Building a gene expression predictive classifier of lymph node positive breast cancer. Br Can Treat Res 2003; 18: 563a.
41. Limentani SA, **Brufsky AM**, Erban JK, Jahanzeb M, Lewis D. Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel and vinorelbine with growth factor support. Br Can Treat Res 2003; 18: 251a.
42. Limentani SA, **Brufsky AM**, Erban JK, Jahanzeb M, Lewis D. Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. Br Can Treat Res 2003; 18: 240a.
43. Overmoyer B., **Brufsky A.**, Volck B., Leach D., Østergaard A. A phase I trial evaluating the safety and immunogenicity of a HER-2 protein vaccine in patients with breast cancer. European Breast Cancer Conference, Hamburg, Germany, March 17th, 2004.
44. Low JA, Wedam SB, **Brufsky A**, Berman A, Croarkin E, Parks R, Steinberg S, Mannan N, Fojo T, Swain S. A phase 2 trial of BMS-247550 (ixabepilone), an epothilone B analog, given daily x 5 in breast cancer. Proc ASCO 2004; 23:545a.
45. Rosenzweig M and **Brufsky A**. Sequential Chemotherapy in Her 2/*neu* Positive Metastatic Breast Cancer (MBC): A Retrospective Single Institution Analysis. Proc ASCO 2004; 23:8257a.
46. Heron DE, , Gerszten KA, **Brufsky AM**, Kurman M. The effect of chemotherapy (CT) and external beam radiotherapy (RT) on bone marrow (BM) toxicity of radionuclides in the treatment of bone metastases secondary to breast cancer. Proc ASCO 2004; 23:796a.
47. Rugo HS, Yardley D, Tan-Chiu E, **Brufsky A**, Kaufman P, Paik S, Ulcickas-Yood M, Mayer M, Tripathy D. registHER: Results from a prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer. Br Ca Treat Res 2004; 19:2042a.
48. **Brufsky A**, Orlando M, Fox K, Jame A, Katherine T, Franco S, Vincent H, Terry E, LaTrice H, Steven S, Allen M. Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC). First stage results. Br Ca Treat Res 2004 19:3047a.

49. **Brufsky A**, Harker G, Beck T, Carroll R, Tan-Chiu E, Seidler C, Lacema L, Thomas E, Perez E. Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): Preliminary results of the Z-FAST trial. *Br Ca Treat Res* 2004 19:1114
50. Sun M, Welsh MJ, Sun M, Allen G, Gierach G, Lyons-Weiler J, **Brufsky A**, Lokshin AE, Modugno F, Bigbee WL. Serum SELDI-TOF-MS protein profiling and classification in women with estrogen receptor positive breast infiltrating ductal carcinoma. *Proc AACR* 2005.
51. **Brufsky A**, Yardley D, Tan-Chiu E, Kaufman D, Paik S, Ulcickas-Yood M, Mayer M, Tripathy D, Rugo H. registHER: a prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer. *Proc ASCO* 2005; 24: 670a.
52. Jahanzeb M, Limentani SA, **Brufsky, AM**, Erban, J, Lewis, D. Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. *Proc ASCO* 2005; 24: 591a.
53. **Brufsky A**, Harker G, Beck T, Carroll R, Tan-Chiu E, Seidler C, Lacerna L, Thomas E, Perez E. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the Z-FAST trial. *Proc ASCO* 2005; 24:533a.
54. Rubin P, **Brufsky A**, Lambert-Falls M, Carroll M, Limentani S. A phase II randomized study to compare the neoadjuvant dose dense administration of docetaxel (D) and vinorelbine (V) or D followed by doxorubicin and Cyclophosphamides (C) administered to women with stage II or III breast cancer. Toxicity data. *Proc ASCO* 2005; 24: 776a.
55. Grant SG, Kelley JL III, Vogel VG, **Brufsky AM**, Bigbee WL, and Latimer JJ. Variability in bone marrow mutational response in breast cancer patients treated with genotoxic chemotherapy. Presented at the joint meeting of the 9th International Conference on Environmental Mutagens and the 2005 annual meeting of the Environmental Mutagen Society. *Environmental and Molecular Mutagenesis* 2005; 577 [supplement 1]: e165.
56. Bender C, Sereika SM, Vogel VG, Berga SL, Ryan C, Casillo FE, Cohen SM, Rastogi P, **Brufsky AM**. Memory impairments with anastrozole versus tamoxifen therapy in women with early stage breast cancer. San Antonio Breast Cancer Symposium 2005, Breast Cancer Research and Treatment 94, (Suppl 1) S274, Abstract #6074, 2005.
57. Limentani SA, **Brufsky, AM**, Erban, J, Jahanzeb M, Lambert-Fells R, Lewis, D. A phase II randomized study to compare the neoadjuvant administration of docetaxel and vinorelbine or docetaxel followed by adriamycin and cytoxan with all chemotherapy administered in a dose dense fashion to women with stage II and stage III breast cancer. *Breast Cancer Treat Res* 2005; 20: 5005a.
58. **Brufsky A**, Rugo H, Tripathy D, Kaufman P, Mayer M, Paik S, Ulcickas-Yood M, Yardley D, Tan-Chiu E. registHER: treatments and clinical outcomes from a prospective observational

cohort study of patients with HER2-positive metastatic breast cancer. *Breast Cancer Treat Res* 2005; 20: 3069a.

59. Miller K, Ng C, Ang P, **Brufsky AM**, Lee SC, Dees EC, Piccart M, Verrill M, Wardley A, Loftiss J, Bal J, Yeoh S, Hodge J, Williams D, Dar M, Ho PTC. Phase II, open label study of SB-715992 (Ispinesib) in subjects with advanced or metastatic breast cancer. *Breast Cancer Treat Res* 2005; 20: 1089a.
60. **Brufsky A**, Fox K, Orlando M, Abraham J, Tan-Chiu E, Haney L, Wang L. Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in first line metastatic breast cancer (MBC) patients (pts) with HER2 overexpression. *J Clin Oncol* 2006; 24 (18S): 10591a.
61. Rosenzweig M, Wiehagen T, **Brufsky AM**, Arnold RM. Symptom distress, quality of life and challenges of illness according to race and income in women with metastatic breast cancer. *J Clin Oncol* 2006; 24 (18S): 8609a.
62. Kaufman P, Mayer M, Paik S, Ulcickas-Yood M, Yardley D, Tan-Chiu E, **Brufsky A**, Rugo H, Tripathy D, Wang L. registHER: Baseline characteristics of a cohort of HER2-positive metastatic breast cancer (MBC) patients. *J Clin Oncol* 2006; 24 (18S): 20095a.
63. **Brufsky A**, Dong M, Lund K, Warsi G, Cobb P, Eisenberg P, Papish S, Lacerna L, Perez E. Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). *Breast Cancer Treat Res* 2006; 21: 5060a.
64. Kaufman PA, Mayer M, Paik S, Ulcickas Yood M, Yardley D, Tan-Chiu E, **Brufsky A**, Rugo H, Tripathy D, Thomas E, Dolezal M. registHER: trastuzumab-based taxane or vinorelbine treatment selection in patients with HER2/neu-positive metastatic breast cancer: patient characteristics and preliminary outcomes. *Breast Cancer Treat Res* 2006; 21: 2066a.
65. **Brufsky A**, Bundred N, Coleman R, Lambert-Falls R, Mena R, Dong M, Schenk N, Lacerna L, Perez E. An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). *Breast Cancer Treat Res* 2006; 21:107a.
66. **Brufsky A**, Bundred N, Coleman R, Lambert-Falls R, Mena R, Dong M, Schenk N, Lacerna L, Perez E. An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). 10th Annual St. Gallen Early Stage Breast Cancer Research Symposium, St. Gallen, Switzerland, March 16th, 2007, Abstract 153.
67. **Brufsky A**, Dong M, Lund K, Warsi G, Cobb P, Eisenberg P, Papish S, Lacerna L, Perez E. Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). 10th Annual St. Gallen Early Stage Breast Cancer Research Symposium, St. Gallen, Switzerland, March 16th, 2007, Abstract 154.

68. **Brufsky A**, Chow S, Kapoor A, Bhargava R, Rosenzweig MR, Surthi U. Women with Her2 Unamplified but Chromosome 17 Hyperdiploid Metastatic Breast Cancer (MBC) respond to Trastuzumab. *J Clin Oncol* 2007; 25(18S): 21051.
69. Kapoor A, **Brufsky A**, Chow S, Bhargava R, Surthi U, Rosenzweig MR. Topoisomerase II-alpha (TOP2A) gene co-amplification does not predict response to therapy and survival in Her 2 Neu positive metastatic breast cancer. *J Clin Oncol* 2007; 25(18S). 21108.
70. Geller BA, Lepisto AJ, Ahrendt GM, Finn OJ, Ramanathan RK, **Brufsky AM**. Immunity of MUC1 in breast and pancreatic cancer. *J Clin Oncol* 2007; 25(18S): 21166.
71. Mani A, Roda J, Caligiuri M, Fleming G, Kaufman P, **Brufsky A**, Carson W, Shapiro C. A phase II trial of trastuzumab and low dose interleukin-2 in patients with metastatic breast cancer who have previously failed trastuzumab. *J Clin Oncol* 2007; 25 (18S): 3028.
72. Yardley DA, Kaufman P, Mayer M, Ulcickas Yood M, Tan-Chiu E, **Brufsky AM**, Rugo H, Tripathy D, Paik S, Brammer MG registHER: Patient characteristics, treatment patterns, and preliminary outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC). *J Clin Oncol* 2007; 25(18S): 21007.
73. Aapro MS, Hadji P, **Brufsky A**, Tubiana-Hulin M, Guise T, Body JJ. Recommendations for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer. *Eur J Ca* 2007; Supp 5(4): 186.
74. **Brufsky A**, Bosserman L, Caradonna R, Haley B, Jones M, Moore H, Dong M, Warsi G, Lacerna L, Perez E. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. *Breast Can Treat Res* 2007; 22: 27a (Plenary Presentation).
75. Striebel JM, Bhargava R, Surti U, **Brufsky A**, Dabbs DJ. The borderline amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management. *Breast Can Treat Res* 2007; 22: 3038a.
76. Yardley DA, Kaufman PA, Mayer M, Ulcickas Yood M, Tan-Chiu E, **Brufsky AM**, Rugo HS, Tripathy D, Brammer MG, Paik S. registHER: patient characteristics and time course of CNS metastases in patients with HER2-positive metastatic breast cancer. *Breast Can Treat Res* 2007; 22: 6049a.
77. Geller BA, Lepisto AJ, McKolanis JR, Ahrendt GM, Potter DM, Finn OJ, **Brufsky AM** Characterization of anti-MUC1 immune response in patients with *in situ*, early and locally-advanced breast cancer. *Breast Can Treat Res* 2007; 22: 2109a.
78. Hadji P, Aapro M, **Brufsky A**, Tubiana-Hulin M, Guise T, Body JJ. Practical guidance for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer. *Breast Can Treat Res* 2007; 22: 504a.

79. van Londen G, Perera S, Vujevich K, Sereika S, Bhattacharya R, Vogel V, **Brufsky A**, Lembersky B, Greenspan S. The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women on SERMS versus aromatase inhibitors: a 2 year trial. *Breast Can Treat Res* 2007; 22: 503a.
80. Liang H, **Brufsky AM**, Lembersky BB, Rastogi P, Vogel VG. A retrospective analysis of the impact of oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center. *Breast Can Treat Res* 2007; 22: 2061a.
81. Burkinshaw R, **Brufsky A**, Coleman RE. Antitumor properties of bisphosphonates and possible prevention of bone metastases in breast cancer. European Breast Cancer Conference, Berlin, Germany, April 15th, 2008.
82. **Brufsky A**, Bosserman L, Caradonna R, Haley B, Jones M, Moore H, Dong M, Warsi G, Lacerna L, Perez E. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 36-month follow-up of the Z-FAST study. European Breast Cancer Conference, Berlin, Germany, April 15th, 2008.
83. Donnenberg V, Landreneau R, **Brufsky A**, Donnenberg A. The interrelationship between stem/progenitor markers on metastatic breast cancer cells. *ISSCR* 2008; 1321a.
84. Seidman A, Conlin A, Bach A, **Brufsky AM**, Saleh MN, Lake M, Dickler M, Traina T, Robson M, Hudis C. Phase II study of weekly nanoparticle albumin bound (nab) paclitaxel in combination with carboplatin and trastuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer (MBC). *J Clin Oncol* 2008; 26(19): 1047a.
85. **Brufsky A**, Hoelzer K, Keaton M, Beck J, Krill-Jackson E, Wang Y, Hu S, Vaughn L, Shonukan O. A randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer (MBC): interim safety results. *J Clin Oncol* 2008; 26(19): 1095a.
86. Rosenzweig M, Sereika S, **Brufsky AM**, Simon J, Underwood S. The ACTS intervention effect on adherence to recommended chemotherapy among black women with breast cancer. *J Clin Oncol* 2008; 26 (19): 20524a.
87. **Brufsky A**, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Yood M, Tripathy D, Birkner, M, Brammer MG, Yardley DA. RegistHER: Patient characteristics and time course of central nervous system metastases in patients with HER2-positive metastatic breast cancer. 2008 ASCO Breast Cancer Symposium, Washington, DC, 89a.
88. Nasir I, **Brufsky A**, Bhargava R, McManus K, Chivukula M. Identification of biomarkers associated with metastatic breast cancer to bone by immunohistochemistry on tissue microarrays. *Breast Cancer Treat Res* 2008; 69(2): 2065a.
89. **Brufsky A**, Harker G, Beck T, Carroll R, Warsi G, Jin L, Argonza-Aviles E, Ericson S, Carroll RR, Robert R. Bone-specific alkaline phosphatase (BSAP) and serum N-telopeptide (sNTX) as predictors of bone loss in postmenopausal women with early stage breast cancer

receiving letrozole as adjuvant therapy: a 5-year study (Z-FAST). *Breast Cancer Treat Res* 2008; 69(2): 2067a.

90. Rugo H, Kaufman P, Tan-Chiu E, Ulcickas YM, Yood M, Paik S, Yardley D, **Brufsky A**, Mayer M, Birkner M, Wang L, Brammer M, Tripathy D. Survival of patients with HER2+metastatic breast cancer and use of trastuzumab following progression: analysis of RegisHER. *Breast Cancer Treat Res* 2008; 69(2): 3142a.
91. Bhargava R, Goldman F, Beriwal S, Dabbs DJ, Johnson R, **Brufsky AM**, Lembersky BC, Ahrendt GM. Breast cancer molecular classification using immunohistochemical surrogate markers predicts response to neoadjuvant chemotherapy. *Breast Cancer Treat Res* 2008; 69(2): 6071a.
92. Picarsic J, **Brufsky A**, Onisko A, Chivukula M. Predictors of invasive breast cancer or DCIS recurrence in estrogen receptor positive (ER+) and estrogen receptor negative ductal carcinoma in situ (DCIS) patients with and without associated invasive carcinoma (IC). *J Clin Oncol* 2009; 27 (15): 11523a.
93. Seidman AD, **Brufsky A**, Ansari RH, Rubinsak JR, Stein RS, Schwartzberg LS, Stewart JF, Zhao L, Tai JD. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). *J Clin Oncol* 2009; 27(15): 1000a.
94. Robert NJ, Dieras V, Glaspy J, **Brufsky A**, Bondarenko I, Lipatov O, Perez E, Yardley D, Zhou X, Phan S. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). *J Clin Oncol* 2009; 27(15): 1009a.
95. El Ayass W, Sereika S, Van Londen G, **Brufsky A**. Predictors of progression of bone metastases in breast cancer patients. *J Clin Oncol* 2009; 27(15):12011e.
96. Hoelzer KL, **Brufsky A**, Hainsworth J, Beck JT, Whorf, R, Keaton M, Korener J, Krill-Jackson E, Hu S, Bromund J. Preliminary results of a randomized phase II study of paclitaxel and bevacizumab \pm gemcitabine as first-line treatment for metastatic breast cancer. *J Clin Oncol* 2009; 27(15):1089a.
97. Onishi T, Singh V, Rosenzweig M, Sereika S, **Brufsky AM**. Long-term treatment with intravenous bisphosphonates in metastatic breast cancer (MBC). *J Clin Oncol* 2009 27(15): 1035a.
98. **Brufsky A**, Harker G, Beck JT, Carroll R, Jin L, Warsi G, Argonza-Aviles E, Ericson S, Perez EA. The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up. *Breast Cancer Treat Res* 2009; 70(2): 4083.
99. **Brufsky A**, Bondarenko IN, Smirnov V, Hurvitz S, Perez E, Ponomarova O, Vynnychenko I, Swamy R, Mu H, Rivera R. RIBBON-2: A Randomized, Double-Blind, Placebo-

Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. *Breast Cancer Treat Res* 2009; 70(2): 42.

100. O'Shaughnessy J, Dieras V, Glaspy J, **Brufsky A**, Miller KD, Miles DW, Koralewski P, Phan S-C, Bhattacharya S. Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC). *Breast Cancer Treat Res* 2009; 70(2): 207a.
101. Coleman R, Bundred N, De Boer R, Llombarto A, Campbell I, Neven P, Barrios C, Dias R, Miller J, **Brufsky A**. Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. *Breast Cancer Treat Res* 2009; 70(2): 4082a.
102. Picarsic JL, **Brufsky A**, Ahrendt GM, Tseng GC, Chivukula M. Role of Transcription Factors [FOXA1,GATA-3] in Predicting Outcomes in Recurrent Ductal Carcinoma-In-Situ (DCIS) or Invasive Carcinoma (IC) in DCIS Patients on Core Needle Biopsies of Breast. *Breast Cancer Treat Res* 2009; 70(2): 2115a.
103. Robert N, Dieras V, Glaspy J, **Brufsky A**, Miller KD, Miles DW, Koralewski P, Bhattacharya S, Phan S-C. Phase III Studies of Bevacizumab (B) in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC): Summary of Selected Adverse Events. *Breast Cancer Treat Res* 2009; 70(2): 6083a.
104. Chivukula M, **Brufsky A**, Carter G, Chandran U, Lyons-Weiler M, Dabbs DJ. Molecular Alterations in Pleomorphic Lobular Carcinoma In Situ (PLCIS) of the Breast. *Breast Cancer Treat Res* 2009; 70(2): 5004a.
105. Robert N, Dieras V, Glaspy J, **Brufsky A**, Bondarenko IN, Lipatov O, Perez E, Yardley D, Phan S-C, Bhattacharya S, O'Shaughnessy J. Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC). *Breast Cancer Treat Res* 2009; 70(2): 6084a.
106. Oakley III GJ, **Brufsky A**, Chivukula M. [6133] Instability in Chromosomes 9, 7, and 5 Correlate with Lymph Node Metastasis at Presentation in Basal Phenotype Carcinoma. *Breast Cancer Treat Res* 2009; 70(2): 6133a.
107. Jankowitz RC, Chivukula M, Ma X, Erlander MG, Mock LL, Mazur LS, Li H, Salunga R, Sereika S, **Brufsky A**. Predictive value of the Theros Breast Cancer Index (TBCI) for distant recurrence and overall survival (OS) in comparison to Adjuvant! Online and clinicopathologic characteristics in women with lymph node (LN)-negative, ER-positive breast cancer (BCa). *J Clin Oncol* 28:15s, 2010 (suppl; abstr 10582).
108. **Brufsky A**, Rivera R, Hurvitz SA, Bondarenko IN, Smirnov V, Valero V, Rugo HS, Swamy R, Mu H, Perez EA. Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line

treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). *J Clin Oncol* 28:15s, 2010 (suppl; abstr 1021).

109. Bhargava R, Dabbs DJ, Beriwal S, Johnson RR, **Brufsky AM**, Lembersky B, Soran A, Ahrendt GM. Semi-Quantitative Estrogen Receptor Expression Level Influences Responses to Trastuzumab Containing Neo-Adjuvant Chemotherapy in HER2 Positive Tumors. *Mod Pathol* 2010; V 23 suppl: 37A.
110. Picarsic J, **Brufsky A**, Ahrendt G, Onisko A, Chivukula M. Role of Transcription Factors [FOXA1, GATA-3] in (ER+) and (ER-) Ductal Carcinoma-In-Situ (DCIS) Patients with and without Invasive Carcinoma (IC): A Retrospective Subset Analysis. *Mod Pathol* 2010;V 23 Suppl 1: 66A.
111. Im A, **Brufsky A**, Reeder JG, Rosenzweig MQ, Jung SY. Repeat use of chemotherapy in breast cancer. *J Clin Oncol* 2011; 29: (suppl, abstract 1088).
112. **Brufsky A**, Valero V, Tiangco B, Dakhil SR, Brize A, Bousfoul N, Rugo HS, Yardley DA. Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2. *J Clin Oncol* 2011; 29 (suppl, abstract 1010).
113. Soni A, **Brufsky A**, Jankowitz RC, Rastogi P, Vogel VG, Puhalla S. Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic. *J Clin Oncol* 2011; 29: (suppl, abstract 9061).
114. Bear HD, Tang G, Rastogi P, Geyer CE, Robidoux A, Atkins JN, Baez L, Brufsky A, Mehta RS, Fehrenbacher L, Pajon ER, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Swain SM, Mamounas EP, Costantino, JP, Wolmark N. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. *J Clin Oncol* 2011; 29 (suppl, abstract LBA 1005).
115. Jung SY, Rosenzweig MQ, Sereika SM, Linkov F, **Brufsky A**, Weissfeld JL. Factors associated with mortality after breast cancer metastasis. *J Clin Oncol* 2011; 29 (suppl 27, abstract 174).
116. Mathew A, Rosenzweig MQ, **Brufsky A**. Association between bisphosphonate use in metastatic breast cancer (MBC) and overall survival. *J Clin Oncol* 2011; 29 (suppl 27, abstract 102).
117. **Brufsky A**, Valero V, Tiangco B, Dakhil SR, Brize A, Bousfoul N, Rugo HS, Yardley DA. Bevacizumab (BEV) plus second-line taxane (TAX) or other chemotherapy (CT) for triple-negative breast cancer (TNBC): Subgroup analysis of RIBBON-2. *J Clin Oncol* 2011; 29 (suppl 27: abstract 290).
118. Mathew A, Rosenzweig MQ, **Brufsky A**. Prognostic role of triple-negative subtype in breast cancer patients with brain metastases. *J Clin Oncol* 2011; 29 (suppl 27, abstract 36).

119. Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, **Brufsky AM**, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE, Swain SM, Costantino JP, Mamounas EP, Wolmark N. NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis. *Breast Cancer Treat Res* 2011; 72 (abstract S2-3).
120. Bear HD, Tang G, Rastogi P, Geyer CE, André R, Atkins JN, Baez-Diaz L, **Brufsky AM**, Mehta RS, Fehrenbacher L, Pajon ER, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy: NSABP Protocol B-40. *Breast Cancer Treat Res* 2011; 72 (abstract PD07-08).
121. Kaufman PA, **Brufsky AM**, Mayer M, Rugo HS, Tripathy D, Ulcickas Yood M, Feng S, Wang LI, Brammer MG, Yardley DA. Treatment Patterns and Clinical Outcomes in Elderly Patients with HER2-Positive Metastatic Breast Cancer from the registHER Observational Study. *Breast Cancer Treat Res* 2011; 72 (abstract P1-08-22).
122. **Brufsky A**, Beck J, Dakhil S, Hallmeyer S, Tezcan H, Yardley D, Tran D, Warsi G, Culver K. Z-ACT1: Zometa Combined with Standard Therapy in Patients with Metastatic Breast Cancer Further Decreases the Proportion of Patients with CTC Counts of 5 or above. *Breast Cancer Treat Res* 2011; 72 (abstract P1-18-01).
123. Dabbs DJ, Hicks D, Tubbs R, Bhargava R, **Brufsky A**. Multicenter Quality Assurance Profile Review of Lobular Breast Carcinomas Versus the 21 Gene Recurrence Score: Assessment of Clinical Relevance. *Breast Cancer Treat Res* 2011; 72 (abstract P4-09-22).
124. Mathew A, Mathew IE, Rosenzweig MQ, **Brufsky AM**. Association between Bisphosphonate Use in Metastatic Breast Cancer (MBC) and Overall Survival. *Breast Cancer Treat Res* 2011; 72 (abstract P4-11-05).
125. Mathew A, Mathew IE, Rosenzweig MQ, **Brufsky AM**. Prognostic Role of Triple Negative Subtype in Breast Cancer Patients with Brain Metastases. *Breast Cancer Treat Res* 2011; 72 (abstract P4-17-06).
126. Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Kuebler JP, Margolese RG, Farrar WB, **Brufsky A**, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP Protocol B-41. *J Clin Oncol* 2012;30(15 Suppl) May.(abstract LBA506).
127. Rios-Perez JA, Abedin S, Rosenzweig MQ, Jung SY, Bhargava R, **Brufsky A**. Methallotionein expression and outcome in patients with metastatic breast cancer (MBC). *J Clin Oncol* 2012;30(15 Suppl) May.(abstract 1085).
128. Swain SM, Tang G, Geyer CE, Rastogi P, Atkins JN, Connellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff J, **Brufsky A**, Biggs DD, Levine EA, Zapas JL, Provencher L,

- Perez EA, Paik S, Costantino JP, Mamounas EP, Wolmark N. NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, cyclophosphamide, and epirubicin (TAC) in women with operable, node-positive breast cancer. *J Clin Oncol* 2012;30(15 Suppl) May.(abstract LBA1000).
129. **Brufsky A**, Yardley DA, Yood MU, Tripathy D, Kaufman PA, Mayer M, Feng S, Abidoye OO, Rugo HS. Racial disparities in treatment patterns and clinical outcomes in patients (pts) with HER2+ metastatic breast cancer (MBC). *J Clin Oncol* 2012;30(15 Suppl) May.(abstract 1526).
130. Rosenzweig MQ, Jung SY, **Brufsky A**. The influence of prognostic factors on metastatic breast cancer survival over time. *J Clin Oncol* 2012;30(15 Suppl) May.(abstract 1589).
131. Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Kuebler JP, Margolese RG, Farrar WB, **Brufsky A**, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP Protocol B-41. *J Clin Oncol* 2012;30(18 Suppl) June 21.(abstract LBA506).
132. Swain SM, Tang G, Geyer CE, Rastogi P, Atkins JN, Connellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff J, **Brufsky A**, Biggs DD, Levine EA, Zapas JL, Provencher L, Perez EA, Paik S, Costantino JP, Mamounas EP, Wolmark N. NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, cyclophosphamide, and epirubicin (TAC) in women with operable, node-positive breast cancer. *J Clin Oncol* 2012;30(18 Suppl) June 21.(abstract LBA1000).
133. **Brufsky AM**, Hurvitz SA, Perez EA, Yamamoto H, Valero V, O'Neill, Rugo HS. Final overall survival (OS) and safety analyses of RIBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naïve metastatic breast cancer (MBC). *J Clin Oncol* 2012;30(27 suppl) Sept. (abstract 100).
134. Yardley DA, Tripathy D, **Brufsky AM**, Rugo HS, Kaufman PA, Mayer M, Feng S, Abidoye OO, Yood MU. Long-term survivor (LTS) characteristics in HER2+ metastatic breast cancer (MBC). *J Clin Oncol* 2012; 30(27 suppl) Sept. (abstract 133).
135. Puhalla SL, Appleman LJ, Beumer JH, Tawbi H, Stoller RG, Owonikoko TK, Ramalingam SS, Belani CP, **Brufsky AM**, Abraham J, Shepherd SP, Giranda V, Chen AP, Chu E. Two phase I trials exploring different dosing schedule of carboplatin (C), paclitaxel (P), and the poly-ADP-Ribose Polymerase (PARP) inhibitor, Veliparib (ABT-888) (V) with activity in triple negative breast cancer (TNBC). *Cancer Res* 2012; 72 (24 Suppl.): Abstract PD 09-06-02.

136. Bhargava R, Klein ME, Shuai Y, **Brufsky AM**, Puhalla SL, Jankowitz R, Dabbs DJ. Prediction of oncotype DX recurrence score using pathology generated equations. *Cancer Res* 2012; 72 (24 Suppl.): Abstract P6-07-02.
137. Yi Z, Schnaabel CA, Schroeder B, Jerevall P-L, Jankowitz RC, Stal O, **Brufsky A**, Sgroi D, Erlander MG. Prediction of early and late distant recurrence in early-stage breast cancer with Breast Cancer Index. *J Clin Oncol* 31, 2013(Supp 15; abstr 584).
138. Leone JP, Cunningham DE, Lee A, Bhargava R, Hamilton RL, Wiener E, Okada H, **Brufsky A**. Prognostic factors and survival of patients with brain metastasis (BM) from breast cancer (BC) who underwent craniotomy. *J Clin Oncol* 31, 2013(Supp 15; abstr 322017).
139. Vacirca JL, Tsai ML, **Brufsky A**, Michaelson RA, Smith FP, Schwartzberg LS, Butler SM, Jamshidian F, Sing AP. Initial results from the 21-gene breast cancer assay registry: A prospective observational study in patients (pts) with ER+, early-stage invasive breast cancer (EBC). *J Clin Oncol* 31, 2013(Supp 15; abstr 565).
140. Gil EMC, **Brufsky A**, Im Y-pH, Bim S-B, Clark E, Knott A, Ross G, Miles D. Efficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumab. *J Clin Oncol* 31, 2013(Supp 15; abstr 600).
141. **Brufsky A**, Yardley DA, Kaurman PA, Yood MU, Rugo HS, Mayer M, Quah CS, Yoo B, Tripathy D. Treatment (tx) patterns and clinical outcomes for patients (pts) with de novo versus recurrent HER2+ metastatic breast cancer (MBC). *J Clin Oncol* 31, 2013 (Supp 15; abstr 523).
142. Bhargava R, **Brufsky AM**, Lembersky BC, Jankovic R, Puhalla SL, Oesterreich S, Lee A, Dabbs DJ. Treatment decisions and five year outcomes of the oncotype Dx test: An independent assessment. *Breast Cancer Treat Res* 2013, abstract P6-06-46.
143. Abedin S, Kruse M, **Brufsky A**, Bhargava R. HER2 copy number on FISH as a predictor of disease severity in HER2- breast cancer. *Breast Cancer Treat Res* 2013, abstract P3-05-02.
144. Mathew A, **Brufsky AM**. Risk of CNS relapse following adjuvant trastuzumab therapy – Updated literature-based meta-analysis. *Breast Cancer Treat Res* 2013, abstract P6-11-08.
145. Lowery A, Bovbjerg D, Beckjord E, **Brufsky A**, Greco C, Low C, Martin J, Posluszny D, Schmidt J, Shaffer J, Belfer I. Persistent pain following breast cancer surgery: Why does it hurt more for some survivors than others? *J Clin Oncol* 32, 2014 (suppl; abstr e20634).
146. Dabbs D, **Brufsky A**, Jankowitz R, Puhalla S, Lee A, Oesterreich S, Lembersky B, Bhargava R. Comparison of test results and clinical outcomes of patients assessed with both MammaPrint and Oncotype DX with pathologic variables: An independent study. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 550).
147. Puhalla S, Wilks S, **Brufsky A**, O'Shaughnessy J, Schwartzberg L, Berrak E, Song J, Cox D, Vahdat L. Clinical effects of prior trastuzumab on combination eribulin mesylate plus

trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 635).

148. Connolly R, Jankowitz R, Zahnow C, Zhang Z, Rudek M, Slater S, Powers P, Jeter S, **Brufsky A**, Piekarz R, Herman J, Ahuja N, Somlo G, Garcia A, Baylin S, Davidson N, Stearns V. Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 569).
149. Miller K, O'Neill A, Dang C, Northfelt D, Gradishar W, Goldstein L, Mayer I, **Brufsky A**, Bloom S, Sparano J, Tevaarwerk A, Fox K, Hendricks C, Balcueva E, Sledge G. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 500).
150. Ganz PA, Wilson JW, Bandos H, Robidoux A, Paterson AHG, Polikoff J, Baez-Diaz L, **Brufsky AM**, Fehrenbacher L, Mangalik A, Ward PJ, Provencher L, Hamm JT, Stella PJ, Carolla RL, Margolese RG, Shibata HR, Perez EA, Wolmark N. Impact of treatment on quality of life (QOL) and menstrual history (MH) in the NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer. *Breast Cancer Treat Res* 2014, abstract P3-12-01.
151. Tripathy D, **Brufsky A**, Cobleigh M, Jahanzeb M, Kaufman P, Mason G, Mayer M, O'Shaughnessy J, Rugo H, Swain SM, Yardley DA, Beattie M, Yoo B, Hurvitz S. Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: Early results from the systemic therapies for HER2-positive metastatic breast cancer registry study. *Breast Cancer Treat Res* 2014, abstract P3-07-14.
152. Samuel JA, Wilson JW, Bandos H, Elledge RM, Robidoux A, Fehrenbacher L, Ward PJ, Polikoff J, **Brufsky AM**, Provencher L, Paterson AHG, Hamm JT, Carolla RL, Baez-Diaz L, Rastogi P, Julian TB, Wickerham DL, Swain SM, Geyer, Jr CE, Mamounas EP, Wolmark N. NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer. *Breast Cancer Treat Res* 2014; abstract S3-02.
153. Pahuja S, McGuire K, Davidson N, **Brufsky A**, Rastogi P, Jankowitz R, Lembersky B, Puhalla S. Response to subsequent therapies after failure to achieve pathologic complete response (pCR) after neo-adjuvant chemotherapy (NAC) in patients (pts) with triple negative breast cancer (TNBC). *Breast Cancer Treat Res* 2014; abstract P3-11-10.
154. Bear HD, Tang G, Rastogi P, Geyer CE, Liu Q, Robidoux A, Atkins JN, Baez-Diaz L, **Brufsky AM**, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or

- antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Breast Cancer Treat Res 2014; abstract PD2-1.
155. Hartmaier RJ, Puhalla SL, Oesterreich S, Bahreini A, Davidson NE, **Brufsky AM**, Lee AV. Identification of base pair mutations and structural rearrangements acquired in breast cancer metastases including a novel hyperactive ESR1-DAB2 fusion gene specifically in hormone-resistant recurrence. Breast Cancer Treat Res 2014; abstract S1-03.
 156. Leone JP, Bhargava R, Lee A, **Brufsky A**. Expression of high affinity folate receptor in breast cancer brain metastasis. Breast Cancer Treat Res 2014; abstract P6-01-15.
 157. Puhalla S, Wang P, Bahreini A, Gyanchandani R, Ambros T, Hartmaier R, Kurland B, Lucas P, Bittar H, Hamilton R, Mathew A, Leone J, Davidson N, Weiss K, Watters R, Nikiforova M, Stern A, **Brufsky A**, Lee A, Oesterreich S; Detection and functional analysis of estrogen receptor mutations (ESR1-mut) in patients with metastatic breast cancer (MBC) . J Clin Oncol 33, 2015 (suppl; abstr 554).
 158. McKee M, Trembath D, Deal A, Keith K, Midkiff B, Feinberg N, Garrett A, Blackwell K, Leone J, Hamilton R, **Brufsky A**, Morikawa A, Brogi E, Seidman A, Ewend M, Moschos S, Anders C, Histopathological markers at craniotomy and outcome in breast cancer brain metastases. J Clin Oncol 33, 2015 (suppl; abstr 2027).
 159. Margolese R, Cecchini R, Julian T, Ganz P, Costantino J, Vallow L, Albain K, Whitworth P, Cianfrocca M, **Brufsky A**, Gross H, Soori G, Hopkins J, Fehrenbacher L, Sturtz K, Wozniak T, Seay T, Mamounas E, Wolmark N. Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. J Clin Oncol 33, 2015 (suppl; abstr LBA500).
 160. Rubinstein M, Gray R, Sparano J, Zujewski J, Whelan T, Albain K, Hayes D, Geyer C, Dees E, Perez E, Keane M, Vallejos C, Goggins T, Mayer I, **Brufsky A**, Toppmeyer D, Kaklamani V, Atkins J, Berenberg J, Sledge G. Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. J Clin Oncol 33, 2015 (suppl; abstr 533).
 161. McAuliffe PF, Brown DD, Oesterreich S, Lee AV, Johnson RR, McGuire KP, Davidson NE, **Brufsky AM**, Dabbs DJ. Developing *in vitro* models of ductal carcinoma *in situ* from primary tissue. Breast Cancer Treat Res 2015; abstract P6-08-02.
 162. Peddi PF, Hurvitz SA, Fasching PA, Wang L, Cunningham J, Weinshilboum RM, Liu D, Quinaux E, Fourmanoir H, Robert NJ, Valero V, Crown J, Falkson C, **Brufsky A**, Pienkowski T, Eiermann W, Martin M, Bee V, Slamon DJ. Genetic polymorphism and correlation with treatment induced cardiotoxicity and prognosis in HER2 amplified early breast cancer patients. Breast Cancer Treat Res 2015; abstract P6-03-09.
 163. Dabbs DJ, Cooper KL, **Brufsky A**, Rosenzweig M, Bhargava R. Pathology data predicts MammaPrint result- The Magee MammaPrint equation. Breast Cancer Treat Res 2015; abstract P5-07-04.

164. Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, **Brufsky A**, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. *Breast Cancer Treat Res* 2015; abstract S6-04.
165. Stearns V, Smith II JW, Patel R, Lu D, Perkins JJ, Cotter MJ, **Brufsky AM**. Safety results of the US expanded access program (EAP) of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) for whom letrozole therapy is deemed appropriate. *Breast Cancer Treat Res* 2015; abstract P4-13-05.
166. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer Jr CE, Dees EC, Perez EA, Olson Jr JA, Zujewski J, Keane MM, Gomez Moreno HL, Reddi RP, Goggins TF, Mayer IA, **Brufsky AM**, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge Jr GW. Prospective trial of endocrine therapy alone in patients with estrogen receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry. *Breast Cancer Treat Res* 2015; abstract P2-08-01.
167. Mayer M, Sampayo I, Bell Dickson R, Citron ML, **Brufsky AM**. The experience of caregivers of women with metastatic breast cancer: Insights from the Make Your Dialogue Count survey. *Breast Cancer Treat Res* 2015; abstract P1-11-06.
168. Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz H, Sarwar S, Margolese RG, Farrar WB, **Brufsky AM**, Shibata HR, Bandos H, Paik S, Costantino JP, Swain S, Mamounas EP, Wolmark N. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41. *J Clin Oncol* 34, 2016 (suppl; abstr 501).
169. Kota K, Gyanchandani R, **Brufsky A**, Lee A, Oesterreich S, Puhalla S. Palbociclib's effect on estrogen receptor mutations in metastatic breast cancer. *J Clin Oncol* 34, 2016 (suppl; abstr 533).
170. Salunga RC, Harris TG, Zhang Y, Ramirez J, SgROI S, **Brufsky A**, Schnabel CA. Evaluation of the analytical performance of the Breast Cancer Index (BCI) assay. *J Clin Oncol* 34, 2016 (suppl; abstr 540).
171. Landmann A, Farrugia DF, Diego E, Soran A, Johnson R, Bonaventura M, Dabbs DJ, Clark B, **Brufsky A**, Davidson NE, Lembersky BC, Jankowitz RC, Puhalla S, Ahrendt GM, McAuliffe PF, Bhargava R. Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER- disease? *J Clin Oncol* 34, 2016 (suppl; abstr 580).
172. Landmann A, Farrugia DF, Diego E, Soran A, Johnson R, Bonaventura M, Dabbs DJ, Clark B, **Brufsky A**, Davidson NE, Lembersky BC, Jankowitz RC, Puhalla S, Ahrendt GM, McAuliffe PF, Bhargava R. HER2 equivocal breast cancer and neoadjuvant therapy: Is

response similar to HER2-positive or HER2- negative tumors? J Clin Oncol 34, 2016 (suppl; abstr 612).

173. Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE, Jacobs SA, Robert NJ, Atkins JN, O'Shaughnessy J, Dang CT, Gomez HL, Fehrenbacher L, Vukelja SJ, Lyss AL, Paul D, **Brufsky AM**, Swain SM, Mamounas EP, Jones SE, Wolmark N. Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2- negative breast cancer. J Clin Oncol 34, 2016 (suppl; abstr 1000).
174. **Brufsky A**, Kim S, Velu TJ, Garcia-Saenz JA, Tan-Chiu E, Sohn J, Dirix L, Vanasek J, Borms MV, Mingorance J, Liu M-C, Moezi M, Kozloff M, Sparano JA, Hsu J, Wongchenko M, Simmons BP, McNally VA, Miles D. Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study. J Clin Oncol 34, 2016 (suppl; abstr 1074).
175. Farrugia DF, Landmann A, Diego E, Soran A, Johnson R, Bonaventura M, Dabbs DJ, Clark B, **Brufsky A**, Davidson NE, Lembersky BC, Jankowitz RC, Puhalla S, Ahrendt GM, McAuliffe PF, Bhargava R. Utilization of Magee equation 3 in ER-positive, HER2-negative/equivocal tumors to determine pathologic response to neoadjuvant therapy. J Clin Oncol 34, 2016 (suppl; abstr 11594).
176. Kornblum NS, Manola J, Klein P, Ramaswamy B, **Brufsky A**, Stella PJ, Burnette B, Telli M, Makower DF, Leach J, Truica CI, Wolff AC, Soori GS, Haley B, Nagarajan A, Wassenaar TR, Goldstein L, Miller KD, Sparano JA. PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy Breast Cancer Treat Res 2016; 39: abstract S1-02
177. Mamounas EP, Bandos H, Lembersky BC, Geyer, Jr CE, Fehrenbacher L, Graham ML, Chia SL, **Brufsky AM**, Hennessy BT, Soori GS, Dakil SR, Seay TE, Wade, III JL, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N. A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42. Breast Cancer Treat Res 2016; 39: abstract S1-05.
178. Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Davidson NE, Oesterreich S, **Brufsky AM**, Young L, Lee AV. Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations. Breast Can Treat Res 2016; 39: abstract PD1-05.
179. **Brufsky A**, Kim S-B, Velu T, Garcia-Saenz JA, Tan-Chiu E, Sohn JH, Dirix L, Borms MV, Liu M-C, Moezi MM, Kozloff MF, Sparano JA, Xu N, Wongchenko M, Simmons B, McNally

- V, Miles D. Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results. *Breast Cancer Treat Res* 2016; 39: abstract P4-22-22.
180. Cobleigh M, Yardley DA, **Brufsky A**, Rugo H, Swain S, Kaufman PA, Tripathy D, Mayer M, Hurvitz S, O'Shaughnessy J, Mason G, Chu L, Antao V, Beattie M, Yoo B, Jahanzeb M. Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR- HER2+ disease from the SystHERs registry. *Breast Cancer Treat Res* 2016; 39: abstract P5-08-08.
181. Jahanzeb M, Tripathy D, Rugo H, Swain S, Kaufman PA, Mayer M, Hurvitz S, O'Shaughnessy J, Mason G, Yardley DA, **Brufsky A**, Chu L, Antao V, Beattie M, Yoo B, Cobleigh M. Treatment patterns and clinical outcomes in patients with hormone receptor (HR)+ HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SystHERs Registry. *Breast Cancer Treat res* 2016; 39: abstract P5-08-27.
182. Yardley D, Coleman R, Conte P, Cortes J, **Brufsky A**, Shtivelband M, Young R, Bengala C, Ali H, Eakel J, Schneeweiss A, de la Cruz Merino L, Wilks S, O'Shaughnessy J, Glack S, Li H, Beck R, Barton D, Harbeck N. nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial. *Breast Cancer Treat Res* 2016; 39: abstract P5-15-03.
183. Oesterreich S, Basudan A, Preideigkeit N, Hartmaier RJ, Bahreini A, Gyanchandani R, Leone JP, Lucas PC, Hamilton RL, **Brufsky AM**, Lee AV. ESR1 amplification and 5'-3' exon imbalance in metastatic breast cancer. *Breast Cancer Treat Res* 2016; 39: abstract P6-07-07.
184. Farrugia DJ, Landmann A, McAuliffe PF, Diego EJ, Johnson R, Bonaventura M, Soran A, Dabbs DJ, Clark B, Lembersky BC, Puhalla SL, **Brufsky A**, Jankowitz R, Davidson NE, Ahrendt GM, Bhargava R. Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer. *Breast Cancer Treat Res* 2016; 39: abstract P6-09-14.
185. Mayer IA, Arteaga CL, Nanda R, Miller KD, Jhaveri K, **Brufsky AM**, Rugo H, Yardley DA, Vahdat LT, Sadeghi S, Audeh MW, Rolfe L, Litten J, Knox A, Raponi M, Tankersley C, Isaacson J, Wride K, Morganstern DE, Vogel C, Connolly RM, Gradishar WJ, Patel R, Pusztai L, Abu-Khalaf M. A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC). *Breast Cancer Treat Res* 2016; 39: abstract P6-11-03.
186. Schroeder BE, Zhang Y, Stal O, Fornander T, **Brufsky A**, Sgroi DC, Schnabel CA. Prognostic impact of genomic risk stratification with breast cancer index in patients with clinically low risk, hormone receptor-positive, node-negative, T1 breast cancer. *Breast Cancer Treat Res* 2016; 39: abstract P2-05-14.
187. Sanft T, Berkowitz A, Schroeder B, Hatzis C, Schnabel C, Aktas B, **Brufsky A**, Pusztai L, vanLonden GJ. A multi-institutional, prospective study of incorporating the genomic platform

breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy. *Breast Cancer Treat Res* 2016; 39: abstract P2-09-15.

188. Prince G, Deal A, McKee M, Trembath D, Keith K, Ramirez J, Midkiff B, Blackwell K, Leone J, Hamilton R, **Brufsky A**, Morikawa A, Brogi W, Seidman A, Ewend M, Carey L, Moschos S, Vincent B, Anders C. Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. *J Clin Oncol* 35, 2017 (suppl; abstr 2072).
189. Narloch J, Luedke C, Broadwater G, Priedigkeit N, Hall A, Hyslop T, Sammons S, Huggins-Puhalla S, Leone J, Ramirez J, Kirkpatrick J, Ewend M, Fecci P, **Brufsky A**, Lee A, Anders C. Number of tumor-infiltrating lymphocytes in breast cancer brain metastases compared to matched breast primaries. *J Clin Oncol* 35, 2017 (suppl; abstr 2049).
190. **Brufsky A**, Davis K, Mitra D, Nagar S, McRoy L, Cotter M, Stearns V. Retrospective assessment of treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR+/HER2- advanced breast cancer enrolled in an early access program. *Breast Can Treat Res* 2017; 40: abstract P5-21-24.
191. **Brufsky A**, Miles D, Zvirbule Z, Eniu A, Lopez-Miranda E, Seo JH, Orbitura M, Le Du F, Wongchenko M, Poulin-Costello M, Simmons B, McNally V, Loi S, Kim S-B. Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort 1. *Breast Can Treat Res* 2017; 40: abstract P5-21-01.
192. Fournier MV, Chen J, Obenauer J, Goodwin EC, Tannenbaum SH, **Brufsky AM**. A predictive test for neoadjuvant chemotherapy in breast cancer identifies a subset of triple negative patients with resistant disease and the poorest prognosis *Breast Can Treat Res* 2017; 40: abstract P2-10-08.
193. Kalra M, Karuturi M, Tripathy D, Jankowitz R, McCann K, **Brufsky A**, Hurvitz S, Bogler O, Housri S, Housri N. Documenting and sharing breast cancer knowledge from National Cancer Institute designated comprehensive cancer centers (NCI-CCCs) with community oncologists. *Breast Can Treat Res* 2017; 40: abstract P5-16-01.
194. Thomas RA, Klar N, Kiedrowski L, Nagy RJ, Lee AV, **Brufsky A**. Utilization of cell-free circulating tumor DNA for management of breast cancer: Practices in academic and community oncology. *Breast Can Treat Res* 2017; 40: abstract P2-02-13.
195. Priedigkeit N, Vareslija D, Basudan A, Watters RJ, Lucas PC, Davidson NE, Blohmer J-U, Denkert C, Machleidt A, Heppner BI, **Brufsky AM**, Oesterreich S, Young L, Lee AV. Highly recurrent transcriptional remodeling events in advanced endocrine resistant ER-positive breast cancers. *Breast Can Treat Res* 2017; 40: abstract GS2-03.
196. Raymond VM, Diaz J, Banks KC, Ahn E, **Brufsky A**, Ellis M, Lippman M, Lee C, Pluard T, Schreeder M, Schwab R, Lanman RB. Cell free DNA analysis identifies

actionable *ERBB2* amplifications in patients with HER2 negative breast cancer. Breast Can Treat Res 2017; 40: abstract P2-02-12.

197. Dabbs DJ, Serdy K, Onisko A, Clark BZ, Bhargava R, Smalley S, Perkins S, **Brufsky AM**. The clinical utility of oncotype Dx for patients with recurrence scores of 10 or less: A value - based pathology study of tumor histopathology and outcomes analysis in an integrated delivery and finance health system. Breast Can Treat Res 2017; 40: abstract P4-08-04.
198. Thomas RA, Klar N, Diergaarde B, Kiedrowski LA, Nagy RJ, Lee AV, **Brufsky A**. Use of cell-free DNA for management of breast and lung cancer by academic and community providers. J Clin Oncol 37, 2018 (suppl; abstr 12046).
199. Dhakal A, Thomas RA, Levine E, **Brufsky A**, Hanna MG, Miller A, Khoury T, Takabe K, Early A, O'Connor T, Opyrchal M. Outcome of everolimus based therapy in hormone receptor positive metastatic breast cancer patients after progression on palbociclib combination. J Clin Oncol 37, 2018 (suppl; abstr 1064).
200. Bardia A, Rich TA, Raymond VM, Fairclough SR, Sartor AO, Lilly MB, Nezami M, Patel SN, Carneiro BA, Fan AC, **Brufsky A**, Parker BA, Bridges BB, Agarwal N, Maughan BL, Lanman RB, Cristofanilli M. Landscape of *BRCA1* and *BRCA2* germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer. J Clin Oncol 37, 2018 (suppl; abstr 12097).
201. Sparano JA, Gray RJ, Wood WC, Makower DF, Lively TG, Saphner TJ, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer D, **Brufsky A**, Goetz MP, Hayes DF, Dees EC, Pritchard KI, Geyer, CE, Olson JA, Sledge GW. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. J Clin Oncol 37, 2018 (suppl; abstr LBA1, plenary session).
202. Klar NJ, Rosenzweig M, Diergaarde B, **Brufsky A**. Features associated with long-term survival in metastatic breast cancer. Breast Can Treat Res 2018; 41: abstract P2-08-48.
203. Vidal G, Kalinsky K, Stringer-Reasor E, Lynce F, Cole J, Valdes-Albini F, Soliman H, Nikolinakos P, Silber A, DeMichele A, Ali H, Graham D, Giguere J, **Brufsky A**, Liang Y, Holland S, Fiji G, O'Keeffe B, Gogineni K. Efficacy and safety of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC): Initial findings from a multicenter, open-label phase 2 study. Breast Can Treat Res 2018; 41: abstract P6-20-07.
204. Rich TA, Raymond VM, Ahn ER, Banks KC, **Brufsky A**, Lee C, Lippman M, Pluard TJ, Schwab RB, Lanman RB. Cell free DNA analysis identifies actionable *ERBB2* amplifications in patients with HER2 equivocal breast cancer Breast Can Treat Res 2018; 41: abstract P4-01-05.
205. Albain K, Gray RJ, Sparano JA, Makower DF, Pritchard KI, Hayes DF, Geyer, Jr. CE, Dees EC, Goetz MP, Olson, Jr. JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis

- MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, **Brufsky AM**, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge, Jr. GW Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial. *Breast Can Treat Res* 2018; 41: abstract GS4-07.
206. Won HH, Selcuklu SD, Piha-Paul SA, Saura C, Rodon J, Mayer IA, Loi S, Shapiro G, Lu J, **Brufsky A**, Zimel C, Melcer M, Scaltriti M, Eli LD, Cutler RE, Lalani AS, Bryce RS, Arteaga C, Meric-Bernstam F, Berger MF, Solit DB, Schram A, Hyman DM. Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial. *Proc AACR 2019*; abstract 929.
207. Kummar S, Li S, Reiss K, Ford JM, Mitchell EP, Zwiebel JA, Takebe N, Gray RL, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, **Brufsky AM**, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. NCI-MATCH EAY131-Z11: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing *BRC1* and *BRC2* mutations. *Proc AACR 2019*; abstract CT 138/4.
208. Saura C, Oliveira M, Feng YH, Dai, MS, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar WJ, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Bryce R, Yao B, Bechuk JD, Keyvanjah K, **Brufsky A**. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. *J Clin Oncol* 2019; 37 (suppl; abstr 1002).
209. Sparano JA, Gray RJ, Makower DF, Lively TG, Saphner TJ, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer D, **Brufsky A**, Goetz MP, Hayes DF, Dees EC, Pritchard KI, Geyer CE, Olson JA, Albain KS, Sledge GW. Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. *J Clin Oncol* 2019; 37 (suppl; abstr 503).
210. **Brufsky A**, Kim SB, Zvirbule Z, Dirix LY, Eniu AE, Carabantes F, Izarzugaza Y, Mebis J, Sohn J, Wongchenko M, Chohan S, Amin R, McNally VA, Miles D, Loi S. Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC). *J Clin Oncol* 2019; 37 (suppl; abstr 1013).
211. Wander SA, Zangardi M, Niemierko A, Kambadakone A, Kim LSL, Xi J, Pandey A, Spring L, Stein C, Juric D, Kuter I, Moy B, Mulvey TM, Vidula N, Isakoff SJ, Yuen M, **Brufsky A**, Ma CX, O'Shaughnessy J, Bardia A. A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). *J Clin Oncol* 2019; 37 (suppl; abstr 1057).
212. Wesolowski R, **Brufsky AM**, Chambers M, Bhattacharya S, Lustberg M, VanDeusen JB, Sardesai S, Williams N, Noonan AM, Phelps M, Grever M, Stephens J, Carson W, Ramaswamy B. Phase 1b study of heat shock protein 90 inhibitor, onalespib in combination

with paclitaxel in patients with advanced, triple negative breast cancer. *Ann Oncol* 2019; 30 (suppl_5): v104-v142.

213. Untch M, Geyer CE, Huang S, Loibl S, Wolmark N, Mano MS, von Minckwitz G, **Brufsky AM**, Pivot X, Polikoff J, Fontana A, Kaufman B, Alcedo JC, Boulet T, Liu H, Song C, Mamounas EP. Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant therapy of Her2 positive EBC. *Ann Oncol* 2019; 30 (suppl_5): v851-v934.
214. LoRusso P, Pilat MJP, Santa-Maria CA, Connolly RM, Roesch EE, Afghahi A, Han HS, Nanda R, Wulf GM, Assad H, Park H, Dees EC, Force JM, Noonan AM, **Brufsky A**, Abramson VG, Haley BB, Buys SS, Sharon E, Schalper KA. Trial in progress: A phase II open label, randomized study of PARP inhibition (Olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, local y advanced or Metastatic non-HER2-positive breast cancer. *Journal of Clinical Oncology*, Volume 38, Issues 15 suppl. TPS 1002.
215. Owusu C, Margevicius SP, Klepin HD, Vogel CL, Alahmadi A, Vuyyala S, **Brufsky A**. Safety and efficacy of single-agent adjuvant trastuzumab in older women with early-stage breast cancer. *Journal of Clinical Oncology* Volume 38, Issue 15 suppl. https://ascopubs.org/doi/abs/10.1200/jco.2020.38.15_suppl.528 .
216. Hyder T, Rosenzweig, MQ, **Brufsky A**. Ixabepilone efficacy and tolerability in metastatic breast cancer (MBC) patients in a real-world setting. *Journal of Clinical Oncology*, Volume 38, Issue 15 suppl. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e13067 .
217. Brufsky A, Crozier JA, Chuba PJ, Lee SH, Menicucci A, Kling HM, Yoder E, Audeh W, FLEX Investigators' Group. Adding precision to 2018 ASCO/CAP HER2 testing guidelines in breast cancer with genomic profiling. *Journal of Clinical Oncology*, Volume 38, Issue 15 suppl. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3570.
218. Gomez Marti JL, Rosenzweig MQ, **Brufsky A**. Assisting decision making on the use of carboplatin for metastatic breast cancer. *Journal of Clinical Oncology*, Volume 38, Issue 15 suppl. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e13008 .
219. D'Abreo N, Crozier Ja, **Brufsky A**, Grady I, Diab S, Mavromatis BH, Dul CL, Rahman RL, Lee LA, Gadi VK, Untch S, Yoder E, Kling HM, Truitt A, Audeh W, FLEX Investigators Group. The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early-stage breast cancer. *Journal of Clinical Oncology*, Volume 38, Issue 15 suppl. TPS 7088.
220. **Brufsky A**, Chen C, Mardekian J, Xianchen L, McRoy I, Torres M. Characteristics of MBC patients receiving first line treatments in the US real-world setting in the ears of CDK4/6 inhibitors. Poster P1-10-26. San Antonio Breast Cancer Symposium, San Antonio, TX. December 11, 2019.

221. Wildiers H, Boni V, Saura C, Oliveria M, Jhaveri K, Won H, Bidard F, **Brufsky AM**, Burkard ME, Cervantes A, Fernandez-Martos C, Haley B, Loi S, Spanggaard I, Panni S, Lu J, Dujka ME, Xu F, Macia S, Eli LD, Lalani AS, Piha-Paul S, Meric-Bernstam F, Solit DB, Hyman DM. Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor=positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial. Poster P1-19-08. San Antonio Breast Cancer Symposium, San Antonio, TX. December 11, 2019.
222. DeMichele A, Cristofanilli M, **Brufsky A**, Liu X, Mardekian J, McRoy L, Layman RM, Rugo HS, Finn RS. Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice. Poster P1-10-02. San Antonio Breast Cancer Symposium, San Antonio, TX. December 11, 2019.
223. Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer Jr CE, Rastogi, P, Fehrenbacher L, Graham ML, Chia SK, **Brufsky AM**, Walshe JM, Sorri GS, Dakhil SR, Seay TE, Wade III JL, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N. Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI). Poster GS4-01. San Antonio Breast Cancer Symposium, San Antonio, TX. December 12, 2019.
224. Gomez JL, **Brufsky A**. Abstract S05-03: Preserving innate memory to overcome SARS-CoV-2 infection through the mevalonate pathway. Oral Presentation, AACR Virtual Meeting: COVID-19 and Cancer; July 20-22, 2020. Clin Can Res, doi: 10.1158/1557-3265. COVID-19-S05-03. Clin Can Res, published September 2020.
225. Crozier J, **Brufsky A**, Grady I, Diab S, Mavromatis B, D’Abreo N, Dul C, Rahman RL, Untch S, Yoder E, Kling HM, Truitt AM, Audeh W, van der Baan B, and Flex Investigators Group. Abstract LB-320: The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early-stage breast cancer. DOI; 10.1158/1538-7445.AM2020-LB-320 Published August 2020.
226. Ademuyiwa FO, Gao F, Chen I, Northfelt DW, Wesolowski R, Arora M, **Brufsky A**, Dees C, Santa-Maria CA, Connolly RM, force J, Moreno-Aspitia A, Larson S, Sharon E, Gillanders W. PD14-09.Nci10013-A Randomized phase 2 study of neoadjuvant carboplatin and paclitaxel, with or without atezolizumab in triple negative breast cancer (TNBC). Virtual Spotlight Poster Discussion, San Antonio Breast Cancer Symposium, December 11, 2020.
227. Saura C, Ryvo L, Hurvitz S, Gradishar W, Moy B, Dealoge S, Kim SB, Oliveria M, Trudeau M, Dai MS, Haley B, Bose R, Landeiro L, Bechuk J, Frazier A, Keyvanjah K, Bryce R, **Brufsky A**. PD13-09. Impact of neratinib on outcomes in HER2-positive metastatic breast cancer patients with central nervous system disease at baseline: Findings from the phase 3 NALA trial. Virtual Spotlight Poster Discussion, San Antonio Breast Cancer Symposium, December 11, 2020.
228. Bardia A, Cristofanilli M, Cha J, Kiedrowski L, Juric D, Park BH, **Brufsky A**, O’Shaughnessy J, Nagy B, Ellisen L, Leshchiner I, Getz G. PD9-07. Genomic landscape of metastatic breast

cancer (MBC): Comprehensive cell-free DNA analysis from over 10,000 patients and comparison with primary breast cancer. Virtual Spotlight Poster Discussion, San Antonio Breast Cancer Symposium, December 10, 2020.

229. Richman AH, Patel AK, Soran A, Diego EJ, McAuliffe PF, Johnson RR, **Brufsky A**, Gorantla V, Steiman J, Lee JS, Beriwal S. PD4-08. Does genomic recurrence score predict for ipsilateral breast tumor recurrence after breast conservation therapy? Virtual Spotlight Poster Discussion, San Antonio Breast Cancer Symposium. December 10, 2020.
230. Mayer IA, Haley BB, Abramson VG, Brufsky A, Rexer B, Stringer-Reasor E, Jhaveri KL, Sanders M, Ericsson-Gonzalez PI, Ye F, Artega CL. PD1-03. A phase Ib trial of fulvestrant + CDK4/6 inhibitor (CDK4/6i) Palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ER+/HER2-negative metastatic breast cancer (MBC). Virtual Spotlight Poster Discussion. San Antonio Breast Cancer Symposium. December 9, 2020.
231. McAuliffe, PF, Carleton NM, Zou J, Fang Y, Koscumb SE, Shah O, Fangyuan Chen Beriwal S, Diego EJ, **Brufsky AM**, Oesterreich S, Shapiro SD, Ferris R, Emens LA, Tseng G, Marroquin OC, Lee AV. PS1-10. Outcomes after sentinel lymph node biopsy and radiation therapy in women over 70 years old with ER+, HER2-, clinically node negative breast cancer. Virtual Poster Session, San Antonio Breast Cancer Symposium. December 9, 2021.
232. Moy B, Oliveria M, Saura C, Gradishar W, Kim SB, **Brufsky A**, Hurvitz S, Ryvo L, fagnani D, Chan N, Kalmadi SR, Silverman P, Deleloge S, Bryce R, Keyvanjah K, Bechuk J, Zhan B, Oestreich N, Bose R. PS9-02. Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and \geq prior HER2-directed regimens. Virtual Poster Session, San Antonio Breast Cancer Symposium. December 9, 2020.
233. Hyder T, Rosenzweig M, **Brufsky AM**. PS13-47. Real world study on the efficacy and tolerability of ixabepilone monotherapy vs. combination therapy with capecitabine in metastatic breast cancer patients (MBC). Virtual Poster Session, San Antonio Breast Cancer Symposium. December 9, 2020.
234. Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, Geyer CE, Fehrenbacher L, Graham M, Chia SKL, **Brufsky A**, Walshe JM, Soori GS, Dakhil SR, Paik S, Swain SM, Sgroi D, Schnabel CA, Wolmark N. Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG Oncology/NSABP B-42. Oral Abstract Session, American Society of Clinical Oncology Annual Meeting. June 2021.
235. Rastogi P, Bandos H, Lucas PC, van t Veer L, Wei JPI, Geyer CE, Fehrenbacher L, Graham M, Chia SKL, **Brufsky A**, Walshe JM, Soori GS, Dakhil SR, Paik S, Swain SM, Menicucci A, Wang S, Audeh MW, Wolmark N, Mamounas EP. Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG oncology/NSABP B-42 trial. American Society of Clinical Oncology, Annual Meeting 2021. Virtual Oral Poster Presentation. June 6, 2021.

236. **Brufsky A**, Liu X, Li B, McRoy L, Layman RM. Real-world effectiveness of Palbociclib plus letrozole vs Letrozole alone for metastatic breast cancer with lung/liver metastases: flatiron database analysis. P1-18-20 Poster Session. San Antonio Breast Cancer Symposium, San Antonio, TX, December 8, 2021.
237. Brett JO, Dubash TD, Niemierko A, Marotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Lloyd MR, Spring LM, Micalizzi D, Onazato M, Che D, **Brufsky A**, Kalinsky KM, Ma CX, O'Shaughnessy J, Han HS, Iafrate AJ, Maheswaran S, Haber DA, Bardia A, Wander SA. Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus Palbociclib or ribociclib. PD2-03 Poster Session. San Antonio Breast Cancer Symposium, San Antonio, TX, December 8, 2021.
238. Hurvitz SA, Chaves J, **Brufsky A**, Montero AJ, Fang B, Yeung K, Patel MR, Parajuli R, Omidpanah A, Gartner E, Fong A, Randolph S, Meric-Bernstam F. Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2) expressing cancers, including breast cancer: A phase 1b/2, multicenter, open label, dose finding and cohort expansion study (ZWI ZW25 204). OT1-14-01 Poster Session. San Antonio Breast Cancer Symposium, San Antonio TX, December 8, 2021.
239. Lin NU, Lueftner D, **Brufsky AM**, Tolaney SM, Melisko ME, Holmes FA, Awada A. Central nervous system metastases as a site of first recurrence in adjuvant therapy trials of HER2+ early breast cancer (EBC). P2-13-05 Poster Session. San Antonio Breast Cancer Symposium, San Antonio, TX, December 8, 2021.
240. Jhaveri K, Park H, Waisman J, Goldman JW, Guerrero-Zotano A, Boni V, Haley b, Mayer IA, **Brufsky A**, Yang ES, Garcia-Saenz JA, Bidard F-C, Crown J, Zhang B, Frazier A, Diala I, Elil LD, Barnett B, Wildiers H. Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: latest updates from the SUMMIT trial. P2-13-50 Poster Session. San Antonio Breast Cancer Symposium, San Antonio, TX, December 8, 2021.
241. Veenstra DL, Hendrix N, Dolan Cm, Fisher KA, Lalla D, Oestreicher N, **Brufsky A**. Estimating the long-term risk of recurrence in patients receiving HER2-targeted agents in HER2+ early-stage breast cancer (ESBC). P2-11-19 Poster Session San Antonio Breast Cancer Symposium, San Antonio, TX, December 8, 2021.
242. **Brufsky A**, Linden H, Rugo H, Vogel C, O'Shaughnessy JA, Getzenberg RH, Barnette KG, Rodriguez D, Steiner MS, Mayer E. Randomized, multicenter, international phase 3 ARTEST study to evaluate the efficacy and safety of enobosarm versus active control for the treatment of AR+ER+Her2- metastatic breast cancer in patients who progressed on a nonsteroidal aromatase inhibitor, fulvestrant and CDK4/6 inhibitor. OT2-17-01 Poster Session. San Antonio Breast Cancer Symposium, December 9, 2021, San Antonio, TX.
243. Cortes J, Bardia A, Loirat D, Tolaney SM, Punie K, Oliveira M, Hurvitz SA, **Brufsky A**, Sardesai S, Kalinsky KM, Traina T, Hamilton E, O'Shaughnessy J, Dieras V, Carey LA,

- Piccart M, Loibl S, Rugo HS, Zhu Y, Gianni L. Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of Sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). P5-16-15. Poster Session. San Antonio Breast Cancer Symposium, San Antonio, TX. December 10, 2021.
244. DeHaven C, Nasrazadani A, **Brufsky A**. Socioeconomic and geographic barriers affect rates of standard of care therapy utilization in patients with hormone receptor positive, HER2 negative metastatic breast cancer. P5-14-18 Poster session. San Antonio Breast Cancer Symposium, San Antonio, TX, December 10, 2021.
245. Rugo HS, **Brufsky A**, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, Demichele A. Overall Survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis. 169P. Poster Display session ESMO Breast Cancer Congress, Berlin, Germany. May 4, 2022.
246. Chan A, Ruiz Borrego M, Marx G, **Brufsky A**, Chien AJ, Thirlwell MP, Trudeau ME, Bose R, Garcia Saenz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Semsek D, Singer CF, Diprimeo D, Foruzan N, McCulloch LM, Barcenas CH. Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Final findings from the CONTROL trial. 73P Poster Display Session, ESMO Breast Cancer Congress, Berlin, Germany. May 4, 2022.
247. **Brufsky A**, Linden H, Rugo HS, Vogel C, O'Shaughnessy J, Getzenberg RH, Barnette KG, Rodriguez D, Steiner MS, Mayer E. Randomized, Multicenter, International Phase 3 ARTEST study to Evaluate Enobosarm Versus Active Control for the Treatment of AR+ ER+HER2- Metastatic Breast Cancer in Patients Who Previously Received and Estrogen Blocking Agent and CDK 4/6 inhibitor. 206TIP, Poster Display Session, EMSO Breast Cancer Congress, Berlin, Germany. May 4, 2022.
248. Nasrazadani A, Gomez Marti JL, Hyder T, Uygun S, Blumencranz LE, Mittempergher L, Audeh W, **Brufsky A**. Investigation of a genomic signature for transcription factor MAF gene amplification and lack of bisphosphonate benefit in early breast cancer. Poster# 331 American Society of Clinical Oncology Annual Meeting, Chicago IL. June 3-7, 2022.
249. Narayanan SP, Rosenzweig MQ, Ren D, Oesterreich S, Lee AV, **Brufsky A**. Effect of socioeconomic status as measured by Neighborhood Deprivation Index on survival in metastatic breast cancer. Abstract #1013. American Society of Clinical Oncology Annual Meeting, Chicago, IL. June 3-7, 2022.
250. **Brufsky A**, Lenz L, Pudusseri A, Wright D, Patel KB, Clifford BT, O'Connor TL, Strain S, Kayali F, Ratzel S, Cummings S, Kronewett R, Slavin TP. Adherence to EndoPredict test scores for extended endocrine therapy management in the prospective EndoPredict Extended Endocrine Trial (EXET). Poster Bd # 309. American Society of Clinical Oncology Annual Meeting, Chicago IL. June 3-7, 2022.

251. Jhaveri KL, Goldman JW, Hurvitz SA, Guerrero-Zotano A, Unni N, **Brufsky A**, Park H, Waisman JR, Shih-Hsin Yang E, Spanggaard I, Reid SA, Burkard ME, Prat A, Loi S, Crown J, Hanker A, Ma CX, Bose R, DeFazio L, Wildiers H. Neratinib plus Fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR +), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial. Poster Bd# 406. American Society of Clinical Oncology Annual Meeting, Chicago IL. June 3-7, 2022.
252. Socoteanu MP, O'Shaughnessy J, Hoskins K, **Brufsky A**, Graham CL, Vukelja SJ, Misleh JG, Tedesco KL, Rahman RL, Lee J, Berrocal J, Sharma K, Begas A, Crozier J, Grady I, D'Abreo N, Kuilman MM, Hguyen H, Blumencranz LE, Audeh MW. Clinical implications for patients with discordant oncotype and MammaPrint results. Poster 332. American Society of Clinical Oncology Annual Meeting, Chicago IL. June 3-7, 2022.
253. Socoteanu MP, O'Shaughnessy J, Hoskins K, **Brufsky A**, Graham CL, Vukelja SJ, Misleh JG, Tedesco KL, Rahman RL, Lee J, Berrocal J, Sharma K, Begas A, Crozier J, Grady I, D'Abreo N, Nguyen H, Blumencranz LE, Audeh MW, Kuilman MM. Whole transcriptome analysis of tumors with discordant oncotype and MammaPrint results in the FLEX Trial. Poster 328. American Society of Clinical Oncology Annual Meeting, Chicago IL. June 3-7, 2022.
254. Ma CX, Whitworth PW, Vukelja SJ, Gray CR, Diab S, Crozier J, Berrocal J, Habibi M, **Brufsky A**, Maganini R, Srkalovic G, Bupathi M, Feinstein T, O'Shaughnessy J, Barone J, Rehmus EH, Lee LA, Nguyen H, Blumencranz LE, Audeh MW. FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data. Poster Bd # 380b. American Society of Clinical Oncology Annual Meeting, Chicago IL, June 3-7, 2022.
255. Bardia A, Tolaney SM, Loirat D, Punie K, Olivera M, Rugo HS, **Brufsky A**, Kalinsky K, Cortes J, O'Shaughnessy J, Dieras VC, Carey LA, Gianni L, Piccart-Gebhart MJ, Loibl S, Zhu Y, Phan SH, Hurvitz S. Sacituzumab Govitecan (SG) versus treatment of physician's choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study. Poster Bd# 449. American Society of Clinical Oncology Annual Meeting, Chicago, IL. June 3-7, 2022.
256. Sivapiragasam A, Denley RC, **Brufsky A**, Rehmus EH, O'Shaughnessy J, Crozier JA, Diab S, Barone J, Yeager J, Menon P, Kuilman MM, Samraj L, Blumencranz LE, Audeh MW. Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study. Poster 126. American Society of Clinical Oncology Annual Meeting, Chicago IL. June 3-7, 2022.
257. Lim E, **Brufsky A**, Rugo HS, Vogel CL, O'Shaughnessy J, Getzenberg RH, Barnette KG, Rodriguez D, Bird G, Steiner MS, Linden HM. Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2-metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy. Poster 491a. American Society of Clinical Oncology Annual Meeting, Chicago IL. June 3-7, 2022.

258. Goetz MP, Plourde P, Stover DG, Bagegni N, Vidal GA, **Brufsky A**, Rugo HS, Portman DJ, Gal-Yam E. Open-label, randomized study of Lasofoxifene (LAS) vs Fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2-breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors. LBA20 Mini Oral Session, ESMO Congress, Paris, France. September 10, 2022.

PROFESSIONAL ACTIVITIES

TEACHING:

Medical School Courses

1986–1988	<u>Instructor</u> , Seminar in Ethics of Biomedical Research University of Connecticut Weekly seminar of 8 students, 2 hours per week.
1987	<u>Preceptor/Advisor</u> Choate Rosemary Hall Senior Thesis Program
1987–1988	<u>Lecturer</u> , Minority Student Scholars Program University of Connecticut Weekly lecture (4h/wk x 10 wk), 100 students.
1988	<u>Lecturer</u> , AIDS and the Law University of Connecticut Law School Monthly lecture x 2 mo to 80 law students.
1996	<u>Preceptor</u> Physical Diagnosis Three second year medical students, six week course.
1996-2000 2001-2009	<u>Course Co-Director</u> <u>Course Director</u> Neoplasia Fourth Year Selective University of Pittsburgh School of Medicine Required one month course/20-30 fourth year medical students
2001-2003	<u>Preceptor</u> MD-PhD Student, Jessica Simpson, 6 month clinical rotation
2007-2014	<u>Preceptor, Scholarly Project</u> Philip Chaffin, MS4, Characteristics of African American Metastatic Breast Cancer

Wendy Schroeder, MS4, Radiological Correlates of Increased Circulating Tumor Cells in Metastatic Breast Cancer
Elizabeth Lin, MS4, Adherence to Breast Cancer Quality Measures in Dailian, China

Housestaff and Fellow Training

- 1994 Preceptor, Medical Oncology Fellows Clinic
Dana-Farber Cancer Institute
6h/wk x 3 wk as clinical resource in adult clinic.
- 1995-1996 Outpatient Teaching Attending
Dana-Farber Cancer Institute
16 hours/month as outpatient clinic attending.
- 1996- Teaching Attending
University of Pittsburgh School of Medicine
Oncology Rotation, Department of Medicine
- 1996- Consult Attending
University of Pittsburgh Cancer Institute
One fellow, one medical resident per month
- 1997- Facilitator, Host Defense Course, Hematology/Medical Oncology
University of Pittsburgh School of Medicine
Nine first year medical students
- 1997- Facilitator, Integrated Life Sciences Selective Course in Clinical
Pharmacology
University of Pittsburgh Medical Center
Nine second year medical students
- 1997- Teaching Attending
University of Pittsburgh School of Nursing
Oncology Rotation, Nurse Practitioner Training Program
1 trainee per month, 3 months per year
- 1998-2002 PhD Thesis Advisor
University of Pittsburgh School of Nursing
Peg Rosenzweig, CRNP (PhD Candidate)
Thesis Title: Anemia and Quality of Life in Women with Metastatic Breast Cancer
- 1999- Teaching Attending

University of Pittsburgh School of Medicine
University of Pittsburgh Cancer Institute
Oncology Rotation, Department of Medicine
1 PGY-2 per month, 10 months per year

- 2001-2004 Research Supervisor
University of Pittsburgh School of Medicine
University of Pittsburgh Cancer Institute
Paul Hergenroder, MD (Medical Oncology Fellow)
Microarray Analysis of Prognosis in Breast Cancer
NIH Loan Repayment Candidate
- 2005-2007 Research Supervisor
University of Pittsburgh School of Medicine
University of Pittsburgh Cancer Institute
Avina Kapoor, MD (Medical Oncology Fellow)
Selina Chow, MD (Medical Resident)
Mechanisms of Clinical Resistance to Trastuzumab
- 2005-2007 Research Supervisor
University of Pittsburgh School of Medicine
University of Pittsburgh Cancer Institute
Brian Geller, MD (Medical Oncology Fellow)
Immune response to MUC-1 and Progression to Invasive Breast
Cancer
- 2006-2008 Residency Subspecialty Education Coordinator
Hematology-Oncology Division
Department of Medicine
University of Pittsburgh School of Medicine
- 2008-2009 Research Supervisor
University of Pittsburgh School of Medicine
Tofumi Onokye, MD (Internal Medicine Resident)
Long Term Treatment with Bisphosphonates in Metastatic Breast
Cancer: Toxicities and Outcome
- 2008-2009 Thesis Advisor
University of Pittsburgh
Department of Medical Genetics
Kelly Knickelbein, AB (Genetic Counseling MS Candidate)
Genetic Basis of Secondary Lymphedema after Breast Surgery
- 2009-present Research Supervisor
University of Pittsburgh
Multiple Medical Residents and Fellows
Multiple Projects in Metastatic Breast Cancer

RESEARCH:

Current Funding:

Federal

National Cancer Institute 1UG1CA233184-01

Title: Network Lead Academic Participating Site: University of Pittsburgh

Role: Principal Investigator (20% effort)

Amount FY23: Direct: \$582,157 Total: \$911,076

Award Period: 5/1/19-2/28/24

National Surgical Breast and Bowel Adjuvant Program (NSABP)

Title: "Site 14 Treatment Grant"

Role: Principal Investigator (7.5% effort)

Amount FY 23: Direct \$357,911 Total \$535,077

Award Period: 8/1/20-7/31/25

Eastern Cooperative Oncology Group (ECOG)

Title: "ECOG Main Institution"

Role: Co-Investigator (Kirkwood, PI) (2.5% effort)

Amount FY 23: Direct \$5,560; Total \$8,312

Award Period: 8/1/20-7/31/25

Non-Federal

Various Clinical Non-Federal Clinical Trials

Title: Non-Federal Clinical Trials

Role: Principal Investigator (30% effort)

Amount: FY 23: Direct \$329,110 Total \$411,387

Award Period: various ending 2/28/24

Prior Funding:

National Institutes of Health Clinical Investigator Award K08 CA67993-02

Title: "Androgen Receptor Associated Proteins in Prostate Cancer"

Role: Principal Investigator (30% effort)

Award Period: 7/17/96-6/30/00

Total Funding: (All FY) \$318,020 total, \$294,463 direct

University of Pittsburgh Cancer Institute American Cancer Society Heckman Award

Title: "Androgens and Increased Risk of Prostate Cancer Among African Americans."

Role: Principal Investigator (5% effort)

Award Period: 7/1/96-6/30/97
Amount: (All FY) \$14,350 total, \$14,350 direct

National Institutes of Health NO1-CN-65024-32
Title: "Phase II Clinical Trials of Chemopreventive Agents, Workstatement 42"
Role: Co-Investigator (Trump, PI) (10% effort)
Award Period: 2/15/97-8/14/99
Amount: (FY 99) \$276,932 total, \$184,621 direct

Biomira Pharmaceuticals
Title "A Multicenter Phase III Randomized, Controlled Study of Theratope Vaccine for Metastatic Breast Cancer"
Role: Principal Investigator (2% effort)
Award Period: 6/1/98-12/31/01
Amount: (All FY) \$72,800 total, \$58,240 direct

Aventis Pharmaceuticals
Title: "Phase II trial of Carboplatin/Taxotere in metastatic breast cancer"
Role: Principal Investigator (2% effort)
Award period: 7/1/98-1/31/03
Amount: (All FY) \$169,200 total, \$135,200 direct

National Institutes of Health 3 P30 CA47904-10S2
Title: "Cancer Center Support: Prostate Cancer Survivor's Quality of Life"
Role: Co-Investigator (Baum, PI) (5% effort)
Award Period: 8/1/98-7/31/99
Amount: (FY 99) \$103,218 total, \$68,812 direct

U.S. Army Medical Research and Development DAMD 17-99-1-9015
Title: "Tobago Prostate Survey: Prostate Cancer Risk in a Population-Based Study of Men of African Descent"
Role: Co-Investigator (Bunker, PI) (5% effort)
Award Period: 10/1/98-9/30/99
Amount: (FY 99) \$187,500 total, \$125,000 direct

National Institutes of Health R0-1
Title: "Molecular Epidemiology of Prostate Cancer in Tobagonians"
Role: Co-Investigator (Bunker, PI) (5% effort)
Award Period: 10/1/99-9/30/04
Amount: (All FY) \$2,851,956 total, \$1,901,184 direct

National Institutes of Health
Title: "Stress & Life Quality in Long Term Cancer Survivors"
Role: Co-investigator (Baum, PI) (5% effort)
Award Period: 4/1/00-3/31/04
Amount: (All FY) \$1,875,000 total, \$1,250,000 direct

Division of Medical Oncology Pilot Funding Program

Title: "SAGE and Prognosis in Breast Cancer"

Role: Principal Investigator (10% effort)

Award Period: 9/1/00-8/30/01

Amount: (FY 01) \$25,000 total, \$25,000 direct

Susan G. Komen Foundation BCTR2000765

Title: "SAGE analysis of cDNAs Associated with Primary Node Positive Breast Cancer"

Role: Principal Investigator (15% effort)

Award Period: 10/1/00-9/30/03

Amount: (All FY) \$250,000 total, \$200,000 direct

Department of Defense US Army Breast Cancer Research Program DAMD17-01-1-0608

Title: "DOD Concept Award FY 00: SAGE in Breast Cancer"

Role: Principal Investigator (5% effort)

Award Period: 7/1/01-6/30/03

Amount: (FY 02) \$75,000 total, \$50,000 direct

Ares-Serono Pharmaceuticals

Title: "A Phase II Multicenter Study of the efficacy of recombinant r-HCG for third line treatment of metastatic breast cancer in post menopausal women."

Role: UPCI Principal Investigator (2% effort)

Award Period: 3/28/01-3/30/05

Amount: (All FY) \$87,500 total

Biomira Corporation

Title: "A Phase III Trial Of Theratope Vaccine In Metastatic Breast Cancer"

Role: UPCI Principal Investigator (2% effort)

Award Period: 3/31/01-12/31/05

Amount: (All FY) \$77,800 total

Novartis Pharmaceuticals

Title: "A Randomized Comparative Trial Of Zolendronate Vs Aredia As An Adjunct To Chemotherapy Or Hormonal Therapy In The Treatment Of Metastatic Breast Cancer."

Role: UPCI Principal Investigator (2% effort)

Award Period: 3/31/01-3/31/05

Amount: (All FY) \$183,200 total

Department of Defense US Army Breast Cancer Research Program

DAMD17-01-1-0374

Title: "The Pittsburgh Breast Cancer Consortium"

Role: Principal Investigator (35% effort)

Award Period: 9/1/01-8/30/05

Amount: (All FY) \$1,797,598 total; \$1,198,350 direct

Aventis Pharmaceuticals

Title: "Phase II trial of Carboplatin/Taxotere/Herceptin in metastatic breast cancer"
Role: Principal Investigator (5% effort)
Award period: 7/1/99-6/30/05
Amount: (All FY) \$196,000 total, \$158,600 direct

Aventis Pharmaceuticals

Title: A Multicenter Phase II Study of RPR 116258 Administered as a 1-hour Intravenous Infusion Every Three Weeks in Taxoid Resistant Metastatic Breast Cancer Patients
Role: UPCI Principal Investigator (2% effort)
Award Period: 4/15/03-3/17/05
Amount (All FY): \$100,000 total

Novartis Pharmaceuticals

Title: "Zolendronate versus Aredia as adjunct to chemotherapy in MBC"
Role: Principal Investigator (2% effort)
Award Period: 10/1/99-2/1/06
Amount: (All FY) \$167,000 total, \$133,600 direct

Hillman Foundation

Title: Multiple Drug Resistance in Breast Cancer Stem Cells
Role: Co-Investigator (Donnenberg, PI) (10% effort)
Award Period: 7/1/04-6/30/06
Amount: (All FY) \$305,000 direct

National Institutes of Health 5R25CA063548-08

Title: "The Educational Resource for Tumor Heterogeneity"
Role: Co-Investigator (Day, PI) (5% effort)
Award Period 10/1/00-9/30/06
Amount: (All FY) \$1,230,657 total, \$615,329 direct

Department of Defense US Army Breast Cancer Research Program DAMD BC 044784

Title: "Breast Cancer Stem Cells: A Novel Therapeutic Target" (Donnenberg, PI)
Role: Co-Investigator (5% effort)
Award Period: 4/1/05-3/31/10
Amount: (All FY) \$2,500,000 direct

National Institutes of Health R01

Title "Fast 3D MR Spectroscopic Imaging of Human Breast Cancer"
Role: Co-Principal Investigator (2.5% effort) (He, Co-PI)
Award Period 7/1/05-6/30/10
Amount (All FY): \$1,779,616 total, \$1,250,000 direct

National Institutes of Health R01 CA 107408-01

Title: "Cognitive Impairment Related to Anastrozole Use in Women"
Role: Co-Investigator (5% effort) (Bender, PI)
Award Period 7/1/05-6/30/10
Amount (All FY): \$1,736,136 total, \$1,250,000 direct

Aventis Pharmaceuticals

Title: "Phase II Studies Of Neoadjuvant Docetaxel And Vinorelbine Followed By Surgery And Then Doxorubicin And Cytosin In Stage IIB And Stage III Breast Cancer"

Role: UPCI Principal Investigator (2% effort)

Award Period: 3/31/02-3/30/11

Amount: (All FY) \$128,500 total

Aventis Pharmaceuticals

Title: "Phase III Studies Of Neoadjuvant Docetaxel And Vinorelbine Followed By Surgery And Then Doxorubicin And Cytosin In Stage IIB And Stage III Breast Cancer"

Role: UPCI Principal Investigator (5% effort)

Award Period: 4/1/04-3/30/11

Amount: (All FY) \$300,000 total

Lilly Pharmaceuticals

Title: "Phase II Study of Gemcitabine and Traztuzumab therapy in Patients with Her2 Overexpressing Metastatic Breast Cancer"

Role: UPCI Principal Investigator (2% effort)

Award Period: 4/30/02-3/17/12

Amount (All FY): \$90,000 total

Orion Pharmaceuticals

Title: Phase III study of Tamoxifen vs toremifene as adjuvant therapy for Women with metastatic breast cancer"

Role: UPCI Principal Investigator (2% effort)

Award period: 4/30/02-10/30/11

Amount: (All FY) \$24,000 total

US Army Breast Cancer Research Program W81XWH-05-1-0182

Title: "Breast Cancer Stem Cells: A Novel Therapeutic Target"

Role: Co-Investigator (Donnenberg, PI) (2.5% effort)

Award Period: 4/5/05-3/31/12

National Institutes of Health HHSN 261201000058C

Title: "The University of Pittsburgh Research Tissue, Data and Biological Specimen Accrual Network Supporting NCIs The Cancer Genome Atlas Project"

Role: Co-Investigator (Dhir, PI) (5% effort)

Award Period: 9/29/10-2/28/12

National Institutes of Health HHSN 261201000058C

Title: "The University of Pittsburgh Research Tissue, Data and Biological Specimen Accrual Network Supporting NCIs The Cancer Genome Atlas Project"

Role: Co-Investigator (Dhir, PI) (5% effort)

Award Period: 9/29/10-2/28/12

Novartis Pharmaceuticals

Title: "An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy"

Role: National Principal Investigator (5% effort)

Award Period: 4/1/03-6/30/13

PA Commonwealth Cancer Research Program SAP# 4100050913

Title: "Breast Cancer Clinical Trials"

Role: Co-Investigator (Levine, PI) (2.5% effort)

Award Period: 1/1/10-12/31/13

American Cancer Society RSGT 09 150 01 CPHPS

Title: "The ACTS Intervention to Reduce Breast Cancer Treatment Disparity"

Role: Co-Investigator (Rosenzweig, PI) (1% effort)

Amount FY 14 Direct \$2,061 Total \$3,081

Award Period: 7/1/09-6/30/14

Stand Up to Cancer JHU PO# 2000904109, UPCI 11-012

Stand Up to Cancer-- Dream Team Translational Research Grant

Title: "Phase I/II Study of MS-275 and 5-Azacytidine in Triple-Negative Metastatic Breast Cancer"

Role: Co-Investigator (Davidson, PI, 10% effort)

Amount FY 14 Direct \$22,659 Total \$33,875

Award Period: 12/1/09-11/30/14

National Institutes of Health HHSN261201000003I

Title: "The Cancer Genome Atlas Project"

Role: Co-Investigator (Dhir, PI) (1.5% effort)

Amount FY 14: Direct \$2,913 Total: \$4,355

Award Period: 1/24/12-9/30/15

Magee-Womens Research Institute Pilot Program

Title: "Differences in Expression of High Affinity Folate receptor in Breast Cancer Brain Metastases in Comparison to Primary Tumor and Metastatic Extracranial Disease"

Role: Principal Investigator (2.5% effort)

Amount FY14: Direct \$25,000 Total \$25,000

Award Period: 7/1/15-6/30/16

Clinical Protocols:

DFCI 93-133 "Finasteride and flutamide: Phase II hormonal therapy for advanced prostate cancer (Co-principal investigator).

DFCI 95-069 "Phase I safety and immunogenicity trial of the UBI® LHRH Immunotherapeutic as androgen ablative therapy for advanced prostate cancer" (Co-principal investigator)

UPCI 94-104 (ECOG 3193) "Phase II comparison of tamoxifen versus tamoxifen and ovarian ablation in premenopausal women with axillary node-negative receptor positive breast cancer." (ECOG Study: PCI principal investigator)

UPCI 95-021 (NSABP B-23) "A clinical trial comparing short, intensive AC ± tamoxifen with conventional CMF ± tamoxifen in node-negative breast cancer patients with ER-negative tumors." (NSABP Study: PCI Co-investigator)

UPCI 95-041 "Phase III study of rhuMab HER2 plus chemotherapy compared with chemotherapy alone in patients with HER2/neu overexpression who have not received cytotoxic chemotherapy for metastatic breast cancer" (PCI principal investigator)

UPCI 95-110 (ECOG EB193) "Phase III double-blind, placebo controlled, prospective randomized comparison of adjuvant therapy with tamoxifen and fenretinide in post menopausal women with involved axillary lymph nodes and positive receptors" (ECOG Study: PCI principal investigator)

UPCI 95-113 (NSABP B-27) "A randomized trial comparing preoperative doxorubicin (adriamycin) cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel (taxotere) and to preoperative AC followed by postoperative docetaxel in patients with operable carcinoma of the breast." (NSABP Study: PCI Co-investigator)

UPCI 96-021 (NSABP B-21) "A clinical trial to determine the worth of tamoxifen and the worth of breast radiation in the management of patients with node-negative, occult, invasive breast cancer treated by lumpectomy." (NSABP Study: PCI Co-investigator)

UPCI 96-023 "An open label extension study with recombinant humanized anti-HER2 monoclonal antibody (rhuMab HER2) for patients whose metastatic breast cancer progressed during treatment on protocol HO648g (PCI 95-041)" (PCI principal investigator)

UPCI 96-095 (ECOG S9623) "A Comparison of Intensive Sequential Chemotherapy Using Doxorubicin plus Paclitaxel plus Cyclophosphamide with High Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary breast cancer in Women with 4-9 Involved Axillary Lymph Nodes, Phase III" (ECOG Study: PCI co-principal investigator)

UPCI 96-086 "Phase II trial of the CTP37A vaccine against beta-hCG as therapy for advanced hormone refractory prostate cancer." (Principal Investigator)

UPCI 97-029 (ECOG C9343) "Evaluation of lumpectomy, tamoxifen, and irradiation of the breast compared with lumpectomy and tamoxifen in women 70 years of age or older who have carcinoma of the breast that is less than or equal to 2 cm and clinically negative axillary nodes: a phase III study." (ECOG Study: PCI principal investigator)

UPCI 97-043 “Phase II open-label study of intravenous 3622W94 for the treatment of patients with hormone refractory prostate cancer.” (PCI principal investigator)

UPCI 97-051 (NSABP B-29) “A clinical trial to evaluate the benefit of adding octreotide (SMS 201-995 PA LAR) to tamoxifen alone or to tamoxifen and chemotherapy in patients with axillary node-negative, estrogen-receptor-positive, primary invasive breast cancer.” (NSABP Study: PCI co-investigator)

UPCI 97-072 “A Phase III pilot trial of modulation of high grade prostatic intraepithelial neoplasia (PIN) by hormonal therapy.” (Co-principal investigator)

UPCI 97-074 “Phase II clinical trial of liposomal annamycin in taxane-resistant breast cancer.” (PCI Principal Investigator)

UPCI 97-098 “A randomized phase III trial of marimastat vs. placebo in patients with metastatic breast cancer who have responding or stable disease after induction chemotherapy.” (PCI Principal Investigator)

UPCI 97-118 “A double-blind, multi-centered, randomized safety and efficacy trial of intravenous aredia (90 mg) versus placebo for the palliation of bone pain in the patient with advanced prostate cancer.” (PCI principal investigator)

UPCI 97-130 “Tissue, serum and urine banking for the University of Pittsburgh breast and prostate cancer tissue bank.” (PCI principal investigator)

UPCI 98-015 “A multicenter, expanded access, open-label, safety study of recombinant humanized anti-p185^{HER2} monoclonal antibody (rhuMAb HER2) in patients with HER2 overexpression who have relapsed following two cytotoxic chemotherapy regimens for metastatic breast cancer.” (PCI principal investigator)

UPCI 98-016 “A randomized, double-blind, placebo-controlled, multicenter, comparative, safety and efficacy study of intravenous zoledronate (4 and 8 mg) in prostate cancer patients with metastatic bone lesions receiving antineoplastic therapy.” (PCI principal investigator)

UPCI 98-017 “A phase II trial of carboplatin/taxotere in patients with metastatic breast cancer.” (PCI principal investigator)

UPCI 98-039 “Phase III Double-Blind Evaluation of the Optimal Schedule of SC-70935 in Patients with Breast Cancer Receiving Chemotherapy with Docetaxel, Doxorubicin and Cyclophosphamide (TAC).” (PCI principal investigator)

UPCI 98-059 “A Randomized, Double Blind, Placebo-controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 mg and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients with Any Cancer with Bone Mets except Breast, Multiple Myeloma or Prostate Cancer.” (PCI principal investigator)

UPCI 98-062 “Phase III Study of Adriamycin/Taxotere vs. Adriamycin/Cytosan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer.” (PCI principal investigator)

UPCI 98-070 “A Multi-Center Phase III, Randomized, Controlled Study of Theratope Vaccine for Metastatic Breast Cancer.” (PCI principal investigator)

UPCI 98-084 “A Randomized, Double-blind Multicenter, Comparative Trial of IV Zoledronate (4 mg or 8 mg) vs. IV Aredia (90 mg), As An Adjunct to Standard Therapies, in the Treatment of Multiple Myeloma and Breast Cancer Patients with Cancer Related Bone Lesions.” (PCI principal investigator)

UPCI 99-054 “A Phase II Study of the Efficacy and Tolerability of L-778123 in the Treatment of Metastatic Breast Cancer.” (PCI principal investigator)

UPCI 99-058 “Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients with Metastatic Breast Cancer.” (PCI principal investigator)

UPCI 99-123 “A Phase III Study of Doxorubicin-Cyclophosphamide therapy followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks In Patients with Axillary Node-Positive Breast Cancer.” (PCI Principal Investigator)

UPCI 00-042 “A Phase III Study of Tamoxifen vs Toremifene as Adjuvant Therapy for Women with Carcinoma of the Breast” (PCI Principal Investigator)

UPCI 00-075 “A Phase II Study of Neoadjuvant Docetaxel and Vinorelbine Followed by Surgery and Then Doxorubicin and Cytosan in Women with Stage IIB and Stage III Breast Cancer” (PCI Principal Investigator)

UPCI 01-013 “A Phase II Study of Neoadjuvant Taxotere/Navelbine plus Herceptin followed by Adjuvant Adriamycin and Cytosan in Women with HER-2 Overexpressing Locally Advanced Breast Cancer” (PCI Principal Investigator)

UPCI 01-040 “BCIRG 006 – Multi-center phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab and with docetaxel, platinum salt and trastuzumab in the treatment of node positive and high risk node negative adjuvant patients with operable breast cancer containing the Her2Neu alteration” (PCI Principal Investigator)

UPCI 01-158 “A phase II study of gemcitabine and trastuzumab therapy in patients with Her2 overexpressing metastatic breast cancer” (PCI Principal Investigator)

UPCI 01-188 “A Phase I/II open-label, multi-center, dose escalation, non-randomized two step study for the evaluation of CpG 7909 and herceptin in patients with breast cancer refractory to herceptin plus chemotherapy” (PCI Principal Investigator)

UPCI 02-004 “A Phase I Dose Escalation Study Of Trice Weekly Recombinant Human Interleukin-2 (12-7001, A Liquid Formulation Of Aldesleukin) In Combination With Trastuzumab In Subjects With Her-2/Neu Positive Metastatic Breast Cancer” (PCI Principal Investigator)

UPCI 02-012 “An open-label compassionate use protocol of faslodex (fulvestrant, ZD9238, ICI 182,780) in postmenopausal women with advanced breast cancer” (PCI Co-investigator)

UPCI 02-029 “A randomized phase III trial of paclitaxel versus paclitaxel and bevacizumab (rhuMAb VEGF) as first-line therapy for locally recurrent or metastatic breast cancer” (PCI Principal Investigator)

UPCI 02-079 “A Phase II Clinical Trial Of BMS-247550 (NSC 710428), An Etoposide B Analog, In Patients With Breast Cancer” (PCI Principal Investigator)

UPCI 02-081 “An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy” (National Principal Investigator)

UPCI 02-084 “A Multicenter Phase II Study of RPR 116258 Administered as a 1-hour Intravenous Infusion Every Three Weeks in Taxoid Resistant metastatic Breast Cancer Patients” (PCI Principal Investigator)

UPCI 02-094 “A Phase II Randomized Open-Label Study Of Letrozole In Combination With Two Dose Levels And Schedules Of Oral CCI-779, Or Letrozole Alone, In Postmenopausal Women With Locally Advanced Or Metastatic Breast Cancer” (PCI Principal Investigator)

UPCI 02-106 “An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent, Second-Line Therapy in Subjects with Advanced or Metastatic Breast Cancer who Failed a First-Line Regimen of Herceptin Plus Chemotherapy” (PCI Principal Investigator)

UPCI 03-026 “Phase II Trial of Paclitaxel or Docetaxel and Herceptin Administered Every 3 Weeks to Subjects with Metastatic Breast Cancer Receiving a First Treatment for Metastatic Disease.” (PCI Principal Investigator)

UPCI 03-073 “A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (Faslodex) vs. Exemestane (Aromasin) in Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer with Disease Progression after Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy” (PCI Principal Investigator)

UPCI 03-086 “A Phase III Study to Compare the Neoadjuvant Administration of Docetaxel and Vinorelbine or Docetaxel Followed by Adriamycin and Cytosine with All Chemotherapy Administered in a Dose Dense Fashion to Women with Stage II and Stage III Breast Cancer” (PCI Principal Investigator)

UPCI 03-102 “Amonafide: Individual phenotype-adjusted chemotherapy for women with metastatic breast cancer who have progressed despite prior chemotherapy” (PCI Principal Investigator)

UPCI 03-110 “Protocol CA 163046: A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients with Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane” (PCI Principal Investigator)

UPCI 04-014 “RegistHER: An Observational Cohort Study of Patients with Her2-Positive Metastatic Breast Cancer” (National Principal Investigator)

UPCI 04-023 “Molecular and Clinical Characterization of Chemoresistance in Individual Women with Metastatic Breast Cancer, Utilizing an Ex Vivo Chemoresponse Assay” (National Principal Investigator)

UPCI 04-037 “Phase II, Open Label Study of SB-715992 in Subjects with Advanced or Metastatic Breast Cancer” (UPCI Principal Investigator)

UPCI 03-076 “A randomized active-controlled study of AMG 162 in breast cancer subjects with bone metastasis who have not previously been treated with bisphosphonate therapy” (UPCI Principal Investigator)

UPCI 04-059 “A Randomized Phase III Trial of Exemestane vs Anastrozole With or Without Celecoxib (as a 2 by 2 Factorial Design) in Postmenopausal Women with Hormone Receptor-Positive Primary Breast Cancer” (UPCI Principal Investigator)

UPCI 04-024 “A Phase II, Randomized, Double-blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients with Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Carcinoma Following Standard First Line Endocrine Therapy” (UPCI Principal Investigator)

UPCI 04-082 “A Randomized, Active Controlled Study of AMG 162 in Subjects with Advanced Cancer Currently Being Treated with Intravenous Bisphosphonates” (UPCI Principal Investigator)

UPCI 05-076 “A Phase II study of weekly dose-dense nanoparticle Paclitaxel (ABI-007), Carboplatin with Herceptin as first-line therapy of advanced HER-2 positive breast cancer” (UPCI Principal Investigator)

UPCI 05-122 “A Multicenter, Phase III, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with chemotherapy Regimens in Subjects with Previously Untreated Metastatic Breast Cancer” (UPCI Principal Investigator)

UPCI 06-002 “RIBBON 1: A randomized phase II trial of paclitaxel and Bevacizumab versus gemcitabine, paclitaxel, and Bevacizumab as first line treatment for locally advanced or metastatic breast cancer” (UPCI Principal Investigator)

UPCI 06-005 “RIBBON 2: A multicenter, phase III, randomized placebo-controlled trial evaluating the efficacy and safety of Bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer” (International Principal Investigator)

UPCI 06-058 “Phase 2 study to investigate the efficacy and safety of ZK-Epothilone (ZK-Epo; ZK 219477) in patients with metastatic breast cancer” (UPCI Principal Investigator)

UPCI 06-082 “Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial” (UPCI Principal Investigator)

UPCI 06-105 “A Phase 2 Study of HKI-272 in Subjects with Advanced Breast Cancer” (UPCI Principal Investigator)

UPCI 07-007 “A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination with Bevacizumab and Paclitaxel in Previously Untreated Patients with Metastatic Breast Cancer AVF4057g” (UPCI Principal Investigator)

UPCI 07-033 “A Phase I/II Study of HKI-272 in Combination with Trastuzumab (Herceptin) in Subjects with Advanced Breast Cancer” (UPCI Principal Investigator)

UPCI 07-055 “A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer” (UPCI Principal Investigator)

UPCI 07-160 “A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer” (UPCI Principal Investigator)

UPCI 08-052 “An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 with Exemestane or Fulvestrant or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metastatic Disease” (UPCI Principal Investigator)

UPCI 08-053 “Phase II Trial of Trastuzumab (Herceptin), Bevacizumab (Avastin), and Docetaxel (Taxotere) in Stage IV Metastatic Breast Cancer (MBC) Patients” (UPCI Principal Investigator)

UPCI 08-066 “A Phase Ib/IIa Trial of LBH589 in Combination with Trastuzumab in Adult Female Patients with HER2 Positive Metastatic Breast Cancer Whose Disease has Progressed on or After Receiving Trastuzumab” (UPCI Principal Investigator)

UPCI 08-078 “A Randomized, Phase 3 Study of Sunitinib in Combination with Capecitabine Compared with Capecitabine in Patients with Previously Treated Breast Cancer” (UPCI Principal Investigator)

UPCI 08-091 “A Phase II, Single-arm, Open-Label Study of Trastuzumab MCC-DM1 Administered Intravenously to Patients with HER2 Positive Metastatic Breast Cancer” (UPCI Principal Investigator)

UPCI 08-095 “An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer” (UPCI Principal Investigator)

UPCI 08-111 “Phase I/II Study of LBH589 in Combination with Letrozole in Patients with ER plus MBC Progressing on Aromatase Inhibitor Therapy Alone” (UPCI Principal Investigator)

UPCI 08-126 “Safety and Efficacy of Single Agent Adjuvant Trastuzumab in Older Women with Early Stage Breast Cancer: A Phase II Trial” (UPCI Principal Investigator)

UPCI 08-137 “Prediction of Response to Neoadjuvant Chemotherapy in Women with Operable Breast Cancer” (DOD) (National Principal Investigator)

UPCI 08-156 “A Randomized, Double-Blind, Multi-Center Phase 2 Trial of Exemestane (Aromasin) plus Dasatinib versus Exemestane plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-steroidal Aromatase Inhibitor” (National Principal Investigator)

UPCI 09-014 “A Randomized Trial of Ixempra vs Taxol in Adjuvant Therapy of Triple-Negative Breast Cancer” (National Principal Investigator)

UPCI 09-018 “A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs Capecitabine plus Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy” (UPCI Principal Investigator)

UPCI 09-023 “A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment” (SWOG 0500) (UPCI Principal Investigator)

UPCI 09-042 “A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer” (3144A2-3004-WW) (UPCI Principal Investigator)

UPCI 09-092 “A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women with HER2/Neu Over-Expressing Locally Advanced or Metastatic Breast Cancer” (UPCI Principal Investigator)

UPCI 09-121 “A Pilot Phase Observational Registry Study to Evaluate the Baseline Measurements and Patterns of Adjuvant and Neoadjuvant Treatment in Patients for Whom an Oncotype DX Breast Cancer Recurrence Score Is Obtained” (UPCI Principal Investigator)

UPCI 10-043 “A Randomized Phase III Trial Of Weekly Paclitaxel Compared To Weekly Nanoparticle Albumin Bound Nab-Paclitaxel Or Ixabepilone Combined With Bevacizumab As First -Line Therapy For Locally Recurrent Or Metastatic Breast Cancer” (UPCI Principal Investigator)

UPCI 10-061 “A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)” (UPCI Principal Investigator)

UPCI 10-064 “Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) For Women with Hormone Receptor-Positive Advanced Breast Cancer” (UPCI Principal Investigator)

UPCI 10-077 “A multicenter, open-label, randomized trial to evaluate the anti-cancer effects of zoledronic acid using circulating tumor cell measurements in patients with newly diagnosed HER2-negative metastatic breast cancer” (UPCI Principal Investigator)

UPCI 11-003 “A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer” (UPCI Principal Investigator)

UPCI 11-100 “Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less” (UPCI Principal Investigator)

NSABP B47 “Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer” (UPCI Principal Investigator)

UPCI 11-100 “Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less” (UPCI Principal Investigator)

UPCI 12-004 “A randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patients with HER2-positive and hormone receptor-positive advanced (metastatic or locally advanced) breast cancer.” (UPCI Principal Investigator)

NSABP B43 “A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal

Carcinoma In Situ Resected by Lumpectomy” (UPCI Principal Investigator)

UPCI 12-039 ““PRESENT”: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment” (UPCI Principal Investigator)

NSABP B50 “A Randomized Multicenter, Open label Phase III study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with HER-2 positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy” (UPCI Principal Investigator)

UPCI 13-039 “Randomized, Double Blind, Placebo Controlled Phase II trial of Fulvestrant plus Everolimus in post menopausal patients with hormone receptor Positive MBC resistant to AI therapy” (UPCI Principal Investigator)

UPCI 13-068 “A phase 2/3, multi-center, open-label, randomized study of nab-paclitaxel in combination with gemcitabine or carboplatin, as compared to gemcitabine/carboplatin, as first-line treatment in subjects with ER, PR and Her2 negative metastatic breast cancer” (UPCI Principal Investigator and International Steering Committee Member)

UPCI 13-081 “A Randomized, Multicenter, Open Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients with Her2-Positive Primary Breast Cancer who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy” (UPCI Principal Investigator)

UPCI 13-144 “An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer” (UPCI Principal Investigator and International Steering Committee Member)

UPCI 14-020 “NSABP B52: A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation” (UPCI Principal Investigator)

UPCI 14-027 “Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer” (UPCI Principal Investigator)

UPCI 15-007: Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (UPCI Principal Investigator)

UPCI 15-059: EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy (UPCI Principal Investigator)

UPCI 15-067: My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of these Agents (UPCI Principal Investigator)

UPCI 15-076: Molecular Analysis for Therapy Choice (MATCH) (UPCI Principal Investigator)

UPCI 15-099: A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) (UPCI Principal Investigator)

UPCI 15-111: Randomized Open-Label Phase III Study of a Single Agent Pembrolizumab vs Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC)-(KEYNOTE-119) (UPCI Principal Investigator)

UPCI 15-112: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (UPCI Principal Investigator)

UPCI 16-036: A Phase 2 Study of Pozitotinib in Patients with HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC (UPCI Principal Investigator)

UPCI 16-072: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (UPCI Principal Investigator)

UPCI 16-106: An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification (UPCI Principal Investigator)

UPCI 16-124: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination with Atezolizumab or Atezolizumab-Placebo in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab (UPCI Principal Investigator)

UPCI 17-006: Pilot Trial of Type I-Polarized Autologous Dendritic Cell Vaccine Incorporating Tumor Blood Vessel Antigen-Derived Peptides in Patients with Metastatic Breast Cancer (UPCI Principal Investigator)

UPCI 17-096 Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC) (UPCI Principal Investigator)

UPCI 17-114 A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer (UPCI Principal Investigator)

UPCI 17-122 A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry (UPCI Principal Investigator)

UPCI 17-132 A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (UPCI Principal Investigator)

UPCI 17-139 A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer (UPCI Principal Investigator)

UPCI 17-142 A Phase IB/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Hormone Receptor Positive HER2-Negative Breast Cancer (Morpheus-HR+ Breast Cancer) (UPCI Principal Investigator)

UPCI 17-162 An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (UPCI Principal Investigator)

UPCI 17-168 MammaPrint, Blueprint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry) (UPCI Principal Investigator)

UPCI 17-172 Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer (UPCI Principal Investigator)

UPCI 17-176 A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients with Early Relapsing Recurrent (Inoperable Locally Advanced or Metastatic) Triple-Negative Breast Cancer (UPCI Principal Investigator)

UPCI 17-179 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Triple-Negative Breast Cancer (MORPHEUS-TNBC) (UPCI Principal Investigator)

UPCI 17-201 A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (UPCI Principal Investigator)

UPCI 17-185 A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

UPCI 17-201 A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1

UPCI 18-012 A Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients with Recurrent or Metastatic Breast Cancer

UPCI 18-015 A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2-/FGFR-amplified metastatic breast cancer (MBC)

UPCI 18-059 A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes "Olaparib Expanded"

UPCI 18-062 Metastatic Breast Cancer Tissue Evaluation for the CELx Multi-Pathway Signaling Function (MPS) Test

UPCI 18-089 Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol K1: EAY131-K1: Phase 2 Study of JNJ-42756493 (erdafitinib) in Patients with Tumors with FGFR Amplifications

UPCI 18-090 Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol K2: EAY131-K2: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions.

UPCI 18-091 MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)

UPCI 18-092 Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1G: EAY131-Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

UPCI 18-093 Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC

UPCI 18-095 A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study of Talazoparib for Neoadjuvant Treatment of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

UPCI 18-110 Phase II study of Pre-emptive Oscillation of ER activity levels through alternation of estradiol/anti-estrogen therapies prior to disease progression in ER+/HER2-metastatic or advanced breast cancer (POLLY)

UPCI 18-125 Retrospective study to investigate clinical utility of BIOARRAY Genetics genomic panel as a predictor of pathological response in breast cancer patients treated with taxane-based neoadjuvant chemotherapy.

UPCI 18-135 A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201A, an Anti-HER2-Antibody Drug Conjugate, Versus ADO-Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated with Trastuzumab and Taxane

UPCI 18-153 A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal women with estrogen receptor-positive advanced breast cancer

UPCI 18-165 Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer

UPCI 18-181 I-SPY2 Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And molecular Analysis 2

UPCI 18-196 A Phase 3, Multicenter, Randomized, Open Label, Active-Controlled Trial of DS-8201A, an Anti-HER2-Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2low, Unresectable and/or Metastatic Breast Cancer Subjects

UPCI 18-205 Translational Breast Cancer Research Consortium Biospecimen and Outcomes Repository

UPCI 19-005 A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Neratinib and ADO-Trastuzumab Emtansine (T-DM1) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases

UPCI 19-006 A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan DS-8201A, an Anti-HER2-Antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated with Prior Standard of Care HER2 Therapies, Including T-DM1

UPCI 19-039 An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer

UPCI 19-041 A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

UPCI 19-045 Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens

UPCI 19-056 AURORA US - Prospective Biospecimen Repository in Metastatic Breast Cancer

UPCI 19-057 Clinical Outcomes Analysis of the Oncotype Dx Breast Cancer test
19-089 A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)

UPCI 19-093 An open-label randomized Phase 2 trial of SAR439859, versus endocrine monotherapy as per physician's choice in premenopausal and postmenopausal patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer with prior exposure to hormonal therapies

UPCI 19-102 Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1K: EAY131-Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
UPCI 19-103 Molecular Analysis for Therapy Choice MATCH Treatment Subprotocol Z1L: EAY131-Z1L: Phase 2 Study of BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations

UPCI 19-110 A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer

UPCI 19-152 Genomically-Guided Treatment Trial in Brain Metastases

UPCI 19-195 EndoPredict® Extended Endocrine Trial (EXET): A prospective registry to evaluate the impact of EndoPredict® in decisions regarding extended endocrine treatment

UPCI 20-013 Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer

UPCI 20-029 An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation

UPCI 20-067 HER-Seq: A Blood-based Screening Study to Identify Patients with HER2 Mutations for Enrollment into Clinical Research Studies of Neratinib

UPCI 20-094 Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan

UPCI 20-099 A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

UPCI 20-195 A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer

UPCI 20-211 A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease

MAJOR RESEARCH INTERESTS:

1. Molecular biology of hormone action and hormone resistance in prostate cancer.
2. Clinical hormonal therapy of advanced prostate cancer.
3. Clinical therapy of hormone-refractory prostate cancer.
4. Clinical therapy of breast cancer.
5. Clinical and translational investigation of genitourinary malignancies.
6. Clinical and translational investigation of breast cancer.

SERVICE:

Peer Review

1998-	Cancer Investigation, Reviewer
1999-	Cancer, Reviewer
1999-2005	Susan G. Komen Foundation, Reviewer, Prognosis Study Section
2000-	Journal of Clinical Oncology, Reviewer
2001-2005	Susan G. Komen Foundation, Leader, Prognosis Study Section
2001-2005	Susan G. Komen Foundation, Leader, Systemic Treatment Study Section
2001-	Oncology, Reviewer
2002-	Cancer, Pharmacology, and Therapeutics, Reviewer
2003-	Clinical Breast Cancer, Reviewer
2006-	National Surgical Adjuvant Breast and Bowel Project, Breast Committee
2007-	Lancet Oncology, Reviewer
2008-	Annals of Oncology, Reviewer

2009- Department of Defense Congressionally Mandated Breast Cancer Research Program, Experimental Therapeutics Study Section, Leader
 2010- Susan G. Komen Postdoctoral Fellowship Study Section, Leader
 2010- Editorial Board, Journal of Clinical Oncology
 2011- Editorial Board, World Journal of Orthopaedics
 2012- Editorial Board, Journal of Bone Oncology
 2013- Member, NIH NCI Study Section, NCORP
 2014- Lancet, reviewer
 2019- BMJ Open, reviewer
 2019- BMJ Cancer, Associate Editor
 2020- Cell Death and Disease, reviewer
 2020- Journal of Medical Virology, Associate Editor

University and Medical School:

1991 Intern Selection Committee, Department of Medicine, Brigham and Womens Hospital
 1995-1996 Patient Information Service, Dana-Farber Cancer Institute
 1996 Patient Education Committee, University of Pittsburgh Cancer Institute
 1996-2008 Protocol Review Committee, University of Pittsburgh Cancer Institute
 1996- Clinical Committee, University of Pittsburgh Cancer Institute
 1997-1999 Co-Medical Director, University of Pittsburgh Medical Center Hospice/ Palliative Care Program
 1997- Cancer Committee, Magee-Womens Hospital
 1998- Clinical Research Unit Use Committee, Magee-Women's Hospital
 1999-2002 Associate Director, Magee-Womens Hospital/UPCI Breast Cancer Center
 2002- Co-Director, Magee-Womens Hospital /UPCI Breast Cancer Center
 1998- Medical Director, Women's Cancer Center, Magee-Womens Hospital
 1998-2008 Cancer Committee, Magee-Womens Hospital
 2000- Pharmacy and Therapeutics Committee, Magee-Women's Hospital
 2001- Clinical Research Steering Committee, University of Pittsburgh
 2002- Institutional Review Board, University of Pittsburgh

2003-	<u>Institutional Review Board</u> , Magee-Womens Hospital
2003-	<u>Associate Division Chief</u> , Hematology-Oncology, Department of Medicine
2004-	<u>UPCI Clinical Council</u> , University of Pittsburgh Cancer Institute
2006-2008	<u>Residency Subspecialty Committee</u> , Department of Medicine
2008-	<u>Executive Committee</u> , University of Pittsburgh Cancer Institute
2009-2017	<u>Associate Director for Clinical Investigation</u> , University of Pittsburgh Cancer Institute
2017-2019	<u>Associate Director for Translational Research</u> , University of Pittsburgh Cancer Institute
2022-	<u>Associate Director for Strategic Initiatives</u> , UPMC Hillman Cancer Center

Invited Lectures (All CME):

1. Tumor Board, Uniontown Hospital, Uniontown, PA. Treatment of Late Stage Prostate Cancer. September 4, 1996.
2. Tumor Board, Mercy Hospital, Pittsburgh, PA. New Horizons in Prostate Cancer Therapy. September 19, 1996.
3. Oncology Grand Rounds, University of Pittsburgh, Pittsburgh, PA. The Androgen Receptor in Prostate Cancer Pathogenesis and Therapy. October 24, 1996.
4. Medical Staff Program, United Community Hospital, Grove City, PA. Current Concepts in Prostate Cancer Diagnosis and Therapy. November 21, 1996.
5. CME Program, Washington Hospital, Washington, PA. Ovarian Cancer. February 12, 1997.
6. Tumor Board, Armstrong Memorial Hospital, Armstrong, PA. Prostate Cancer: Refractory Disease Management. April 30, 1997.
7. Screening for Prostate Cancer. New Developments in Oncology, Greensburg, PA. May 8, 1997.
8. Tumor Board, Westmoreland Regional Hospital, Greensburg, PA. New Therapies for Hormone Refractory Prostate Cancer. May 13, 1997.
9. Hematology-Oncology Fellows Lecture Series. University of Pittsburgh Cancer Institute, Pittsburgh, PA. Prostate Cancer. August 15, 1997

10. Comprehensive Breast Cancer Center, Pittsburgh, PA. Breast Cancer Translational Research. August, 1997.
11. New Horizons in Prostate Cancer. University of Pittsburgh, Pittsburgh, PA. September 13, 1997.
12. Acute Care Nurse Practitioner Program, University of Pittsburgh, Pittsburgh, PA. Bladder and Prostate Cancer. October 22, 1997.
13. Ankara Numene Hospital, Ankara, Turkey. Herceptin in Breast Cancer. October 25, 1997.
14. Comprehensive Breast Cancer Center, Pittsburgh, PA. Serial Analysis of Gene Expression in Breast Cancer. November, 1997.
15. Washington (PA) Hospital Grand Rounds. Ovarian Cancer. February 12, 1998.
16. US TOO Lay Support Group, University of Pittsburgh Cancer Institute, Pittsburgh, PA. Overview of Prostate Cancer. February 18, 1998.
17. Medical Residents Lecture Series. University of Pittsburgh, Pittsburgh, PA. Spinal Cord Compression. March 25, 1998.
18. Prostate Cancer: Refractory Disease Management. April 30, 1998.
19. Tumor Board, DuBois Regional Medical Center, DuBois, PA. New Horizons in Metastatic Breast Cancer Therapy. May 4, 1998.
20. Grand Rounds, UPMC McKeesport Hospital, McKeesport, PA. Aromatase Inhibitors in Breast Cancer. September 11, 1998.
21. Public Education Program, Shearton Station Square, Pittsburgh, PA. Take Action Against Prostate Cancer. September 26, 1998.
22. Grand Rounds, St. Joseph's Hospital, Burbank, CA. Beyond Tamoxifen: Monoclonal Antibodies and Novel Antihormones in the Treatment of Metastatic Breast Cancer. October 1, 1998.
23. Grand Rounds, Henry Ford Hospital, Detroit, MI. Biphosphonates and Their Use in treating Metastatic Myeloma, Breast, and Prostate Cancer. October 16, 1998.
24. Treasure Lake Country Club, DuBois, PA. Advances in the Treatment of Anthracycline Resistant Metastatic Breast Cancer. October 22, 1998.
25. Magee Women's Hospital, Pittsburgh, PA. New Treatments and Strategies for the Prevention of Breast Cancer. October 29, 1998.
26. UPCI Hematology-Oncology Grand Rounds, Pittsburgh, PA. Her 2 Neu in Human Cancers. November 5, 1998.
27. Marshall University Hematology Society, Huntington, WV. Herceptin in Breast Cancer. November 9, 1998.

28. Grand Rounds, Oakwood Medical Center, Detroit, MI. HER2 Neu in Metastatic Breast Cancer. November 13, 1998.
29. Western New York Oncology Association, Williamsville, NY. Implications of HER2 Oncogene Overexpression in Advanced Breast Cancer. November 30, 1998.
30. Grand Rounds, Kettering Medical Center, Dayton, OH. Herceptin in Metastatic Breast Cancer. December 11, 1998.
31. Integrated Life Sciences Neoplastic Disease Course, University of Pittsburgh. Breast Cancer: Clinical Aspects. March 22, 1999.
32. Tumor Board, DuBois Regional Medical Center, DuBois, PA. Herceptin in Metastatic Breast Cancer. June 14, 1999.
33. Grand Rounds, Highland Hospital, Rochester, NY. Advances in the Treatment of Metastatic Breast Cancer. September 22, 1999.
34. Seventh Annual Cancer Symposium, St. Elizabeth's Hospital, Youngstown, OH. Breast Cancer: Medical Treatment Modalities. September 30, 1999.
35. Update on the Role of Endocrine Therapy in the Treatment of Breast Cancer, Pittsburgh, PA. October 13, 1999.
36. Grand Rounds, Newark Beth Israel Medical Center, Englewood, NJ. Therapy of Bone Metastases in Breast Cancer and Prostate Cancer. October 15, 1999.
37. Outreach Videoconference, University of Pittsburgh Medical Center/Shenango Valley, Greenville, PA. Herceptin in Metastatic Breast Cancer. November 3, 1999.
38. Grand Rounds, Potomac Hospital, Woodbridge, VA. Advances in Metastatic Breast Cancer. November 15, 1999.
39. Us Too Support Group, Pittsburgh, PA. Novel Therapies for Prostate Cancer, March 15, 2000.
40. Seventh Annual Schott Cancer Conference, Bluefield, WV. Medical Management of Breast Cancer. April 15, 2000.
41. Grand Rounds, Kettering Medical Center, Dayton, OH. Medical Management of Breast Cancer: Case Studies. April 27, 2000.
42. ASCO 2000 Breast Update, University of Maryland, Baltimore, MD, June 1, 2000.
43. Grand Rounds, Doctor's Hospital, Columbus, OH. Advances in the Management of Metastatic Breast Cancer. August 25, 2000.
44. Oncology Grand Rounds, Highlands Hospital, Rochester, NY. Herceptin in the Management of Breast Cancer. September 14, 2000.

45. Oncology Grand Rounds, Henry Ford Hospital, Detroit, MI. Treatment of Metastatic Bone Disease in Breast and Prostate Cancer. November 15, 2000.
46. Grand Rounds, St. Mary's Hospital, Cumberland, MD. Development of Herceptin as Therapy for Metastatic Breast Cancer. November 28, 2000.
47. Annual Cancer Symposium, Franklin Hospital Medical System, Franklin, PA. Medical Management of Breast Cancer in the Year 2000: Case Studies. December 4, 2000.
48. Medical Grand Rounds, Coliseum Medical Center, Macon, GA. New Innovations in Breast Cancer Therapy. February 13, 2001.
49. Oncology Grand Rounds, University of Maryland, Baltimore, MD. Adjuvant Therapy of Breast Cancer, April 2, 2001.
50. Grand Rounds, Beaver Medical Center, Beaver, PA. Medical Management of Breast Cancer. April 4, 2001.
51. Grand Rounds, St. Elizabeth's Medical Center, Youngstown, OH. Medical Management of Breast Cancer. April 12, 2001.
52. Breast Cancer Debate Series, Magee-Women's Hospital. Survival Improvements in Breast Cancer: The Case for Adjuvant Therapy. May 3, 2001.
53. Oncology Nursing Society Annual Meeting, San Diego, CA. Herceptin in the Management of Breast Cancer, Case Studies. May 18, 2001.
54. Grand Rounds, Geisinger Clinic, Allentown, PA. Adjuvant Therapy for Breast Cancer in the Year 2001. October 4, 2001.
55. Oncology Grand Rounds, Karmanos Cancer Institute, Detroit, MI. Novel Hormonal Therapies for the Treatment of Breast Cancer. November 8, 2001.
56. Oncology Grand Rounds, Henry Ford Hospital, Detroit, MI. Novel Hormonal Strategies for the Treatment of Breast Cancer. November 9, 2001.
57. Grand Rounds, Fitzgerald Mercy Hospital, Philadelphia, PA. Novel Therapies for Breast Cancer. January 9, 2002.
58. Grand Rounds, Westmoreland Regional Hospital, Greensburg, PA. Breast Cancer Update 2002. January 22, 2002.
59. Oncology Tumor Board, Lankenau Hospital, Philadelphia, PA. Herceptin in the Treatment of Breast Cancer: An Update. February 1, 2002.
60. Oncology Tumor Board, Redding Hospital, Redding, CA. Adjuvant Therapy for Breast Cancer. February 19, 2002.

61. Grand Rounds, The Medical Center at Beaver, Beaver, PA. Hormonal Therapy of Breast Cancer. March 22, 2002.
62. Grand Rounds, Roswell Park Cancer Institute, Buffalo, NY. Adjuvant Therapy of Breast Cancer in 2002. June 14, 2002.
63. Tumor Board, DuBois Regional Cancer Center, Dubois, PA. Advances In The Treatment Of Metastatic Breast Cancer. August 26, 2002.
64. Baylor-Sammons Cancer Center Annual Symposium, Hilton Head, SC. Systemic Treatment of Breast Cancer in the Elderly. October 4, 2002.
65. Oncology Grand Rounds, Lombardi Cancer Center, Georgetown University, Washington, DC. Systemic Treatment of Breast Cancer. November 6, 2002.
66. West Virginia University Oncology Society, Morgantown, West Virginia. Systemic Treatment of Breast Cancer 2002. November 13, 2002.
67. Medical Grand Rounds, Providence Holy Cross Medical Center, Los Angeles, CA. Medical Treatment of Breast Cancer. November 15, 2002.
68. Oncology Grand Rounds, Medical College of Philadelphia, Philadelphia, PA. Systemic Treatment of Breast Cancer 2002. November 25, 2002.
69. Oncology Grand Rounds, State University of New York at Syracuse, Syracuse, NY. Neoadjuvant Therapy of Breast Cancer. January 21, 2003.
70. Tumor Board, Dubois Regional Medical Center, Dubois, PA. Metastatic Breast Cancer. February 3, 2003.
71. Medical Grand Rounds, Bryn-Mawr Hospital, Bryn-Mawr, PA. Medical Treatment of Breast Cancer. February 6, 2003.
72. Mid-Ohio Oncology Society, Columbus, OH. Breast Cancer Update 2003. March 18, 2003.
73. Oncology Grand Rounds, University of Pittsburgh Cancer Institute, Pittsburgh, PA. Systemic Treatment of Breast Cancer 2003. March 26, 2003.
74. Post ASCO Update 2003, Omni William Penn, Pittsburgh, PA. Hormonal Therapy of Breast Cancer. June 13, 2003
75. Grand Rounds, Akron General Medical Center, Akron, OH. Medical Management of Breast Cancer 2003. June 20, 2003.
76. Grand Rounds, Trumbull Memorial Hospital, Youngstown, OH. Medical Management of Breast Cancer 2003. June 20, 2003.
77. Tumor Board, Jefferson Regional Medical Center, Pittsburgh, PA. Breast Cancer: Adjuvant Treatment. October 16, 2003.

78. Oncology Grand Rounds, Good Samaritan Hospital, Islip, NY. Medical Management of Breast Cancer 2003. November 20, 2003.
79. Medical Grand Rounds, Mulenberg Hospital, Plainfield, NJ. Medical Management of Breast Cancer 2003. December 5, 2003.
80. Oncology Symposium, Hackensack University Medical Center, Hackensack, NJ. San Antonio Breast Symposium Update: Neoadjuvant Therapy. January 9, 2004.
81. Tumor Board, State University of New York at Stony Brook, Stony Brook, NY. San Antonio Breast Cancer Symposium Update. January 22, 2004.
82. Medical Grand Rounds, Methodist Hospital, Brooklyn, NY. Medical Management of Breast Cancer 2004. February 6, 2004.
83. Tumor Board, St. Vincent's Hospital, New York, NY. Her2 Dysregulation in Breast Cancer. Update and Current Management. February 6, 2004.
84. US TOO/Y-ME Support Group, St. Clair Hospital, Pittsburgh, PA. Clinical Trials in Prostate and Breast Cancer. February 9, 2004
85. Oncology Grand Rounds, Hillcrest Medical Center, Cleveland Clinic, Cleveland, OH. Growth Factor Dysregulation and Breast Cancer Therapy: An Update. February 12, 2004.
86. Medical Grand Rounds, MetroHealth Medical Center, Case Western University, Cleveland, OH. Medical Management of Breast Cancer 2004. February 12, 2004.
87. Housestaff Conference, University of Pittsburgh, Pittsburgh, PA. Medical Management of Breast Cancer 2004. February 23, 2004.
88. San Antonio Breast Cancer Symposium Review, Atlantic Hospital System, Short Hills, NJ. Targeted Therapies for Breast Cancer. February 28, 2004.
89. Annual Oncology Symposium, Divine Providence Hospital, Williamsport, PA. Breast Cancer 2004: Where are we going? March 2, 2004.
90. Tumor Board, Craven Memorial Hospital, New Bern, NC. Medical Management of Breast Cancer 2004. March 9, 2004.
91. Grand Rounds, Beaver Medical Center, Beaver, PA. Medical Management of Breast Cancer 2004. March 12, 2004.
92. Grand Rounds, Shands Hospital, Jacksonville, FL. Medical Management of Breast Cancer 2004. May 11, 2004.
93. Oncology Grand Rounds, Mayo Clinic, Jacksonville, FL. Novel Therapeutics for Breast Cancer. May 12, 2004.

94. Oncology Tumor Board, Charleston University Medical Center, Charleston, WV. Hormonal Management of Breast Cancer. May 21, 2004.
95. ASCO Review Conference, Hershey Medical Center, Hershey, PA. ASCO Breast Cancer 2004. June 25, 2004.
96. Medical Grand Rounds, University of Pittsburgh School of Medicine, Pittsburgh, PA. Oncologic Emergencies. July 23, 2004.
97. Oncology Fellows Lecture Series, University of Pittsburgh, Pittsburgh, PA, Oncologic Emergencies. August 13, 2004.
98. Oncology Grand Rounds, Monongahela Valley Hospital, Monongahela, PA. Breast Cancer Update 2004. August 16, 2004.
99. Medical Grand Rounds, Shady Grove Adventist Hospital, Rockville, MD. Medical Management of Breast Cancer 2004. September 2, 2004.
100. Medical Oncology Lecture Series, New York Hospital Queens, New York, NY. Targeted Therapies for Breast Cancer. September 22, 2004.
101. Breast Cancer and the Environment Lecture Series, Highmark Health Care, Pittsburgh, PA. Hormones and Breast Cancer Risk and Treatment. October 4, 2004.
102. Reason to Hope Lecture Series, Hillman Cancer Center, Pittsburgh, PA. Advances in **Breast** Cancer Treatment. October 14, 2004.
103. Pan Sicilian Breast Cancer Conference, Villa Santa Teresa Hospital, Bagheria, Sicily, Italy. Medical Management of Breast Cancer 2004. October 23, 2004.
104. Tumor Board, Franklin General Hospital, Franklin, PA. Medical Management of Breast Cancer 2004. November 15, 2004.
105. Update in Internal Medicine 2004, University of Pittsburgh School of Medicine. Breast Cancer: Update in Diagnosis and Treatment. November 19, 2004.
106. Medical Grand Rounds, Dubois Hospital, Dubois, PA. Management of Breast Cancer Therapy Induced Osteopenia. December 6, 2004.
107. Medical Resident Conference, Shadyside Hospital, Pittsburgh, PA. Breast Cancer Management. December 13, 2004.
108. Oncology Grand Rounds, Stamford Hospital, Stamford, CT. Targeted Therapy for Breast Cancer 2005. January 6, 2005.
109. San Antonio Breast Cancer Conference 2004 Review, Penn State School of Medicine, Hershey, PA. Adjuvant and Neoadjuvant Therapy. January 7, 2005.

110. San Antonio Breast Cancer Conference 2004 Review, University of Pittsburgh School of Medicine, Pittsburgh, PA. Adjuvant and Neoadjuvant Therapy. January 13, 2005.
111. Reason to Hope Lecture Series, Greensburg, PA. Advances in Breast Cancer Treatment. February 2, 2005.
112. Oncology Grand Rounds, Shands Hospital, University of Florida, Gainesville, FL. Targeted Therapy for Breast Cancer. February 9, 2005.
113. 20th Annual University of Florida Breast and Prostate Cancer Symposium, Amelia Island Florida. Medical Management of Prostate Cancer. February 11, 2005.
114. 20th Annual University of Florida Breast and Prostate Cancer Symposium, Amelia Island Florida. Targeted Therapy for Breast Cancer. February 11, 2005.
115. Breast Oncology Rounds, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Breast Cancer and Bone: Therapeutic Aspects and Dilemmas. February 15, 2005.
116. Medical Grand Rounds, Robert Packer Hospital, Sayre, PA. Medical Management of Breast Cancer. April 5, 2005.
117. Medical Grand Rounds, Chambersburg Hospital, Chambersburg, PA. Medical Management of Breast Cancer. April 26, 2005.
118. Oncology Grand Rounds, West Virginia University Hospital, Morgantown, WV. Management of Metastatic Breast Cancer 2005. May 6, 2005.
119. Medical Grand Rounds, University of Pittsburgh School of Medicine, Pittsburgh, PA. Oncologic Emergencies. July 15, 2005.
120. 4th Annual Breast Congress, Hamilton, Bermuda, Update on Novel Chemotherapy for Breast Cancer. July 21, 2005.
121. ACS Survivor Day Plenary Lecture, American Cancer Society, Pittsburgh, PA. Reason to Hope: Breast Cancer 2005 and Beyond.
122. Oncology Grand Rounds, Dubois Regional Medical Center, Dubois, PA. ASCO Update: Breast Cancer. August 1, 2005.
123. Tumor Board, Johnston Willis Hospital, Richmond, VA. Systemic Therapy of Breast Cancer, August 3, 2005.
124. Tumor Board, Watson Clinic, Lakeland, FL. Update on Monoclonal Antibody Therapy of Breast Cancer, August 10, 2005.
125. Breast Cancer Community Forum, Patient Power, Pittsburgh, PA. Novel Therapies for Breast Cancer: Are They for You? September 20, 2005.

126. Tumor Board, Armstrong County Regional Medical Center, Kittaning, PA. Therapy for Metastatic Breast Cancer 2005. October 26, 2005.
127. Tumor Board, Western Pennsylvania Hospital, Pittsburgh, PA, Therapy for Metastatic Breast Cancer 2005, October 27, 2005.
128. Panel Discussion, 9th Annual University of Pittsburgh Cancer Conference, Pittsburgh, PA. Breast Cancer in the Age of Biologics. October 28, 2005.
129. Bone Club, University of Pittsburgh School of Medicine, Department of Medicine, Division of Endocrinology. Zolendronic Acid as Therapy for Aromatase Inhibitor Induced Bone Loss in Breast Cancer: The Z-FAST Trial. November 1, 2005.
130. Update in Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine. Breast Cancer Update 2005. November 4, 2005.
131. 10th Annual Grand Rapids CCOP Conference, Grand Rapids CCOP, Grand Rapids, MI. Breast Cancer in 2005 and Beyond. November 11, 2005.
132. Tumor Board, Ohio Valley Hospital, Wheeling, WV. Breast Cancer New Horizons 2006. January 4, 2006.
133. San Antonio Breast Cancer Conference 2005 Review, University of Pittsburgh School of Medicine, Pittsburgh, PA. Metastatic Disease. January 17, 2006
134. Grand Rounds, Marshall Medical College, Huntington, WV. Novel Therapies for Advanced Breast Cancer. January 23, 2006.
135. Medical Grand Rounds, Shadyside Hospital, Pittsburgh, PA. Oncological Emergencies. February 2, 2006.
136. Medical Grand Rounds, Horizon Hospital, Greenville, PA. Breast Cancer Update for Internists 2006. May 5, 2006.
137. Oncology Grand Rounds, North Shore University Hospital, Manhasset, NY. Breast Cancer and Bone. May 16, 2006.
138. Tumor Board, Jefferson Regional Hospital, Pittsburgh, PA. Systemic Chemotherapy for Breast Cancer 2006. May 25, 2006.
139. Grand Rounds, Moffit Cancer Center, Tampa, FL. Metastatic Breast Cancer in 2006. June 12, 2006.
140. Oncology Grand Rounds, Latrobe Hospital, Latrobe, PA. Systemic Therapy for Breast Cancer 2006. July 27, 2006.
141. Medical Grand Rounds, Methodist Hospital, Philadelphia, PA. Novel Therapeutics for Breast Cancer. August 23, 2006.

142. Oncology Tumor Board, Metro Health Hospital, Cleveland, OH. Systemic Chemotherapy for Breast Cancer. August 31, 2006.
143. Medical Grand Rounds, Marietta Hospital, Marietta, OH. Novel Therapeutics for Breast Cancer 2006. September 8, 2006.
144. Phase I Developmental Meeting, National Cancer Institute, Bethesda, MD. Phase II Trial of SB715992 (ispensisib) in Metastatic Breast Cancer. September 19, 2006.
145. Oncology Grand Rounds, TRHMC Medical Center, Reading, PA. Novel Therapeutics for Breast Cancer. September 21, 2006.
146. Magee Breast Cancer Symposium: Primary Care of Breast Cancer, Magee-Women's Hospital, Pittsburgh, PA. Long Term Follow-Up of the Breast Cancer Survivor. September 29, 2006.
147. Update in Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine. Breast Cancer Update 2006. October 26, 2006.
148. 10th Annual Breast Cancer Symposium, University of Cincinnati School of Medicine, Cincinnati, OH. Update on Hormonal Therapy for Breast Cancer and Its Complications. October 28, 2006.
149. Oncology Tumor Board, Virginia Piper Hospital, Scottsdale, AZ. Novel Therapeutics for Metastatic Breast Cancer 2006. November 13, 2006.
150. Tumor Board, DuBois Hospital, DuBois, PA. Novel Therapeutics for Breast Cancer 2006. November 20, 2006.
151. Oncology Grand Rounds, Hennepin County Medical Center, Minneapolis, MN. Novel Therapeutics for Metastatic Breast Cancer 2006. November 30, 2006.
152. Oncology Grand Rounds, University of Wisconsin Comprehensive Cancer Center, Madison, WI. Novel Therapeutics for Breast Cancer. December 20, 2006.
153. San Antonio Breast Cancer Conference 2006 Review, University of Pittsburgh School of Medicine, Pittsburgh, PA. Metastatic Disease. January 11, 2007.
154. Oncology Tumor Board, Valley Hospital, Ridgewood, NJ. Novel Therapies for Breast Cancer 2007. February 21, 2007.
155. San Antonio Breast Cancer Conference 2006 Review, Hahne Regional Cancer Center, Dubois, PA. March 12^t 2007.
156. Medical Grand Rounds, Forum Health Regional Medical Center, Youngstown, PA. Novel Therapeutics for Breast Cancer. March 15, 2007.
157. Latin American Breast Cancer Conference, Rio De Janeiro, Brazil. Novel Therapeutics for Metastatic Breast Cancer. March 23, 2007.

158. Internal Medicine Grand Rounds, St. Elizabeth's Hospital, Youngstown, OH. Breast Cancer Update. April 26, 2007.
159. Tumor Board, Lankenau Cancer Center, Wynnewood, PA. Metastatic Breast Cancer Update. May 7, 2007.
160. Tumor Board, UPMC Franklin Hospital, Franklin, PA. Novel Therapeutics for Breast Cancer. May 10, 2007.
161. Internal Medicine Grand Rounds, City Hospital, Martinsberg, WV. Novel Therapeutics for Breast Cancer. June 26, 2007.
162. Breast Cancer Tumor Board, Cambridge City Hospital, Boston, MA. Bone Health in Breast Cancer. June 28, 2007.
163. Oncology Grand Rounds, Sylvester Cancer Center, University of Miami, Miami, FL. Treatment of Her2 Neu Positive Breast Cancer. August 29, 2007.
164. UPCI Grand Rounds, Pittsburgh, PA. Update on Clinical Trials at UPCI. September 19, 2007.
165. Spanish National Bone Health in Cancer Symposium, Madrid, Spain. Use of Bone Markers to Predict Response to Bisphosphonates. October 9, 2007.
166. Intersession Neoplasia Second Year Course, University of Pittsburgh School of Medicine, Pittsburgh, PA. Oncology Emergencies. October 24, 2007.
167. Oncology Grand Rounds, Jefferson Hospital, Pittsburgh, PA. Update in Breast Cancer 2007. October 24, 2007.
168. Internal Medicine Update, University of Pittsburgh, Pittsburgh, PA. Breast Cancer 2007. October 26, 2007.
169. Tumor Board, Advocate Christ Hospital, Oak Lawn, IL. Metastatic Breast Cancer 2007. November 5, 2007.
170. Tumor Board, Cancer Institute of New Jersey, Hamilton, NJ. Novel Treatments for Metastatic Breast Cancer. November 7, 2007.
171. Lunch and Learn Series, University of Pittsburgh Cancer Institute, Pittsburgh, PA. Breast Cancer Update. December 5, 2007.
172. San Antonio Review 2007, University of Pittsburgh Cancer Institute, Pittsburgh, PA. Bone Health in Breast Cancer. January 10, 2008.
173. ZENITH 2008, Lisbon, Portugal. Bone Health in Breast Cancer and the Z-FAST/ZO-FAST trials. January 18, 2008.
174. SABCS Review 2007, Penn State College of Medicine, Hershey, PA. Bone Health in Breast Cancer 2008, January 25, 2008.

175. SABCS Review 2007, Aultman Cancer Center, Canton, OH. Adjuvant Therapy for Breast Cancer 2008. January 29, 2008.
176. 1st Asian Breast Cancer Congress, New Delhi, India. Future of Hormonal Therapy and Bisphosphonate Therapy for Breast Cancer. February 10, 2008.
177. Australian Breast Cancer Symposium, Melbourne, Australia. Bone Health and Breast Cancer Therapy. March 1 2008.
178. Oncology Grand Rounds, City of Hope Cancer Center, Duarte, CA. Bone Health and Breast Cancer. March 3, 2008.
179. Grand Rounds, Rabb Cancer Center, University of West Virginia, Morgantown, WV. Management of Breast Cancer and Bones. March 5, 2008.
180. Japanese Breast Cancer Symposium, Tokyo, Japan. Bone Health, Breast Cancer, and Prevention of Cancer Recurrence. March 29, 2008.
181. Innovations in Genetic and Molecular Therapy for Breast Cancer Symposium, Akron General Hospital, Akron, OH. Molecular Therapeutics for Breast Cancer. May 7, 2008.
182. Breast Cancer Symposium, Guangzhou, China. Breast Cancer Update 2008. June 27, 2008.
183. Breast Cancer Symposium, Shanghai, China. Novel Therapeutics for Breast Cancer 2008. July 1, 2008.
184. Oncology Grand Rounds, Rochester General Hospital, Rochester, NY. Bone Health and Breast Cancer. July 22, 2008.
185. Breast Cancer Symposium, Beijing, China. Novel Therapeutics for Breast Cancer. July 2, 2008.
186. Oncology Grand Rounds, New York Medical College, Valhalla, NY. Breast Cancer Update 2008. September 4, 2008.
187. Medical Grand Rounds, Manchester Memorial Hospital, Manchester, CT. Bisphosphonates as adjuvant therapy for breast cancer. December 4, 2008
188. Medical Grand Rounds, Bayfront Medical Center, St Petersburg, FL. Current and evolving therapeutic strategies in the management of metastatic breast cancer. December 11, 2008.
189. SABCS 2008 Update. University of Pittsburgh Cancer Institute, Pittsburgh, PA. Novel agents. January 15, 2009.
190. SABCS Update. Taussig Cancer Institute, Cleveland, OH. Bisphosphonates. February 4th, 2009.
191. SABCS Update. John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ. Molecular testing for breast cancer. February 20, 2009

192. Early Breast Cancer: Making the Difficult Decisions, Satellite Symposium, 11th St. Gallen Early Stage Breast Cancer Conference, St Gallen, Switzerland. Should bisphosphonates be standard of care for early stage breast cancer? March 13, 2009.
193. Australian Breast Cancer Symposium, Sydney, Australia. Expanding the horizons of bisphosphonate use. March 27, 2009.
194. Taiwan Breast Cancer Symposium, Taipei, Taiwan. Expanding the horizons of bisphosphonate use. March 29, 2009.
195. Breast Rounds, Massachusetts General Hospital, Boston, MA. The future use of bisphosphonates in breast cancer. May 26, 2009.
196. ASCO Satellite Symposium. Novel Mechanisms of Action in Adjuvant Therapy: Bisphosphonates and Targeted Agents in Solid Tumors. Orlando, FL, May 29, 2009.
197. Cancer Summit 2009. Strategies to Treat Bone Loss in Breast Cancer Therapy. Hilton Head, SC, July 24, 2009.
198. Oncology Grand Rounds, Memorial Hospital West. Pertuzumab in Breast Cancer. Pembroke Pines, FL, August 25, 2009.
199. Oncology Grand Rounds, Maimonides Cancer Center, Brooklyn, NY, Treating the HER2-positive breast cancer patient: Challenges and Controversies, September 30, 2009.
200. Oncology Rounds, Ohio Valley Hospital. Her2 Positive Breast Cancer. McKees Rocks, PA, October 13, 2009.
201. Annual Breast Cancer Symposium, Jefferson Regional Medical Center, Breast Cancer Update 2009, Clairton, PA, October 15, 2009.
202. 3rd Annual Symposium on Hereditary Cancers: What Health Care Professionals Need to Know, Introduction to BRCA. Pittsburgh, PA, December 3, 2009.
203. San Antonio Breast Cancer Symposium 2009 Update, Aultman Cancer Center, Hormonal Therapy Update, Canton, OH January 26, 2010.
204. UPCI San Antonio Breast Cancer Symposium Review, Bevacizumab and other VEGF inhibitors, Pittsburgh, PA, January 28, 2010.
205. SABCS Update. John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ. Molecular testing for breast cancer. February 12, 2010.
206. Oncology Grand Rounds. Medical College of Wisconsin, Milwaukee, WI. The future use of bisphosphonates in breast cancer. March 5, 2010.
207. Surgical Oncology Educational Conference. University of Pittsburgh, PA. Metastatic Breast Cancer. March, 25, 2010.

208. Grand Rounds, VA Pittsburgh Healthcare System, Pittsburgh, PA. Bone metastasis and therapy-related bone loss: Emerging issues in cancer treatment. July 20, 2010.
209. Medical Staff Education Series. Bone Health in Cancer: Updates and insights to an evolving story. Baptist Hospital, Pensacola, FL. July 23, 2010.
210. Medical Staff Education Series. Genesis Healthcare System, Zanesville, OH. Bone Health in Breast Cancer. July 29, 2010.
211. Medical Staff Education Series. Mercy Medical Center, Canton, OH. Bone Health in Cancer: Updates and insights to an evolving story. July 30, 2010.
212. Grand Rounds. Pittsburgh VA Medical Center, Pittsburgh, PA. Bone complications of Cancer. August 24, 2010.
213. Grand Rounds. Louis A. Johnson VA Medical Center. Clarksburg, WV. Bone metastases and therapy-related bone loss: Emerging issues in cancer treatment. August 26, 2010.
214. Breast Cancer Program. Hillcrest Hospital, Mayfield Heights, OH. State of the Art Breast Cancer Care – The next decade of novel therapies. October 4, 2010.
215. Clinical Perspectives on the Treatment of Bone Metastasis Conference, University of Pittsburgh, Pittsburgh, PA. Management of cancer therapy induced bone loss. October 9, 2010.
216. Breast Cancer Symposium. Passavant Cancer Center, Pittsburgh, PA. Keynote Speaker. October 12, 2010.
217. Grand Rounds. Bay Pines VA Healthcare System. St Petersburg, FL. Bone Health in Breast Cancer, October 12, 2010.
218. Oncology Grand Rounds. University of Pittsburgh Medical Center, Pittsburgh, PA. Angiogenesis inhibition for metastatic breast cancer: Fact, Myth, and the FDA. October 27, 2010.
219. Lynn Sage Breast Cancer Symposium, Chicago, IL. Management of cancer therapy induced bone loss. October 29, 2010.
220. Breast Cancer Educational Symposium, Amherst, NY. New trends in Genomic indicators and markers. November 6, 2010.
221. Breast Cancer Educational Symposium, Amherst, NY. Bone health in breast cancer. November 6, 2010.
222. Satellite Symposium: San Antonio Breast Cancer Conference: Bone-targeting agents as anti-cancer therapy: Evaluation of the future of care in breast cancer. Inhibiting tumor growth w Bone-targeting Therapies in BC Pts: are we there yet? San Antonio, TX, December 10, 2010.
223. Grand Rounds, Tata Memorial Cancer Hospital. Breast Cancer in the Year 2011. Mumbai, India, December 16, 2010.

224. 2nd Pan Asian Cancer Symposium, Rajiv Gandhi Institute of Biomedical Sciences. Bisphosphonates as Anti-Cancer Agents. Trivandrum, India. December 21, 2010.
225. San Antonio Breast Cancer Symposium Review, University of Pittsburgh Cancer Institute. Chemotherapy, Targeted Therapy, and Bisphosphonates. Pittsburgh, PA. January 27, 2011.
226. San Antonio Breast Cancer Symposium Review, Hackensack University Medical Center. Genomic Assays, Cellular Assays, and Bisphosphonates. Hackensack, NJ. February 18, 2011.
227. Grand Rounds, Halifax Health Center for Oncology, Breast Cancer Update 2011. Daytona Beach, FL. March 23, 2011
228. Grand Rounds, Louis A Johnson VA Medical Center, Bone Health in Breast Cancer. Clarksburg, WV. March 31, 2011.
229. Grand Rounds, Reading Hospital Regional Cancer Center, Lebanon, PA. Bisphosphonates as Adjuvant Therapy for Breast Cancer. April 28, 2011.
230. Twenty-fifth UPCI Anniversary/Jeff Shogan Memorial Symposia on Personalized Medicine, Herberman Conference Center, Pittsburgh, PA. Course Director. May 5, 2011.
231. Third Annual Ohio Breast Surgery Fellow Research Symposium, Akron General Hospital, Akron, OH. Triple Negative Breast Cancer. May 13, 2011.
232. Grand Rounds, Drexel University College of Medicine, Philadelphia, PA. Bone Health In Breast Cancer”, June 1, 2011.
233. Grand Rounds, Alexandria Hospital. Breast Cancer Treatment Updates 2011. Alexandria, VA. June 22, 2011.
234. 2011 UPCI ASCO Review, Metastatic Breast Cancer: Treatment. Herberman Conference Center, Pittsburgh, PA. September 17, 2011.
235. Oncology Grand Rounds, Breast Cancer Treatment Updates 2011. Maimonides Medical Center, Brooklyn NY. September 21, 2011.
236. Oncology Grand Rounds, University of Pittsburgh Medical Center. Targeting the Tumor Microenvironment in Breast Cancer: Clinical Trials and Future Directions. Pittsburgh, PA. October 26, 2011.
237. Her2 Positive Breast Cancer Management. Mercy Medical Center, Rockville Centre, NY. November 29, 2012
238. Oncology Grand Rounds. HER2+ Breast Cancer Management. William Beaumont Hospital. Royal Oak, MI. December 11, 2012.
239. Oncology Grand Rounds, University of Pittsburgh Medical Center. Update in Systemic Therapy for Breast Cancer. University of Pittsburgh Cancer Institute, Pittsburgh, PA. December 12, 2012.

240. Chemotherapy Foundation Symposium XXIX, Bevacizumab in the Therapy of Breast Cancer. New York City, NY. November 10, 2011
241. San Antonio Breast Cancer Review 2011, University of Pittsburgh Cancer Institute, Breast Cancer and Bone. Pittsburgh, PA, January 25, 2012.
242. San Antonio Breast Cancer Review 2011, Hackensack University Medical Center, Breast Cancer and Bone. Pittsburgh, PA, February 17, 2012.
243. Cleveland Clinic Symptom Management Symposium. Bone Maintenance Strategies for AI-induced Bone Loss. Key Largo, FL, February 24, 2012.
244. 2012 Breast Cancer Symposium. Plenary Speaker: Bisphosphonates in Breast Cancer Therapy—Beginning of the End or End of the Beginning? Wayne State University. Dearborn, MI. March 3, 2012.
245. Women Living with Metastatic Breast Cancer Annual Conference. Triple Negative Breast Cancer. Philadelphia, PA, April 28, 2012.
246. Oncology Grand Rounds, University of Pittsburgh Medical Center. Clinical Pathways in the Management of Breast Cancer. University of Pittsburgh Cancer Institute, Pittsburgh, PA. June 20, 2012.
247. Grand Rounds. HER2+ Breast Cancer Management: Practical Strategies for Everyday Use. Chesapeake Regional Medical Center. Chesapeake, VA. August 9, 2012.
248. 2012 ASCO Review. Breast Cancer and Bisphosphonates. University of Pittsburgh School of Medicine. Herberman Conference Center, Pittsburgh, PA. September 22, 2012.
249. Oncology Tumor Board. HER2+ Breast Cancer Management. Lankenau Hospital, Wynnewood, PA. September 24, 2012.
250. Breast Cancer Genetics for Series on Health and Wellness, Beth Shalom, Pittsburgh, PA. February 5, 2013.
251. University of Pittsburgh Cancer Institute San Antonio Breast Cancer Symposium Review 2012, Breast Older Drug/Newer Data: Update on bevacizuma, Pittsburgh, PA. March 1, 2013.
252. Grand Rounds, Update in Her 2 Positive Breast Cancer, Norwalk Medical Center, Norwalk, CT. May 13, 2013
253. Cancer Survivor Workshop, Clinical Update for Patients with Breast Cancer and Research Update for Patients with Breast Cancer, Sheraton Station Square, Pittsburgh, PA. May 14, 2013.
254. Oncology Tumor Board, Update in Her 2 Positive Breast Cancer, Lankenau Medical Center, Wynnewood, PA. July 10, 2013.

255. Grand Rounds, Update in Her 2 Positive Breast Cancer, Albert Einstein Medical Center, Philadelphia, PA. July 10, 2013.
256. Medical Grand Rounds, Update in Her 2 Positive Breast Cancer, Bryn Mawr Hospital, Bryn Mawr, PA. July 10, 2013.
257. Oncology Grand Rounds, Update in Her 2 Positive Breast Cancer, Ocala Medical Center, Ocala, FL. July 30, 2013.
258. Grand Rounds Cancer Program, Update in Her 2 Positive Breast Cancer, Northside Hospital, Atlanta, GA. August 12, 2013.
259. Oncology Grand Rounds, Monongohela Valley Hospital, Management of Her2 Positive Breast Cancer. Monongohela, PA, August 28, 2013.
260. Oncology Grand Rounds, University of Pittsburgh Medical Center. Genomic Tests for Breast Cancer: Fact, Myth, and Everything in Between. Pittsburgh, PA, September 30, 2013.
261. Oncology Grand Rounds, William Beaumont Hospital, Management of Her2 Positive Breast Cancer. Royal Oak, MI, October 1, 2013.
262. Grand Rounds, Hochiminh City Hospital, Endocrine Therapy for Breast Cancer. Hochiminh City, Vietnam, October 17, 2013.
263. Grand Rounds, K Hospital, Endocrine Therapy for Breast Cancer, Hanoi, Vietnam, October 18th, 2013.
264. Satellite Meeting, Mexican Society for Clinical Oncology, Her2 Positive Metastatic Breast Cancer, Past History and Future Therapies. Puerto Vallarta, Mexico, January 31, 2014.
265. Update in Breast Cancer, Ochsner Clinic, Bisphosphonates for Breast Cancer: from Prevention of Bone Loss to Prevention of Recurrence, New Orleans, LA, February 7, 2014.
266. Genomic Assays for Breast Cancer, SABCS 2013. Hackensack University Medical Center, Hackensack, NJ, February 28, 2014.
267. Genomic Assays for Breast Cancer: Fact, Myth, and Everything in Between. Centro Medico, San Juan, Puerto Rico, March 11, 2014.
268. Balancing Efficacy with Toxicity in the Treatment of Metastatic Breast Cancer. Grand Rounds, NY Medical College, Valhalla, NY, May 7, 2014.
269. Genomic Assays for Breast Cancer: Fact, Myth, and Everything in Between. Delaware Society for Clinical Oncology, Wilmington, DE, May 13, 2014.
270. Genomic Assays for Breast Cancer: Fact, Myth, and Everything in Between. Grand Rounds, Schiffler Cancer Center, Weirton, WV, June 12, 2014.

271. Balancing Efficacy with Toxicity in the Treatment of Metastatic Breast Cancer. Grand Rounds, Blumenthal Cancer Center, Paramus, NJ, June 23, 2014.
272. Novel Treatments for Metastatic Breast Cancer in 2014. Oncology Conference, Beijing, People's Republic of China, June 27, 2014.
273. How I Treat Metastatic Breast Cancer in 2014. Oncology Conference, Shanghai, People's Republic of China, June 29, 2014.
274. Bevacizumab in Breast Cancer for Potential Palliative and Clinical Benefit, Japan Society for Breast Oncology Annual Meeting, Osaka, Japan, July 11, 2014.
275. Monoclonal Antibodies for the Palliative Treatment of Metastatic Breast Cancer. Sapporo Conference for Palliative and Supportive Care in Cancer 2014, July 12, 2014.
276. Genomic Assays for Breast Cancer: Fact, Myth, and Everything in Between, Breast Tumor Board, St Francis Hospital, Hartford, CT, August 27, 2014.
277. How I Treat Metastatic Breast Cancer in 2014, CONFIRM Breast Symposium, Jaipur, India, September 20, 2014.
278. Novel Therapies for Breast Cancer, Kazakh Cancer Symposium, Astana, Kazakhstan, September 24, 2014.
279. Bisphosphonates for Breast Cancer: From Prevention of Bone Loss to Prevention of Recurrence. Medical Grand Rounds, Shadyside Hospital, Pittsburgh, PA, October 2, 2014.
280. Novel Therapies for Breast Cancer 2014, Oncology Grand Rounds, Virginia Piper Cancer Center, Scottsdale, AZ, October 7, 2014.
281. Bisphosphonates for Breast Cancer: From Prevention of Bone Loss to Prevention of Recurrence. Medical Grand Rounds, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, October 14, 2014.
282. Novel Therapies for Breast Cancer 2014, Oncology Grand Rounds, Aultman Hospital Cancer Center, Canton, OH, October 16, 2014.
283. The Case Against Screening Mammography: Breast Cancer Controversies. Internal Medicine Update, University of Pittsburgh School of Medicine, October 23, 2014.
284. Bisphosphonates for Breast Cancer: From Prevention of Bone Loss to Prevention of Recurrence. WIP Conference, Magee-Women's Research Institute, Pittsburgh, PA, November 4, 2014.
285. The Molecular Biology of Breast Cancer. Grand Rounds, Shands Hospital, University of Florida, Gainesville, FL, January 14, 2015.

286. Controversies in the Management of Metastatic Breast Cancer. Medical Grand Rounds, Halifax Hospital, Daytona Beach, FL, January 23, 2015.
287. Her2 Update SABCS. San Antonio Breast Symposium Review, University of Pittsburgh Cancer Institute, February 6, 2015
288. Update in Metastatic Breast Cancer. Medical Grand Rounds, Pocono Medical Center, East Stroudsburg, PA, March 16, 2015.
289. Advances in Her2 positive Breast Cancer. Breast Cancer Innovations Conference, The Peres Center for Peace, Tel-Aviv, Israel, April 17, 2015.
290. Management of Metastatic Breast Cancer in 2015. Medical Grand Rounds, Good Samaritan Hospital, Troy, NY, May 18, 2015.
291. Clinical Trials in Cancer: A Primer, Nazarbayev University, Astana, Kazhakstan, October 14, 2015.
292. Adjuvant Bisphosphonates for Breast Cancer, International Bone Health Experts Forum, Dubai, UAE, October 16, 2015.
293. Genomic Tests for Breast Cancer: Fact, Myth, and Everything in Between, Medical Grand Rounds, St. Mary's Hospital, San Francisco, CA, October 19, 2015.
294. Management of Metastatic Breast Cancer in 2015. Oncology Grand Rounds, Inova Hospital, Fairfax, VA, October 26, 2015.
295. Bisphosphonates for Breast Cancer: From Prevention of Bone Loss to Prevention of Recurrence, Medical Grand Rounds, Beaumont Hospital, Oakmont, MI, November 25, 2015.
296. Breast Cancer Management in 2016. Oncology Grand Rounds, Rush University Medical Center, Chicago, IL, January 20, 2016
297. Update on Management of TNBC. Best of SABCS China, Beijing, China, January 23, 2016.
298. Update on Management of Luminal A Breast Cancer. Best of SABCS China, Shanghai, China, January 24, 2016.
299. Update on the Management of TNBC. University of Pittsburgh SABCS Review, Pittsburgh, PA, January 29, 2016.
300. Immunotherapy for Breast Cancer: SABCS 2016 Update. SABCS Review, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, February 26, 2016.
301. CDK4/6 Inhibitors in the Treatment of Breast Cancer. 2016 Annual ACOS Meeting, Delhi, India, April 8, 2016.

302. Genomic Assays for Breast Cancer: Fact, Myth, and Everything in Between. Oncology Grand Rounds, Hoag Cancer Center, Huntington Beach, CA, April 27, 2016.
303. Biotherapies for Breast Cancer. Regional Cancer Center Nursing Conference, Erie, PA, May 20, 2016.
304. Bisphosphonates for Breast Cancer: From Prevention of Complications of Bone Metastasis to Prevention of Recurrence. Ohio State University James Cancer Center Conference, Stefanie Spielman Comprehensive Breast Center, Columbus, OH, June 14, 2016.
305. Genomic Assays for Breast Cancer: Fact, Myth, and Everything in Between. Grand Rounds Baylor Scott and White, Temple TX, June 16, 2016.
306. Therapy for Estrogen Receptor Positive MBC. India Oncology Society, Delhi, India, September 16th, 2016.
307. Therapy for Estrogen Receptor Positive MBC. Oncology Tumor Board, Lucknow, India, September 17th, 2016.
308. Genomic Assays for Breast Cancer: Fact, Myth, and Everything in Between. Breast Cancer Grand Rounds, Indiana University Goshen, Goshen, Indiana, November 3rd, 2016.
309. Therapy for Estrogen Receptor Positive MBC. Malaysian Oncology Society Annual Meeting, Johor Bahru, Malaysia, November 11th, 2016.
310. How I Treat Her2 Positive MBC. Malaysian Oncology Society Annual Meeting, Johor Bahru, Malaysia, November 12th, 2016.
311. Genomic Assays for Breast Cancer: 2017 Update. Oncology Grand Rounds, University of Pittsburgh Cancer Institute, Pittsburgh, PA, January 18th, 2017.
312. Bisphosphonates for Breast Cancer: From Prevention of Complications of Bone Metastasis to Prevention of Recurrence. Oncology Grand Rounds, ASAN Medical Center, Seoul, South Korea, February 3rd, 2017.
313. Where are we now and future horizons – Focus on treatment advances in ER+ HER2- metastatic breast cancer. Oncology Grand Rounds, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China, February 6th, 2017.
314. Where are we now and future horizons – Focus on treatment advances in ER+ HER2- metastatic breast cancer. Oncology Grand Rounds, Queen Elizabeth Hospital, Hong Kong, China, February 7th, 2017.
315. Where are we now and future horizons – Focus on treatment advances in ER+ HER2- metastatic breast cancer. Oncology Grand Rounds, Hong Kong Sanatorium Hospital, Hong Kong, China, February 8th, 2017.

316. Genomic Assays for Breast Cancer: Fact, Myth, and Everything in Between. COEDS Grand Rounds, University of Miami Sylvester Cancer Center, Fort Lauderdale, FL, February 28th, 2017.
317. Novel mechanisms and Pathways in CDK4/6 use in Breast Cancer. Rush University Medical Center, Chicago, IL, April 26, 2017.
318. CDK 4/6 Inhibitors: New Choices for HR-Positive, HER2-Negative Metastatic Breast Cancer. UCLA Olive View Medical Center, Los Angeles, CA, May 2, 2017.
319. CDK 4/6 Inhibitors: New Choices for HR-Positive, HER2-Negative Metastatic Breast Cancer. Cook County Hospital, Chicago, IL, June 22nd, 2017.
320. Management of ER Positive Metastatic Breast Cancer in 2017. Stavenger Hospital, Stavenger, Norway, September 26th, 2017.
321. Metastatic Triple Negative Breast Cancer Management, Bergen Hospital, Bergen, Norway, September 27th, 2017.
322. Management of ER Positive Metastatic Breast Cancer in 2017. Akershus Hospital, Oslo, Norway, September 28th, 2017.
323. Bisphosphonates for Breast Cancer: From Prevention of Complications of Bone Metastasis to Prevention of Recurrence. Cancer Chemotherapy Symposium, New York, New York, November 9th, 2017.
324. Treatment of Breast Cancer by Intrinsic Subtype Classification, 20th Annual Meeting of the Vietnamese Society for Clinical Oncology, Ho Chi Minh City, Vietnam, November 29th, 2017.
325. Treatment of Early Stage Her2 Positive Breast Cancer: Novel Insights in 2017, 20th Annual Meeting of the Vietnamese Society for Clinical Oncology, Ho Chi Minh City, Vietnam, November 30th, 2017.
326. Management of ER Positive Metastatic Breast Cancer in 2017. Parkview Regional Medical Center, Fort Wayne, IN, December 12th, 2017.
327. Bone Targeted Agents SABCS 2018. Annual UPMC SABCS Review, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, February 1st, 2018.
328. Immunotherapy for Breast Cancer 2018. SABCS 2017 Review, John Theurer Cancer Center, Hackensack, NJ, February 23rd, 2018.
329. Treatment of Estrogen Receptor Positive Metastatic Breast Cancer, Oncology Grand Rounds, Roger Williams Cancer Center, Providence, RI, April 3rd, 2018.

330. Treatment of Estrogen Receptor Positive Metastatic Breast Cancer, Oncology Grand Rounds, Tideland Health Cancer Center, Murrells Inlet, SC, April 23rd, 2018.
331. Approach to Treatment of Progressive Endocrine Positive MBC, Latin American Breast Cancer Symposium, Panama City, Panama, April 25th, 2018.
332. Advances in the Treatment of ER Positive Metastatic Breast Cancer, Oncology Grand Rounds, SYSCC Hospital, Taipei, Taiwan, May 4th, 2018.
333. Treatment of Her2 Positive Breast Cancer in the Neoadjuvant Setting, Oncology Symposium, Tainan, Taiwan, May 4th, 2018.
334. Advances in the Treatment of ER Positive Metastatic Breast Cancer, Taiwan Joint Cancer Conference, Taipei, Taiwan, May 5th, 2018.
335. Advances in the Treatment of ER Positive Metastatic Breast Cancer, Oncology Grand Rounds, Iowa Cancer Center, Des Moines, IA, May 15th, 2018.
336. Molecular Tumor Board, Christus Mary Hospital, Tyler, TX, May 22nd, 2018.
337. Treatment of ER Positive Metastatic Breast Cancer, Brazil Oncology Symposium, Sao Paulo, Brazil, June 29th, 2018.
338. Bone Targeted Agents for Breast Cancer: From Prevention of Complications of MBC to Prevention of Recurrence, Oncology Grand Round, UT Southwestern Cancer Center, Dallas, TX, July 9th, 2018.
339. Treatment of ER Positive Metastatic Breast Cancer, Oncology Rounds, Watson Clinic, Lakeland, FL, July 27th, 2018.
340. Scientific Basis for Treatment of ER Positive MBC, Oncology Rounds, Chulalongkorn Hospital, Bangkok, Thailand, August 1st, 2018.
341. Treatment of ER Positive Metastatic Breast Cancer, Oncology Rounds, Ramathibodi Hospital, Bangkok, Thailand, August 2nd, 2018.
342. Treatment of ER Positive Metastatic Breast Cancer, Thai Oncology Cancer Society Best of ASCO Symposium, Bangkok, Thailand, August 3rd, 2018.
343. Treatment of ER Positive Metastatic Breast Cancer, Grand Rounds, Beckley Memorial Hospital, Beckley, WV, August 15th, 2018.
344. Treatment of Early Stage Breast Cancer, Best of ASCO Symposium, Portland, OR, August 17th, 2018.

345. Treatment of Early Stage Breast Cancer, Best of ASCO Symposium, UPMC Cancer Center, Pittsburgh, PA, September 14th, 2018.
346. Biosimilars in Oncology: Breast Cancer Experience, Association of Oncology Hospital Pharmacists, Chicago, IL, September 15th, 2018.
347. Treatment of ER Positive Metastatic Breast Cancer, Grand Rounds, Cancer Treatment Centers of America, September 18th, 2018.
348. Treatment of ER Positive Metastatic Breast Cancer, Grand Rounds, University of Vermont Medical Center, Burlington, VT, September 25th, 2018.
349. Treatment of ER Positive Metastatic Breast Cancer, Grand Rounds, Meadville General Hospital, Meadville, PA, September 26th, 2018.
350. Metastatic Breast Cancer ASCO 2018, Phillipines Society of Medical Oncology Best of ASCO Symposium, Manila, Phillipines, October 10th, 2018.
351. Treatment of ER Positive Metastatic Breast Cancer, Phillipines Society of Medical Oncology Best of ASCO Symposium, Manila, Phillipines, October 10th, 2018.
352. Treatment of ER Positive Metastatic Breast Cancer, 16th Women's Cancer Initiative Breast Conference, Goa, India, October 27th, 2018.
353. Treatment of ER Positive Metastatic Breast Cancer, Indian Society of Medical Oncology Metastatic Breast Cancer Symposium, Delhi, India, October 28th, 2018.
354. Treatment of Triple Negative Metastatic Breast Cancer, State of the Science Summit: Breast Cancer, Pittsburgh, PA, October 31st, 2018.
355. State of the Art Approaches in Neoadjuvant Therapy for Breast Cancer, Cancer Chemotherapy Foundation, Symposium, New York, NY, November 8th, 2018.
356. Treatment of Breast Cancer with PARP Inhibitors, Fall Managed Care Forum, Las Vegas, NV, November 9th, 2018.
357. Treatment of ER Positive Metastatic Breast Cancer, Oncology Grand Rounds, Novant Health Forsyth Medical Center, Winston-Salem, NC, February 4th, 2019.
358. Adjuvant Therapy for Her2 Positive Breast Cancer, 5th Biennial Meeting of the Society of Israeli Breast Surgery, Zichron Yaakov, Israel, February 20th, 2019.
359. Genomic Testing for Breast Cancer, 5th Biennial Meeting of the Society of Israeli Breast Surgery, Zichron Yaakov, Israel, February 21st, 2019.

360. Treatments for BRCA Positive MBC, Miami Breast Symposium, Miami, FL, March 9th, 2019.
361. Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer, Oncology Grand Rounds, University of Alabama Birmingham, St. Vincent's East Hospital, Birmingham, AL, March 26th, 2019.
362. Resistance to CDK4/6 Inhibitors in ER Positive MBC, GEICAM Annual Meeting, Toledo, Spain, March 28th, 2019.
363. Treatment of Breast Cancer in the Era of Genotyping, Society of Breast Imaging Annual Meeting, Fort Lauderdale, FL, April 6th, 2019.
364. Breast Cancer Therapy in 2019, Cancer Caring Center, Pittsburgh, PA, April 30th, 2019.
365. Navigating the current management for HR+ HER2- metastatic breast cancer, Asia Pacific Oncology Society Annual Meeting, Taipei, Taiwan, May 12th, 2019.
366. Treatment of Breast Cancer in an Era of Targeted Therapies, Grand Rounds, Western Maryland Health System, Cumberland, MD, June 18th, 2019.
367. Treatment of Early Stage Her2 Positive Breast Cancer, Monongahela Valley Hospital Research Day, Monongahela, PA, June 26th, 2019.
368. Genomic Tests for Breast Cancer: Fact, Myth, and Everything in Between, Tumor Board, Trinity Medical Center, Trinity, FL, August 13th, 2019.
369. Emerging Perspectives in Breast Cancer, Mayo Clinic Oncology Rounds, Mayo Clinic Jacksonville, Jacksonville, FL, August 28th, 2019.
370. Adjuvant Therapy for Her2 Positive Breast Cancer in 2019, Pittsburgh, PA, September 5th, 2019.
371. Genomic Tests for Breast Cancer: Fact, Myth, and Everything in Between, 4th Annual Breast Health Symposium, NYU Winthrop Medical Center, Garden City, NY, September 20th, 2019.
372. Real World Evidence and Outcomes of Palbociclib in ER Positive MBC, Satellite Symposium, Annual Meeting of the European Society for Clinical Oncology, Barcelona, Spain, September 28th, 2018.
373. Treatment of Her2 Positive Breast Cancer, Fellows Conference, UPMC Hillman Cancer Center, Pittsburgh, PA, October 11th, 2019.
374. Treatment of Metastatic Breast Cancer Guided by Next Generation Sequencing, Oncology Grand Rounds, UPMC Hillman Cancer Center, October 16th, 2019.
375. Evolving Standards for the Treatment of Her2 Positive Metastatic Breast Cancer, Malaysian Oncology Society, Penang, Malaysia, October 19th, 2019.

376. Treatment of Triple Negative Breast Cancer, Malaysian Oncology Society, Penang, Malaysia, October 19th, 2019.
377. Future of Therapy for Her2 Positive Breast Cancer, SIMOS, Shanghai Medical Oncology Society Symposium, Shanghai, China, November 9th, 2019.
378. Brain Metastases in Her2 Positive Breast Cancer, China Southwest Oncology Group Meeting, Wuhan, China, November 10th, 2019.
379. SABCS 2020: Her2 Positive Metastatic Breast Cancer. SABCS Review, UPMC Hillman Cancer Center, Pittsburgh, PA, February 7th, 2020.
380. PI3K Inhibitors in the Treatment of Metastatic Breast Cancer, Cancer Treatment Centers of American, Philadelphia, PA. February 12th, 2020.
381. Genomic Tests for Breast Cancer 2020, Oncology Grand Rounds, Northwell Hospital, Lake Success, NY, February 13th, 2020.
382. Immunotherapy at SABCS 2019, 27th Annual SABCS Review, John Theurer Cancer Institute, Hackensack Medical Center, Hackensack, NJ, February 28th, 2020.
383. Bone Health in Metastatic Breast Cancer, Living Beyond Breast Cancer, Philadelphia, PA (virtual), June 13th, 2020.
384. Optimizing Personalized Medicine for Her2 Positive Early Breast Cancer, Hong Kong Breast Oncology Group, Hong Kong, CN (virtual). June 30th, 2020.
385. Real World Evidence and Use of CDK4/6 Inhibitors in Metastatic Breast Cancer. Indian Oncology Society, Mumbai, IN (virtual), September 11th, 2020.
386. How to fit in chemotherapy as subsequent treatment after a CDK 4/6 inhibitor in management of HR+/HER2- MBC. Filipino/Asia Oncology Group, Singapore (virtual), October 24th, 2020.
387. Use of Tyrosine Kinase Inhibitors in the Treatment of Her2 Positive Breast Cancer, 2020 Taipei International Breast Symposium, Taipei, Taiwan (virtual), November 7th, 2020.
388. SABCS 2020: Novel Treatments for Early-Stage High Risk Breast Cancer, Hematology/Oncology Grand Rounds (Virtual), Pittsburgh PA. January 6, 2021.
389. Novel Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer. 9th Asia-Pacific Breast Cancer Summit (APBCS) (Virtual), Singapore. January 10, 2021.
390. Genomic Testing Updates in ER+ Breast Cancer, 2020 San Antonio Breast Cancer Symposium Review. UPMC Hillman Cancer Center, Pittsburgh PA. February 12, 2021.

391. Immunotherapy for Metastatic Breast Cancer. San Antonio Breast Cancer Review (virtual), John Theurer Cancer Center, Hackensack NJ. February 9, 2021.
392. Immunotherapy of Early-Stage Triple Negative Breast Cancer, International Breast Cancer Forum, Dailan, China (virtual) April 23rd, 2021.
393. Therapy of Hormone Receptor Positive MBC in 2021, Oncology Grand Rounds, UPMC Hillman Cancer Center, September 29th, 2021.
394. Therapy for Triple Negative Breast Cancer. Oncology Grand Rounds, Beaumont Hospital, Detroit, MI (virtual), January 5th, 2022.
395. HER2 Positive Breast Cancer San Antonio Breast Cancer 2021 Review Virtual Symposium, Atlantic Health System Cancer Care (virtual), Morristown, NJ. January 22nd, 2022.
396. Her2Neu and ADC Updates. UPMC Virtual Comprehensive Review of the 2021 San Antonio Breast Cancer Symposium. Pittsburgh PA, February 18th, 2022.
397. Immunotherapy of Breast Cancer at SABCS 2021, 29th Annual SABCS Review, John Theurer Cancer Institute (virtual), Hackensack Medical Center, Hackensack, NJ, February 25th, 2022.
398. Breast Cancer Basics and Medical Management, Neoplasia Course, University of Pittsburgh, School of Medicine, Pittsburgh, PA, March 14th, 2022.
399. Advances in the Management of Breast Cancer Brain Metastases, 2022 Northside Hospital Cancer Institute Symposium, Whitley Hotel, Atlanta, GA, March 26th, 2022.
400. Real World Evidence and the Use of CDK46 Inhibitors in Metastatic Breast Cancer. Ontario Breast Cancer Symposium, Ontario, Canada (virtual), May 19th, 2022.
401. Use of Bone Targeted Agents in Metastatic Breast Cancer. Cema Oncologica, Mexican Society of Hematology-Oncology (virtual), Cancun, Mexico, May 21st, 2022.
402. Therapy of Her2 Positive Metastatic Breast Cancer: 2022 Update. Asian Society of Surgical Oncology Annual Meeting (virtual), Singapore, June 13th, 2022.
403. Genomic Assays in Early-Stage Breast Cancer. International Breast Cancer Forum, Dailan, China (virtual) June 18th, 2022.
404. Novel Therapies for Estrogen Receptor Positive Metastatic Breast Cancer. 1st UPMC Hillman Cancer Summit, Pittsburgh, PA, July 16th, 2022.
405. Use of Antibody-Drug Conjugates in Metastatic Breast Cancer. Brazil Breast Cancer Symposium, September 19th, 2022.
406. Real World Evidence and the Use of CDK46 Inhibitors in Metastatic Breast Cancer. Vietnam Breast Cancer Symposium, Ho Chi Minh City, Vietnam, September 16th, 2022.

407. Real World Evidence and the Use of CDK4/6 Inhibitors in Metastatic Breast Cancer. Vietnam Breast Cancer Symposium, Hanoi, Vietnam, September 17th, 2022.
408. Breast Cancer Update: ASCO 2022. ASCO Review, Advent Health, Orlando, FL, September 20th, 2022.
409. Metastatic Breast Cancer Update 2022. Pennsylvania Society of Hematology-Oncology Annual Meeting, King of Prussia, PA, October 7th, 2022.
410. HER2+ Breast Cancer. Fellows Lecture Series, University of Pittsburgh, School of Medicine, Pittsburgh, PA, October 7, 2022.